The Modulation of Tau Aggregation in a Cell Model of Alzheimer’s Disease by the Proteasome Adaptor Protein NUB1 by Richet, E
  
The Modulation of Tau Aggregation in a 
Cell Model of Alzheimer’s Disease by 
the Proteasome Adaptor Protein NUB1 
 
 
 
Emma Richet 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
 
March 2012 
 
University College London, 
Institute of Ophthalmology
  2 
 
Declaration 
 
I, Emma Richet, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been 
indicated in the thesis. 
  3 
 
 
Abstract 
 
Neurofibrillary tangles (NFT) in Alzheimer’s disease (AD) are mainly composed 
of hyperphosphorylated and aggregated wild-type tau. NFTs are decorated by 
the ubiquitin-like modifier NEDD8, a protein targeted for proteasomal 
degradation by the NEDD8 Ultimate Buster 1 (NUB1). NUB1 has been shown to 
reduce synphilin-1 positive inclusions in a model of Parkinson’s disease. 
Therefore, this study examined the subcellular localisation of NUB1 as well as 
the effect of NUB1 on tau phosphorylation and aggregation. Furthermore, the 
effect of reducing NUB1 expression by RNA interference was investigated.  
Brain sections from AD patients showed that NUB1 and NEDD8 were 
expressed in the pyramidal neurons of the hippocampus, where the 
accumulation of NFTs is most abundant. In rat primary cortical neurons, NUB1 
and tau co-localised in neurites and signalling structures such as varicosities, 
suggesting a functional interaction between them. The upregulation of the tau 
kinase GSK3β in AD leads to increased tau hyperphosphorylation and 
accumulation. In SK-N-SH neuroblastoma cells, which lack endogenous tau, 
ectopic wild-type tau formed inclusions when it was co-expressed with GSK3β, 
and this was enhanced by proteasome inhibition. NUB1 co-localised with both 
tau and GSK3β and significantly reduced tau inclusion formation. In 
neuroblastoma cells, NUB1 could interact with both tau and GSK3β, disrupt 
their interaction, and decrease the GSK3β-dependent phosphorylation of tau. 
NUB1 can directly bind synphilin-1 and induce its proteasomal degradation. 
Therefore, the ability of NUB1 to regulate GSK3β degradation was investigated 
in neuroblastoma cells. The upregulation of NUB1 accelerated the turnover of 
GSK3β, and the ubiquitin-associated (UBA) domains of NUB1 were necessary 
for NUB1 to exert its effect. Conversely, the downregulation of endogenous 
NUB1 by RNA interference increased the stability of endogenous GSK3β. Thus, 
NUB1 might have a role in tau inclusion formation by modulating GSK3β levels. 
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Chapter 1  
Introduction  
 
1.1. Alzheimer’s disease 
Dementia is described as a severe impairment of cognitive abilities, which often 
correlates with ageing. The most common dementia is Alzheimer’s disease 
(AD), discovered in 1907 by Alois Alzheimer, who identified two 
histopathological hallmarks, neurofibrillary tangles (NFTs) and Amyloid-β (Aβ) 
plaques, in patients brains affected with the disorder. About 24 million people 
worldwide are affected by AD, and this number is expected to more than triple 
by 2040 (Reitz et al., 2011). Therefore, AD is a universal therapeutic challenge. 
The pathological and molecular mechanisms have been thoroughly studied for 
the last century, yet the causes and consequences of the disease are not fully 
understood (Ballard et al., 2011).  
 
1.1.1. Epidemiology, symptoms and diagnosis   
1.1.1.1. Epidemiology 
Dementia is particularly difficult to classify and to differentiate between 
neurodegenerative disorders. However, ∼ 70% of cases of dementia are 
thought to be caused by AD. The highest prevalence of people developing AD 
is in North America, Western Europe and China. AD occurs mainly as a 
sporadic late-onset disease (LOAD), but also as an early-onset familial disorder 
(FAD) in less than 10% of cases. Currently, AD diagnosis can only be certain 
post-mortem with the detection of NFTs and Aβ plaques (Ballard et al., 2011).  
 
1.1.1.2. Symptoms and diagnosis  
Cognitive tests. Early symptoms of cognitive decline include deficient memory, 
language breakdown and disorientation. Cognitive decline is always combined 
with behavioural changes (social withdrawal, agitation), and often with 
  Chapter 1 - Introduction 
  23 
depression, anxiety, apathy, insomnia and paranoia (Hort et al., 2010, 
http://www.aafp.org/afp/2001/0215/p703.html). After detection of the first 
symptoms, the most common cognitive test physician’s use is the Mini-Mental 
State Examination (MMSE), although it cannot accurately diagnose dementia. 
To further assess cognitive decline, other tests, such as the Alzheimer Disease 
Assessment Scale Cognitive (ADAS-Cog) or Blessed test can be performed 
(www.alzheimersresearchuk.org; www.alzforum.org). With good cognitive tests, 
it is possible to determine whether the patient is suffering from dementia or not. 
However, it is still very difficult to precisely diagnose the type of dementia. 
Therefore, depending on the score, the patient will be subjected to further 
analysis, such as brain scans, tests for biomarkers in blood and cerebrospinal 
fluid (CSF) or electroencephalography (EEG) (Hort et al., 2010). 
Scans and imaging. Magnetic Resonance Imaging (MRI) or Computer 
Tomography (CT) brain scans can be used to detect brain shrinkage, 
hippocampal atrophy, and vascular changes, but are not considered specific 
markers for AD. Changes in brain cognitive activities occur in AD, and can be 
measured with a functional MRI (fMRI). However, cognitive abilities are not 
secluded to one part of the brain, and the impairment of one region of the brain 
might be compensated by others, thus rendering the diagnosis more difficult to 
make (Hort et al., 2010; Hampel et al., 2011). 
Other diagnostic techniques. A promising way of diagnosing AD might be the 
analysis of CSF and plasma components. The difficult diagnosis of AD has 
raised an intensive search for potential early biomarkers of the disease present 
in the blood and the CSF. Other methods used to diagnose AD include Positron 
Emission Tomography (PET). However, even with the numerous diagnostic 
methods available, there is still a pressing need to accurately distinguish 
between the different dementias in order for the treatment to target the right 
abnormalities. Nevertheless, great progress has been made in AD diagnostic 
assessments, providing valuable information on the disease progression. 
AD is still an incurable neurodegenerative disease. Neuronal death in the 
hippocampus and the limbic system induce memory loss and language 
disorder, before the disease spreads to the neocortex (also called isocortex) 
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and eventually leads to death. AD is an amyloid-associated disorder, in that it is 
characterised by the abnormal accumulation of protein in β-cross fibrils, also 
typified by other neurodegenerative disorders including the Prion diseases 
(CJD), Parkinson’s disease (PD) and Huntington’s disease (HD) (Duyckaerts et 
al., 2009; Finder 2010; Ballard et al., 2011).  
 
1.1.2. Amyloid-β  
1.1.2.1. Amyloid-β Precursor Protein  
Aβ is produced by the cleavage of the Amyloid Precursor Protein (APP). APP is 
a transmembrane protein with a large extracellular domain (ectodomain) 
containing two heparin-binding domains (HBD) and a single small membrane 
spanning domain, formed by a hydrophobic α-helix (Multhaup, 2006). 
Alternative splicing of the APP transcript results in 8 different isoforms of the 
protein, 3 of which are the most highly expressed: the 695, 751 and 770 forms 
(O’Brien and Wong, 2011). APP is largely expressed in the brain, particularly in 
neurons where it is recruited to the presynaptic membrane (Wilquet and De 
Strooper, 2004; Zheng and Koo, 2006). Unexpectedly, the physiological role of 
APP is not yet known, although it has been reported to be involved in axonal 
growth, synaptic transmission, reactive oxygen species (ROS) detoxification 
and mitochondrial dysfunction. With respect to a role for APP in synaptic 
transmission, APP is recruited to the synapses, secreted APP levels correlate 
with synaptogenesis, and APP binding with Fe65 appears to be important for 
growth cone dynamics and cell motility. Another potential role for APP is in cell 
signalling, as APP is structurally similar to the receptor Notch. Like Notch, APP 
is also cleaved and produces an intracellular domain (AICD) and an 
extracellular fragment (Zheng and Koo, 2006). 
 
1.1.2.2. Amyloid-β peptide formation  
APP undergoes proteolytic cleavage following two pathways, the non-
amyloidogenic pathway, which involves the α-secretase, and the amyloidogenic 
pathway, which involves the β-secretase (Figure 1.1). The first truncation by the 
α-secretase, a member of the ADAM metaloprotease family, cuts APP into the 
extracellular soluble sAPPα fragment, and the C83 fragment, which remains in  
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Figure 1.1. APP processing. APP is cleaved by α, β and γ secretases following two 
mechanisms: the non-amyloidogenic and amyloidogenic pathways. Only the 
amyloidogenic pathway, involving the β and γ secretases, produces Aβ. 
 
the plasma membrane. The neuronal β-secretase is called BACE1 for β-site 
APP cleavage 1, and produces an extracellular fragment, sAPPβ, and an 
intramembrane fragment, C99. The γ-secretase, a complex of proteins that 
includes presenilin (PS) (Wilquet and De Strooper, 2004; Zheng and Koo, 2006; 
O’Brien and Wong, 2011), cleaves the C83 and C99 intramembrane fragments. 
PS mutation has been shown to be responsible for most of the familial forms of 
AD (Reitz et al., 2011). C83 cleavage produces an APP intracellular domain 
(AICD) and a short fragment called P3 (3 kDa), whereas C99 truncation 
produces the AICD and a range of Aβ, a peptide from 38 to 44 kDa. The Aβ40 
and Aβ42 fragments are the most extensively studied, as both have been shown 
to accumulate in Aβ plaques. Although APP KO mice develop age-dependent 
cognitive impairment, they do not exhibit hippocampal neuron or synapse loss. 
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Thus, it implies that the increased neuronal death and synaptic dysfunction 
observed in the hippocampus of AD patients is probably a result of abnormal 
APP processing into Aβ rather than a loss of function of APP (Phinney et al., 
1999). Indeed, neurons exposed to Aβ die in 24h, with Aβ42 as the most toxic 
form (LaFerla et al., 2007). Aβ is normally degraded by enzymes, including the 
insulin degrading enzyme (IDE) and neprilysin (NEP). One hypothesis in Aβ 
accumulation is that NEP can be easily overwhelmed by Aβ production as it is 
rate-limiting in the brain (Wang YJ et al., 2006). 
 
1.1.2.3. Aβ accumulation  
Aβ is the main component of senile plaques (Finder, 2010; Bugiani et al., 1989). 
Aβ deposits can also occur with normal ageing in the absence of dementia, and 
in individuals with mild cognitive impairment (MCI) or with Down’s syndrome. 
Normally undetectable in young adult brains, the production of Aβ appears to be 
the result of 2 imbalances: the increase of the amyloidogenic pathway over the 
non-amyloidogenic pathway, and the dysregulation of the production/clearance 
of the Aβ.  
 
According to Braak staging, amyloid deposits are first found in the basal layers 
of the neocortex (stage A), then progress to the neocortex excluding the primary 
cortices (the hippocampus, for instance, is free of deposit) (stage B), and finally 
reach all parts of the neocortex (stage C) (Braak and Braak, 1991). Other Aβ 
progression schemes have been described which take into account other parts 
of the brain besides the cerebral cortex, for example the eventual deposition of 
Aβ in the cerebellum (Thal et al.,2002). Senile plaques are composed of a focal 
deposit of Aβ, surrounded by a corona, containing astrocytic and neuritic 
components. Aβ plaques can be decorated by lipids that include cholesterol and 
several proteins such as Apolipoprotein E, a ligand in receptor-mediated 
endocytosis of lipoprotein, of which the allele ε4 remains the principal genetic 
risk factor in the sporadic form of AD (Reitz et al., 2011; Duyckaerts et al., 2009; 
Selkoe 2001, Selkoe 2011). Although most Aβ deposits described are the senile 
plaques, diffuse and focal Aβ accumulations can also be observed. 
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1.1.3. Tau 
In the middle of the 1970’s, Weingarten et al. described a new protein that 
promotes microtubule assembly, which they called tau. It is the presence of the 
microtubule-binding domain (MBD) and a projection domain that defines tau as 
a microtubule-associated protein (MAP) (Dye et al., 1993). Tau belongs to the 
MAP2/tau protein sub-family, the most abundant MAP family in the neuronal 
system (Kanai and Hirokawa, 1995; Dehmelt and Halpain, 2005).  
 
1.1.3.1. Tau protein  
Tau gene and protein isoforms. The single tau gene is located on chromosome 
17 and is composed of 16 alternatively spliced exons generating six different 
isoforms of tau, which range from 352 to 441 amino acids (aa) (Goedert et al., 
1989; Hernandez et al., 2008; Morris et al., 2011; Buee et al., 2000). The 
insertion of one or two 29 amino acid regions in the N-terminus occurs as a 
result of the alternative splicing of exon 2 and 3 (called N), whereas the 
presence of  exon 10 produces an additional repeat region (called R) (Figure 
1.2, A). Therefore, the tau isoforms are divided into two main groups, with 3 
(3R) or 4 (4R) repeat regions respectively, which in turn possess 0 
(0N3R/0N4R), 1 (1N3R/1N4R) or 2 (2N3R/2N4R) N-terminal insertions (Figure 
1.2, A). All six isoforms are expressed in the adult brain, but only the 0N3R 
isoform is found at the foetal stage. Some particularly long and large axons in 
the spinal chord and retina possess an unusual splicing form of exon 4, called 
exon 4A (Georgieff et al., 1993). Tau protein is composed of 4 main domains, 
the N-terminus, a proline rich domain, a microtubule-binding domain (MBD) also 
called the repeat domain region and a C-terminus (Figure 1.2, B).  
Tau localisation. Tau is mainly expressed in neurons, (Trojanowski et al., 1993; 
Kanai and Hirokawa, 1995; Dehmelt and Halpain, 2005), although it can be 
found in pancreatic cells (Vanier et al., 1998) and fibroblasts (Ingelson et al., 
1996) in humans, in heart, skeletal muscle, lung and kidney in rats (Gu et al., 
1996) and in oligodendrocytes in rats and mice (Muller et al., 1997; Klein et al., 
2002). In neurons, tau localisation is mostly axonal, whereas MAP2, another 
member of the MAP2/tau family is essentially found in the cell body and 
dendrites (Trojanowski et al., 1993; Kanai and Hirokawa, 1995). However, 
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studies suggest that tau is also localised in the dendrites and synapses (Ittner et 
al., 2010). Moreover, tau has been described to be recruited to organelles, the 
plasma membrane and in lipid-rich microdomains, important platforms for cell 
signalling (Brandt et al.,1995; Farah et al., 2006; Rendon et al., 1990; Pooler 
and Hanger, 2010). 
 
Figure 1.2. Tau splicing and domain structure. (A) The alternative splicing of exon 2 
and 3 in the N-terminus and exon 10 in the C-terminus generates 6 different isoforms 
of tau, all expressed in adult brain. Exon 3 is always spliced with exon 2. The splicing 
of exon 10 produces an extra repeat region (R2), important for binding microtubules. 
(B) Tau protein is composed of 4 main domains, the N-terminus, the proline-rich region, 
the microtubule-binding domain (MBD) and the C-terminus. The N-terminus and the 
proline-rich region comprise the projection domain. 
 
1.1.3.2. Tau domains and function  
Microtubule-binding domain (MBD). Tau longitudinally decorates the 
microtubule protofilaments via its MBD domain, with its N-terminus projecting 
outward. In this arrangement, tau increases the rigidity of the microtubules by 
bridging the protofilaments (Hirokawa et al., 1988; Al-Bassam et al., 2002). 
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Interestingly, the MBD interacts directly with protein phosphatase 2A (PP2A), 
which is involved in tau regulation via its dephosphorylation. The repeat regions 
are also important for binding PS1 (Takashima et al., 1998).  
Projection domain. With the MBD attached to the microtubules, the rest of the 
N-terminus of the tau protein, including the proline-rich region, acts as a 
projection domain. The projection domain of tau regulates the spacing between 
microtubules and therefore, is an important modulator of axon diameter. The 
MAP projection domains, highly variable in length and rather small in the tau 
family, are thought to interact with proteins and other cell components (Feng 
and Walsh, 2001). The N-terminal region of tau interacts with the plasma 
membrane, organelles such as mitochondria and Golgi, and components of the 
cytoskeleton, including actin (Buee et al., 2000; Morris et al., 2011; Pooler and 
Hanger, 2010).  
The proline-rich domain of tau is able to interact with phospholipase C-γ (PLC-
γ) and with the SH3 domain Src-family non-receptor tyrosine kinase (SRK), in 
particular the SRK Fyn (Morris et al., 2011, Lee G., 2005). In the dendrites, tau 
binds Fyn and is important for the recruitment of Fyn to the post-synaptic sites 
(Ittner et al., 2010), and particularly to the NMDA-receptor, a substrate for the 
Fyn kinase. Therefore, the presence of the proline-rich domain suggests that 
tau is implicated in cell signalling. 
Other tau functions. By regulating microtubule polymerisation and stabilisation, 
tau is involved in neurite formation. Tau is necessary for the correct formation of 
the growth cones in neurons, and might link the microtubules and 
microfilaments of actin to allow neuronal growth (DiTella et al., 1994). Another 
potential role for tau and MAP is to regulate cell trafficking. Tau overexpression 
has been shown to inhibit the transport of organelles in cells and to block the 
anterograde transport in axons (Ebneth et al., 1998; Dubey et al., 2008). The 
MAP, via its interaction with the microtubules, reduces the availability for motor 
molecules such as kinesin to bind the tubulin heterodimers. Therefore, it blocks 
the plus-end directed transport and, consequently, the retrograde transport is 
increased (Stamer et al., 2002). 
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1.1.3.3. Tau Regulation 
Tau activity is regulated by several post-translational modifications. 
Glycosylation, glycation and nitration sites have been found in the tau 
sequence, and tau truncation by caspases and calpain has been detected in AD 
and tauopathies. However the most studied and important regulatory 
mechanism for tau remains phosphorylation/dephosphorylation (Martin et al., 
2011).  
Tau phosphorylation. Tau phosphorylation regulates its interaction with the 
microtubules, and therefore, influences microtubule polymerisation, the 
outgrowth of neuronal processes and axonal transport Johnson and Stoothoff, 
2004; Cuchillo-Ibanez et al., 2008). A single phosphorylation of tau in the MBD, 
for instance on residues Ser262 and Ser356 alone, or on residue Thr231 in the 
proline-rich domain can inhibit tau interaction with microtubules (Biernat and 
Mandelkow, 1999; Fischer et al., 2009; Sengupta et al., 1998; Cho and 
Johnson, 2003). Dysregulation of tau phosphorylation is a common 
characteristic of tauopathies and tau associated diseases, and tau 
hyperphosphorylation promotes tau aggregation.  
Forty-five serines (Ser), 35 threonines (Thr) and 5 tyrosines (Tyr) have been 
identified as putative phosphorylation sites on tau (on the longest splicing 
isoform). Among these 85 sites, 45 have been shown to be phosphorylated in 
control and patients affected with AD (Hanger et al., 2009; Martin et al., 2011). 
Interestingly, most of the phosphorylation sites are found in the proline-rich 
domain and the C-terminus (Hanger et al., 2009).  
Tau kinases. Numerous kinases have been described to phosphorylate tau and 
can be divided into three classes: the proline-directed protein kinases (PDPK), 
the non-PDPKs and the tyrosine specific kinases (Hanger et al., 2009; Martin et 
al., 2011). Glycogen synthase kinase 3 (GSK3) and cyclin-dependent kinase 5 
(cdk5) play a major role in the phosphorylation of tau and have therefore been 
studied extensively, and together with the mitogen-activated protein kinases 
(MAPKs), c-Jun N-terminal kinase (JNK) and p38, are members of the PDPK 
family implicated in tau phosphorylation. MAP/microtubule-affinity regulating 
kinase (MARK), cAMP-dependent protein kinase (PKA), protein kinase C 
(PKC), dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), 
  Chapter 1 - Introduction 
  31 
calcium/calmodulin-dependent protein kinase II (CaMKII) and casein kinase 1 
(CK1) are examples of non-PDPKs involved in tau phosphorylation. The 
tyrosine specific kinases for tau belong to the SRC kinase family such as Src, 
Lck and Fyn. The specificity of each kinase and its importance in tau 
phosphorylation and regulation is not yet fully understood.  
GSK3. GSK3 is expressed as two isoforms, α and β, that are not redundant. 
GSK3 is a Ser/Thr kinase first described to be involved in the glycogen 
synthase pathway, but has since been implicated in a wide range of 
mechanisms such as cell signalling, embryogenesis, metabolic control and cell 
death. The constitutively active GSK3 kinase is regulated through 
phosphorylation. Indeed, phosphorylation at Ser9 and Ser21 inhibits GSK3β 
and GSK3α respectively, while phosphorylation at Tyr216 and Tyr279 increases 
GSK3β and GSK3α activity respectively (Johnson and Stoothoff, 2004; Hanger 
et al., 2009). Its overexpression in cells and upregulation of expression in 
transgenic mice enhances tau phosphorylation (Cho and Johnson, 2003; Lucas 
et al., 2001). On the contrary, lithium treatment, which inhibits GSK3 activity, 
reduces tau phosphorylation in cells and in mice (Lovestone et al., 1999; 
Caccamo et al., 2007).  
GSK3 alone cannot phosphorylate all the putative tau phosphorylation sites, 
and some of the GSK3 target residues must first be primed by primary 
phosphorylation of the substrate by other kinases. It is thought that the kinases 
cdk5 and DYRK1A may prime tau in order for GSK3 to phosphorylate tau (Li et 
al., 2006; Woods et al., 2001). Cdk5 activity is regulated by the activator p35 
and its cleaved form p25. Interestingly, cdk5 overexpression seems to decrease 
GSK3β activity, whereas its inhibition enhances GSK3β activity (Wen et al., 
2008). Almost all tau residues targeted by cdk5 are also phosphorylated by 
GSK3 and both have been reported to phosphorylate tau on Thr231, thus 
enhancing subsequent tau phosphorylation, reducing tau interaction with 
microtubules and promoting tau aggregation (Martin et al., 2011). It is 
interesting that a range of proteins are detected in NFTs. GSK3β and cdk5 
antibodies label NFTs, which further confirm their role in tau aggregation and 
aggregate formation (Duyckaerts et al., 2009). 
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Tau phosphatases. Tau is a substrate for protein phosphatases 1, 2A and 2B 
(PP1A, PP2A and B) and PP5, the expression of which are all decreased in AD 
thereby stabilising tau phosphorylation (Tian and Wang, 2002; Gong et al., 
1995; Martin et al., 2011). PP2A can directly bind tau and is the most important 
phosphatase for tau regulation. Its inhibition by okadaic acid (OA) induces the 
hyperphosphorylation of tau and upregulates several tau kinases such as cdk5 
or MAPK in neurons and rat brains (Tian and Wang, 2002).  
 
1.1.3.4. Tau aggregation 
Although the precise mechanism by which tau accumulates in NFTs remains 
unclear, its dephosphorylation/phosphorylation status is probably one of the first 
events. A precise balance between phosphorylation and dephosphorylation 
regulates tau activity and small changes in this equilibrium lead to tau 
hyperphosphorylation and aggregation. In AD, hyperphosphorylation of tau 
triggers its release from the microtubules. Following conformational changes, 
phosphorylated tau associates into anti-parallel stable dimers, which polymerise 
in β-sheet structures called protofilaments. Paired helical filaments (PHF) are 
composed of two twisted protofilaments, and in turn accumulate into NFT 
(Figure 1.3) (Martin et al., 2011). Tau accumulation in AD is limited to neurons. 
Besides the formation of NFTs, tau aggregates are found in dendrites as 
neuropil threads (NT), and decorate the corona of the Aβ neuritic plaques in 
structures called dystrophic neurites. The progression of NFT formation in AD 
patients’ brains is closely related to cognitive decline, and defines the six main 
stages of AD, called Braak stages (Duyckaerts et al., 2009). 
 
1.1.3.5. Tauopathies and tau associated neurodegenerative diseases 
Since the discovery of tau being the main component of NFTs in AD, several 
other diseases characterised by the neuropathological accumulation of tau have 
been described. Tau neuropathology has been secondarily implicated in AD, 
but is also a primary neuropathological feature for a group of diseases called 
“tauopathies”. The “tauopathies” describe a group of diseases where tau 
aggregation is the principal feature and is linked to neuronal loss, such as 
corticobasal dementia (CBD), frontotemporal dementia and parkinsonism linked 
to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP) and 
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Pick’s disease (PiD).  Other neurodegenerative pathologies exhibit tau 
aggregation, yet always associated with other pathological features, as is the 
case in AD, Myotonic dystrophy, Postencephalitic parkinsonism, Prion disorder 
and Down’s syndrome (Yancopoulou and Spillantini, 2003; Lee et al., 2001; 
Hernandez et al., 2008). 
 
Figure 1.3. Tau aggregation into NFTs. Tau is normally attached to the microtubules, 
but is released when hyperphosphorylated and forms anti-parallel dimers. Dimers form 
β-sheet protofilaments, which aggregate in twisted structures called PHFs. PHFs 
accumulate in bigger aggregates called NFTs. 
 
Frontotemporal dementia. Frontotemporal dementia (FTD), like AD, occurs in 
sporadic and familial forms. FTDP-17 is an inherited form of FTD, associated 
with tau mutations. Pathological features include severe neuronal loss, gliosis 
and atrophy of the frontal and temporal lobes. The discovery of mutations in tau 
in FTDP-17 demonstrated for the first time that tau alone could be a cause of 
neurodegeneration, and could thus induce neuron loss in other 
neurodegenerative diseases such as AD. 
FTDP-17 is characterised by a wide range of tau mutations, more than 40 of 
which have been described so far in over 80 different families (Goedert, 2004; 
Rademarkers et al., 2012). Missense, deletion and silent mutations in the 
coding region, but also mutations in the intronic region that alter the splicing of 
exon 10, have been described. The intronic mutations do not alter the coding 
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sequence of tau but lead to an increase in the ratio of the 4R tau isoforms 
compared to the 3R isoforms (Lee et al., 2001). Therefore, a simple imbalance 
between the ratio of the 3R and 4R isoforms can cause tau aggregation, which 
emphasises the fact that dysregulation of normal tau, like in AD, can lead to 
neurodegeneration. Missense mutations usually reduce tau capacity to promote 
microtubule assembly, although some of them are also responsible for 
alternative splicing of exon 10. The mutated protein tau is then found to 
aggregate in straight filamentous structures or PHF (Buee et al., 2000; Lee et 
al., 2001). The tau mutations P301L and P301S found in familial frontotemporal 
dementia are used in mice models for tau degeneration, as the characteristic 
feature of the 4R isoforms aggregated in filamentous structures associated with 
neuronal loss and gliosis are observed (Yancopoulou and Spillantini, 2003; 
Goedert, 2004, Schneider and Mandelkow, 2008).  
Tau-positive frontotemporal lobar degeneration, “PiD, PSP and CBD”. PiD, PSP 
and CBD are newly classified as tau-positive frontotemporal lobar degeneration 
(tau-positive FTLD) (Mackenzie et al., 2009). PiD is characterised by an atrophy 
of the frontotemporal lobe and limbic system associated with neuronal loss and 
gliosis, and like FTDP-17, is therefore also classified as causing FTD. Neurons 
are rounded, and exhibit tau-positive inclusions called Pick bodies. Interestingly, 
similarly to AD, tau aggregation occurs in the hippocampus, although in the 
granular cells rather than the pyramidal neurons (Lee et al., 2001). PSP and 
CBD seem to share common clinical and pathological features. PSP exhibits 
atrophy of the basal ganglia, subthalamus and brainstem, due to neuronal loss 
and gliosis. Similarly to AD, tau accumulates in NFTs and NT, yet filaments are 
straight and also occur in glial cells. Although PSP is not considered an 
inherited disease, a polymorphism in the splicing region between exon 9 and 10 
of the tau gene might promote the occurrence of the disease, at least in the 
Caucasian population (Buee et al., 2000; Lee et al., 2001). CBD is a rare 
neurodegenerative disorder, affecting the cerebral cortex and substancia nigra, 
with severe neuronal loss and gliosis, and characterised by tau filamentous 
inclusions in neurons and glial cells. Glial pathology includes tau plaques in 
astrocytes and tau-positive inclusions in the white matter. Both straight 
filaments and PHF are detected in tau accumulations. 
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In conclusion, the common feature of filamentous hyperphosphorylated tau in 
numerous degenerative disorders supports the crucial role for tau in 
neurodegeneration.  
 
1.1.4. Molecular mechanisms 
The molecular mechanism by which tau and Aβ influence one another’s toxicity, 
and the chronology of pathogenic events is beginning to emerge, as currently 
described by the Amyloid-β and GSK3 hypothesis. 
The Aβ hypothesis. It is thought that the β-amyloid accumulation precedes NFT 
formation. This is supported by several findings. First, the familial form of AD is 
caused by mutation of the PS gene, which enhances the formation of Aβ 
peptides. Moreover, most of the genes considered as a risk factor for LOAD 
have been linked to Aβ formation and clearance. Second, patients with Down’s 
syndrome develop an early form of AD, with amyloid deposits and NFTs. 
Down’s syndrome is caused by trisomy of chromosome 21, where the 
APP gene is located. FAD and Down’s syndrome patients develop tau 
pathology although the primary cause of the disease is directly related to APP 
processing (FAD) or APP expression levels (Down’s syndrome), thus 
emphasising the potential upstream role of APP in Aβ and tau pathology. Finally 
yet importantly, severe dementias such as FTDP-17, caused by tau mutations 
and aggregation, do not exhibit any amyloid-β deposits (Hardy and Selkoe, 
2002). Thus, tau aggregation as a primary cause of disease is never 
secondarily associated with Aβ accumulation. Recent findings have shown that 
while tau does not induce Aβ formation, the toxicity of Aβ in cultured cells and in 
animal models is mediated by tau and Fyn, a kinase involved in tau 
phosphorylation and recruitment to lipid rafts. Therefore, the amyloid and tau 
aggregation and neurotoxicity in AD would not be a linear event, but rather a 
deleterious cycle (Ittner and Götz, 2011).  
The GSK3 hypothesis. One of the most promising links between Aβ and tau 
accumulation are the kinases, including GSK3, cdk5, Fyn and CK1 (Ittner and 
Götz, 2011; Wen et al., 2008; Flajolet et al., 2007). For instance, the interplay 
between insulin, GSK3 and the Wnt signalling pathway might bridge APP and 
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tau processing. Both the insulin and Wnt signalling pathways inhibit GSK3. 
Briefly, insulin activates PI3 kinase (PI3K), which in turn enhances Akt activity. 
Akt phosphorylates GSK3 on Ser9 and Ser21 (for the β and α isoforms 
respectively) thereby inhibiting its activity. Conversely, in the canonical Wnt 
signalling pathway, GSK3β activity is inhibited upon binding of the Wnt ligand to 
its receptor complex (composed of frizzled and the low-density lipoprotein 
receptor related protein) by a mechanism that does not involve the inhibitory 
phosphorylation on Ser9. Thus, β-catenin, the downstream effector of the 
canonical Wnt signalling pathway, escapes GSK3β-mediated phosphorylation 
and ubiquitination, and translocates to the nucleus to activate transcription 
(Hooper et al., 2008; Hernandez et al., 2010). It has been shown that in primary 
neurons, the Aβ peptide acts as an antagonist of insulin, thus inhibiting PI3K 
and Akt activity, which would enhance GSK3 activity and tau phosphorylation 
(Townsend et al., 2007). Similarly, in cell culture, the Aβ peptide blocks the 
canonical Wnt signalling pathway, which would result in increased levels of 
active GSK3 and phosphorylated tau (Magdesian et al., 2008).  
Other mechanisms. The formation of NFTs and Aβ aggregations are not the 
only neuropathological features of AD. Mitochondrial deficiency, chronic 
neuroinflammation in the hippocampus, the activation of endoplasmic reticulum 
(ER) stress and the unfolded protein response (UPR), and defects in signalling 
pathways and cell cycle dysregulation have all been described (Crouch et al., 
2008; Hernandez-Ortega et al., 2011; Nijholt et al., 2011).  
In addition, aggregation of Aβ and tau are symptomatic of a dysregulation of the 
quality control of proteins. Indeed, molecular chaperones, the ubiquitin-
proteasome system (UPS) and autophagy are impaired or overwhelmed in AD 
and thus unable to reduce tau and Aβ accumulation. 
 
1.2. Protein misfolding and aggregation 
Protein homeostasis is exquisitely regulated in cells. Several steps are needed 
to ensure the correct folding of proteins from the native to the final folded 
conformation necessary for their function. A failure in this system can lead to 
misfolding, aggregation and eventually cell death. Newly synthesised proteins 
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are regulated by the housekeeping chaperones, which are also the first line of 
defence against misfolded proteins. 
 
1.2.1. Molecular chaperones in Alzheimer’s Disease 
The correct 3-dimensional conformation of a protein is necessary for its function 
and stabilisation, as most of the hydrophobic residues which would otherwise 
be exposed to the hydrophilic cytoplasmic environment, are buried within the 
protein (Frydman, 2001). Although nascent proteins contain all the information 
to fold correctly in vitro, in the crowded intracellular milieu, they require the 
assistance of chaperones, the guardian of the proteome. Chaperones are 
constitutively expressed, but are upregulated in the case of stress. The 
chaperones are therefore also called stress proteins, or Heat shock proteins 
(HSP) (Hartl and Hayer-Hartl, 2002). Until recently, they were essentially 
classified according to their molecular weight, but a new nomenclature has 
emerged, and describes 6 classes of proteins based on their gene structure: 
HSPA (HSP70), HSPB (small HSPs), HSC (HSP90), HSPH (HSP110), DNAJ 
(HSP40) and chaperonins (HSP60 and CCT) (Kampinga et al., 2009).  
Protein chaperones are responsible for the correct folding of proteins. Molecular 
chaperones are probably impaired or overwhelmed in neurodegenerative 
disorders, and their failure is the first step towards protein aggregation. Several 
inclusion bodies in neurodegenerative diseases are decorated with chaperones. 
Moreover, in cells, overexpression of chaperones often prevents aggregation, 
thus confirming that the HSPs and their co-factors play a crucial role in the 
regulation of misfolded proteins. 
In AD, Aβ plaques are decorated by several chaperones, including HSP70, 
HSP27, GRP78 and HSP90, while NFTs are labelled with HSP90 and HSP27 
(Muchowski and Wacker, 2005). In cells, both tau and Aβ are modulated by 
HSP70. HSP70 upregulation increases tau solubility and binding to the 
microtubules, and decreases its phosphorylation (Dou et al., 2003). HSP70 has 
been reported to reduce the toxicity of Aβ and its ability to aggregate (Luo et al., 
2010). The co-chaperone carboxy terminus of HSC70-interacting protein (CHIP) 
has been found to be upregulated in AD patients, with the levels of CHIP 
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inversely proportional to the levels of tau. In mice, CHIP has been shown to 
attenuate tau aggregation (Sahara et al., 2005). In cells, CHIP and other HSPs 
are able to interact with APP and to influence Aβ formation (Kumar et al., 2007). 
Therefore, the upregulation of chaperones and co-chaperones is thought to be 
neuroprotective. On the other hand, inhibition of HSP90 by geldanamycin 
reduces insoluble and phosphorylated tau. Geldanamycin disrupts the 
interaction of HSP90 with the transcription factor HSF1, thus promoting the heat 
shock response and the increased expression of HS proteins.  
 
1.2.2. Protein misfolding 
Protein misfolding increases dramatically after exposure to stress, such as heat-
shock or oxidative stress. When nothing can be done to repair or eliminate 
misfolded proteins, they tend to aggregate and cause numerous conformational 
protein diseases, including neurodegenerative diseases.  
Misfolding and aggregation. In non-pathological situations, misfolding can occur 
as large proteins (more than 100 aa) form a partially folded intermediate state 
prone to misfolding and aggregation, before reaching their optimal conformation 
(Kopito, 2000; Hartl and Hayer-Hartl, 2009). However, it can also be a 
consequence of various defects, including mutations in the protein sequence, 
impairment of the chaperone system, abnormal post-translational modifications 
and structural modifications induced by environmental changes. The misfolding 
of the protein is driven mainly by hydrophobic forces and often leads to self-
aggregation, in amorphous/globular or β-strand structures. The β-cross sheets 
are found in numerous diseases called amyloidosis, that includes AD and other 
neurodegenerative diseases. This type of association is extremely favourable 
for polymerisation and aggregation, and tends to form oligomers, protofibrils 
and fibrils. Oligomers are soluble, and often considered as the most toxic form 
of aggregation. Self-aggregation is exponential, and can also have dominant 
negative effects on the native protein, like the pathogenic form of prion protein, 
PrPsc, that converts the normal protein PrPc into misfolded aggregates (Moreno-
Gonzalez and Soto, 2011). 
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Inclusions. Aggregates are considered an abnormal localisation (extra or 
intracellular) of poorly soluble non-native proteins. Inclusions describe any 
aberrant intracellular accumulation of protein, without distinction of secondary or 
tertiary structures. In contrast, inclusion bodies refer to the large, low number of 
foci where aggregated proteins are sequestered (Kopito, 2000; Ross and 
Poirier, 2005). In the seeding/nucleation model of protein aggregation and 
inclusion formation in cells, the soluble oligomers or aggregates are considered 
as “seeds”. The first phase of the model, called the lag phase, consists of a 
slow and low production of oligomers or aggregates in “nuclei”. These nuclei 
“seed” the formation of polymers, which elongate in a fast exponential manner. 
From the seeding/nucleation theory, inclusions are the fast-growing forms of 
polymer formation (Kopito, 2000; Moreno-Gonzalez and Soto, 2011).  
Aggresomes. Microtubule-dependent inclusion bodies are called aggresomes. 
Aggresomes consist of the accumulation of aggregates at the microtubule 
organising centre (MTOC), located near the nucleus and the Golgi. Aggresomes 
are covered with vimentin or neurofilaments in neurons (Taylor et al., 2003). 
Depolymerisation of microtubules prevents the formation of aggresomes, but 
once formed, microtubule destabilisation does not disrupt the aggresome. 
Therefore, the aggresome is not a dynamic but a rather stable structure, 
thought to be protective by enhancing degradation (Kopito, 2000, Moreno-
Gonzalez and Soto, 2011). 
Quality control compartments. Juxtanuclear quality control (JUNQ) and 
insoluble protein deposit (IPOD) are two types of sequestration of misfolded 
proteins that differ by their intracellular localisation and association with protein 
clearance pathways. JUNQ refers to a compartment that interacts with the ER 
and preferably sequesters proteins that can be refolded or degraded by the 
UPS. Conversely, protein aggregated in the IPOD is not associated with either 
the UPS or chaperones, but with the autophagic protein Atg8. IPOD is thought 
to be the last of the two centres to form, when the insoluble protein is no longer 
able to be refolded or degraded by the UPS (Kaganovich et al., 2008). 
Cells possess several mechanisms that respond to the toxicity of aggregated 
proteins. Nevertheless, the formation of aggregates is primarily a consequence 
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of the failure of chaperone systems to correctly fold proteins coupled with the 
failure of protein degradation pathways that try to eliminate the misconformed 
proteins.  
 
1.2.3. Protein aggregation clearance  
Homeostasis of the proteome is meticulously regulated by chaperones and 
degradation pathways (Figure 1.4). The best-known degradation system is the 
UPS, described in detail in chapter 1.3, that modulates the elimination of short-
lived, misfolded or non-functional proteins. Misfolded proteins are first targeted 
by the UPS. However, due to its barrel-like shape, the proteasome needs the 
proteins to be partially or totally unfolded to enter the narrow cavity. Thus, in 
numerous pathologies associated with aggregate-prone proteins, once the 
protein starts to accumulate in a globular or β-sheet form, the UPS has been 
described to be impaired, overhelmed or unable to process them. Thus, 
aggregated proteins are targeted to the autophagy pathway. Lysosomal 
degradation is responsible for the degradation of long-lived proteins or 
organelles through autophagy, or exogenous elements through endocytosis and 
phagocytosis.  
Three types of autophagy have been described: Macroautophagy (usually 
referred as “autophagy”), CMA and microphagy. Most of the conformational and 
neurodegenerative diseases are associated with impairment of CMA and 
macroautophagy.  
Chaperone-mediated autophagy. Proteins than contain a lysine-phenylalanine- 
glutamic acid-arginine-glutamine (KFERQ) motif are specifically targeted by the 
chaperone HSC70/HSP70 to the lysosomes. The Lamp2a transmembrane 
protein of the lysosomes is a receptor for the CMA pathway. CMA is activated in 
normal conditions but is upregulated in conditions of stress, probably to recycle 
amino acids. CMA cannot degrade inclusions, and has therefore been 
described as “impaired” in several conformational diseases (Martinez-Vicente 
and Cuervo, 2007; Arias and Cuervo, 2011). 
Autophagy. Autophagy is referred to as “in bulk” degradation as it engulfs the 
substrate without specificity. Autophagy occurs in response to stress, such as 
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starvation or heat-shock, and is necessary to promote the recycling of non-
essential proteins and the degradation of misfolded proteins. Autophagy 
requires the formation of a double-membrane vesicular compartment called an 
autophagosome.  
 
 
Figure 1.4. Mechanisms of protein homeostasis. Nascent proteins/folding 
intermediates are targeted by chaperones for correct folding. If this system fails, 
proteins are targeted to the proteasome or degraded by chaperone-mediated 
autophagy (CMA). Impairment of the CMA and UPS induce autophagy. If not 
degraded, aggregates accumulate and form inclusions.  
 
The formation of autophagosomes involves the protein LC3/Atg8 and the 
complex Atg5/Atg12/Atg16, and requires a 3-step mechanism, similar to the E1, 
E2 and E3 cascade of ubiquitylation. Once formed, the autophagosome fuses 
with the lysosomes, allowing degradation of the substrate (Martinez-Vicente and 
Cuervo, 2007; Cheung and Ip, 2011).  
Cross-talking. It is thought that the UPS, CMA and autophagy are 
complementary mechanisms in the clearance of aggregates. Thus, misfolded 
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proteins are preferentially refolded by chaperones, degraded by the UPS or 
CMA. However, if these systems fail, autophagy is enhanced. Indeed, inhibition 
of the UPS and CMA enhances autophagy mechanisms (Martinez-Vicente and 
Cuervo, 2007; Cheung and Ip, 2011). Impairment of this last degradation 
mechanism would exacerbate aggregation and lead to inclusion formation 
(Figure 1.4). Some hypotheses are beginning to emerge concerning the 
mechanism by which aggregates induce autophagy. P62, a protein that is 
detected in several inclusion bodies in neurodegenerative diseases, has been 
shown to target ubiquitylated aggregates and promote autophagy (Pankiv et al., 
2007). The protein HDAC6, upon proteasome inhibition, co-localises with 
aggregated proteins and aggresomes and can trigger autophagy. Indeed, in a 
drosophila model of neurodegeneration, HDAC6 rescues neurodegeneration 
induced by UPS impairment via the activation of the autophagy pathway 
(Pandey et al., 2007). 
 
1.3. The ubiquitin-proteasome system 
In the 1970s, a new but highly conserved small protein was discovered that was 
involved in protein clearance: ubiquitin (Ub). Ub tags proteins for recognition by 
an efficient protein homeostasis regulator, the proteasome. Taken together, the 
UPS is, so far, the most important degradation system of the cell.  
 
1.3.1. The 26S proteasome 
The proteasome is an ATP-dependent machinery involved in protein 
degradation. The 26S proteasome is composed of a central core, the 20S 
subunit, and two 19S subunits at the top and bottom of the 20S core (Figure 
1.5). The 19S subunit is the regulatory unit of the 26S proteasome which, with 
its ATPase activity, unfolds proteins before they enter the catalytic 20S unit 
(Herrmann et al., 2007). The 19S subunit consists of a base and a lid. The base 
is composed of six ATPase units that form an hexameric ring, three non-
ATPase units and the proteasome subunit, non-ATPase, 4 (PSMD4, also called 
S5a) that recognises Ub and connects the base to the lid (Xie, 2010; Voges et 
al., 1999). The structure of the lid contains 13 regulatory non-ATPase subunits 
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(Lasker et al., 2012; Xie, 2010, Deveraux et al., 1994) and 6 regulatory AAA-
ATPases subunits (Lasker et al., 2012). The barrel-shaped 20S subunit is 
composed of two symmetrical heptameric rings, α and β. The two outer α rings 
are composed of 7 α-subunits, and are called the “gatekeeper”, opposed to the 
“catalytic core” made of the 2 inner heptameric β rings (Lasker et al., 2012; Xie, 
2010, Deveraux et al., 1994).  
The β rings possess 7 β subunits including the β5, β2 and β1 subunits with 
chymotrypsin-like, trypsin-like and peptidyl-hydrolase catalytic activity 
respectively, which catalyse the cleavage of the protein substrate into small 
peptides (Voges et al., 1999). 
 
1.3.2. Ubiquitin 
Ub is a small polypeptide of 76 aa (8.5 kDa). Ub is highly conserved from 
protozoa to vertebrates, and is essential to all eukaryotic cells. Ub is known for 
its role in targeting proteins for their proteasomal degradation, but also for its 
role in conformational regulation and cell signalling. Ubiquitylation (or 
ubiquitination) of proteins involves a cascade of three enzymes that conjugate a 
monomer or a chain of polyubiquitin (polyUb, 4 to 7) to the protein target 
Figure 1.5. Composition of the 
proteasome. The two regu-
latory 19S units consist of a 
base and a lid, connected 
through the PSMD4 subunit. 
The catalytic 20S unit pos-
sesses 2 outer “gatekeeper” α 
rings, and 2 inner “core” β 
rings. The α and β rings are 
composed of heptamers of α 
and β subunits respectively. 
The heptameric β rings contain 
the chymotrypsin-like, trypsin-
like and peptidyl-hydrolase 
catalytic units.  
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(Hershko and Ciechanover, 1998; Herrmann et al., 2007). First, the ubiquitin-
activating enzyme (E1) activates Ub for transfer to the ubiquitin-conjugating 
enzyme (E2) in an ATP-dependent manner. E2 transfers Ub to the ubiquitin-
ligase (E3), which covalently conjugates Ub to its target (substrate) (Figure 1.6).  
 
Figure 1.6. Ub conjugation pathway. Ub is bound to an E1 activating enzyme using 
ATP, then transferred to an E2 conjugating enzyme and finally to an E3 ubiquitin-
ligase. The E3 ubiquitin-ligase binds Ub to its substrate. The substrate is 
polyubiquitinated before its degradation by the proteasome. 
 
For the system to be efficient and specific, the number of different enzymes 
increases exponentially from E1 to E3. Indeed, only 2 isoforms of the E1 and 37 
genes coding E2 enzymes have been found in human so far, while several 
hundred of E3 have been discovered (Herrmann et al., 2007, Shang and Taylor, 
2011). E3 ligases are classified in two groups, based on their interaction with 
the substrate: the RING (really interesting new gene) domain and HECT 
(Homologous to E6-associated protein C terminus) type E3 ligases.  
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The number of Ub attached, but also the type of bond between the Ub 
monomers determines the pathway proteins are targeted for. Ub polymerises on 
its lysine residues. Ub possesses 7 lysine residues (K6, K11, K27, K29, K33, 
K48, K63), all thought to be involved in different mechanisms. For instance, if 
polyUb chains are linked by their lysine 48 (K48), the protein substrate will be 
targeted for proteasomal degradation. On the other hand, if polyUb are ligated 
via their lysine 63, the target protein will preferably be involved in regulatory 
functions such as signalling events (Shang and Taylor, 2011). 
Monoubiquitination can lead to a modification of the protein activity, but also to 
degradation (Herrmann et al., 2007). Therefore, Ub is now not only considered 
a crucial element of the protein degradation system, but also an active regulator 
of protein function and conformation. Mono or polyubiquitylation has been 
shown to be implicated in meiosis, DNA repair, translation, transcription, 
autophagy and endocytosis (Hicke, 2001).  
Ubiquitylation is a reversible mechanism, which involves proteins called 
deubiquitinating enzymes (DUBs). So far, genes coding for nearly 100 DUBs 
have been discovered in the human genome. DUBs can remove polyUb chains 
or monoubiquitin (MonoUb) from the target protein, but also hydrolyse Ub from 
unanchored polyUb chains (Reyes-Turcu and Wilkinson, 2009).  
 
1.3.3. Ubiquitin-proteasome system and neurodegeneration 
As a regulator of protein homeostasis, the UPS plays an important role in 
neurodegenerative diseases. Indeed, Ub is found to decorate inclusions which 
suggests that although Ub targets the misconformed and aggregated protein, 
the UPS fails to degrade them. Indeed UPS impairment has been reported in 
numerous neurodegenerative disorders, such as AD, Parkinson’s disease (PD), 
Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS) 
(Ciechanover and Brundin, 2003; Dennissen et al., 2012). In such cases, the 
question remains whether the UPS both contributes to and is a consequence of 
neurodegeneration. Importantly, a reduction of UPS activity is a natural process 
of ageing, although it is not considered as pathological but rather as a 
consequence of decreased protein synthesis (Low, 2011). In pathological 
conditions, particularly late onset neurodegenerative diseases such as AD and 
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PD, there is already a functional decline in proteasome activity, which may 
increase the vulnerability of neurons to the pathological insult and contribute to 
neuron loss and dementia (Ciechanover and Brundin, 2003; Dennissen et al., 
2012). 
Huntington’s disease (HD). HD is an autosomal dominant disorder, caused by 
abnormal repetition of the codon CAG at the N-terminus of the huntingtin gene. 
Therefore, the huntingtin protein (htt) exhibits a larger number of glutamine 
(polyQ) than usual, prone to aggregate. In patients with HD, the htt aggregates 
are decorated with ubiquitin, and in cells mutant htt has been reported to impair 
proteasome activity and exacerbate aggregation (Diaz-Hernandez et al., 2006; 
Ciechanover and Brundin, 2003). 
Parkinson’s disease (PD). PD is the second most common form of dementia 
after AD. A deficiency in the catalytic subunits of the 26S proteasome has been 
reported in the sporadic form of PD. Moreover, mutations in parkin, an E3 
ubiquitin-ligase, cause autosomal recessive juvenile parkinsonism (AR-JP) 
(Ciechanover and Brundin, 2003; Chaugule et al., 2011). The ubiquitin-carboxy-
terminal hydrolase (UCH-L1), a deubiquitinating enzyme, if mutated on its 
isoleucine 93 residue, causes parkinsonism (Ciechanover and Brundin, 2003; 
Andersson et al., 2011). Therefore, the UPS components parkin and UCH-L1 
are directly implicated in neuropathogenesis in these cases, underlying the 
importance of the UPS in neurodegeneration. 
Alzheimer’s disease (AD). In the brains of patients with AD, an impairment of 
the UPS has been reported in areas related to dementia and the accumulation 
of senile plaques and NFTs, including the hippocampus (Keller et al., 2000). 
Indeed, Aβ peptides and PHFs have been reported to inhibit proteasome 
activity (Oddo, 2008). NFTs and senile plaques are labelled by the UBB+1 
mutant of Ub. UBB+1 is generated by molecular misreading of the Ub gene, 
which produces an aberrant frameshifted Ub mRNA due to dinucleotide 
deletions (Chadwick et al., 2012). Thus, the UBB+1 mutant lacks the Gly 76 and 
possesses 19 aa more than Ub, and can form polyUb chains that cannot be 
depolymerised by DUBs and might inhibit proteasome activity (Chadwick et al., 
2012; Upadhya and Hegde, 2007). Moreover, the deubiquitinating enzyme 
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UCH-L1 is downregulated in AD. UCH-L1 is abundantly expressed in neurons, 
and is involved in normal synaptic functions (Andersson et al., 2011). In double 
transgenic mice APP/PSEN (with APP and PS mutations), UCH-L1 rescues the 
decline of synaptic function and contextual memory (Riederer et al., 2011). An 
interesting new partner of the proteasome, ubiquilin-1, is also involved in AD. 
Ubiquilin-1 contains a ubiquitin-like (UBL) domain that binds the PSDM4 subunit 
of the 19S proteasome, and a ubiquitin-associated (UBA) domain that interacts 
directly with Ub and targets polyubiquitinated proteins. A single-nucleotide 
polymorphism downstream the exon 8 of the UBLQN1 gene has been reported 
to be a risk factor for LOAD (Bertram et al., 2005). However, this remains 
controversial (Smemo et al., 2006). Moreover, ubiquilin-1 can interact with both 
APP and PS, and modulate APP trafficking to the plasma membrane (2010, 
Haapasalo et al., 2010). Finally, the levels of the co-chaperone and E3 
ubiquitin-ligase CHIP have been shown to be inversely proportional to tau levels 
in AD brains (Sahara et al., 2005; Riederer et al., 2011). CHIP, an E3 Ub ligase 
for tau ubiquitination and degradation, interacts with tau phosphorylated by 
GSK3β.  
In summary, defects in the UPS system have been implicated in 
neurodegenerative disorders at multiple and complex levels.  
 
1.4. NUB1 and the ubiquitin-like modifiers  
Besides Ub, new small proteins have been implicated in marking proteins for 
proteasomal degradation. The ubiquitin-like modifiers (ULM) share sequence 
homology with Ub, yet the biggest similarity is in the tertiary structure and 
mechanism of conjugation to target proteins. The ULM family includes various 
proteins such as SUMO, ISG15, FUB, Atg8/LC3, and Atg12, involved in a wide 
range of mechanisms from DNA transcription to autophagy (Herrmann et al., 
2007). Among the ULMs, NEDD8 and FAT10 target proteins for degradation 
and are shuttled to the proteasome by the NEDD8 ultimate buster 1, NUB1.  
NEDD8 is a small molecule of 81 aa that is most similar to Ub, with 60% identity 
and 80% homology. One the other hand, the two UBL domains of FAT10 at the 
N-terminus and C-terminus share only 29% and 36% identity with Ub 
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respectively (Lim et al., 2006). However, the tertiary structures of Ub, NEDD8 
and the two UBL domains of FAT10 are very similar. They are all composed of 
2 β-strands, a large α-helix and α-loop, and the characteristic β-strand-α-loop-β-
strand motif (Figure 1.7). 
 
Figure 1.7. Tertiary structure of Ub and the ULM NEDD8 and FAT10. For each protein, 
the three dimensional (3D) structure is represented by a rainbow, from dark blue at the 
N-terminus to red at the C-terminus. Ub, NEDD8 and the two UBL of FAT10 are 
composed of (1) β-strand, (2) β-strand, (3) α-helix, (4) α-loop, (5) β-strand, (6) α-loop, 
(7) β-strand. The 3D structures were obtained from the aa sequence using the protein 
fold recognition server, PHYRE2, freely available on www.sbg.bio.ic.ac.uk/phyre2/ 
(Kelley and Sternberg, 2009). 
 
1.4.1. The ubiquitin-like modifier NEDD8 
1.4.1.1. NEDD8 conjugation  
NEDD8 is a ULM first discovered as the neural precursor cell expressed 
developmentally downregulated 8 (NEDD8) (Kumar et al., 1992). Despite its 
significant homology to Ub, NEDD8 requires a specific set of E1, E2 and E3 
enzymes to be conjugated to proteins (Figure 1.8).  
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NEDD8 is first processed by the E1-activating enzyme NAE (NEDD8 activating 
enzyme), composed of a heteromer of the amyloid precursor protein-binding 
protein 1 (APP-BP1) and Uba3. The second step is the transfer of NEDD8 to 
the E2 conjugating enzyme Ubc12. Several E3 ligases have been described for 
NEDD8, including Rbx1, Rbx2, Mdm2, SCFFBX011 and DCN1, all of which are 
RING finger domain E3 ligases with the exception of DCN1 (Watson et al., 
2011). It is generally accepted that only one molecule of NEDD8 is covalently 
attached to its targets, yet NEDD8 is able to form chains on lysine 11, 22 and 
48. Moreover, formation of mixed Ub and NEDD8 chains have been found, but 
their function is unknown (Jones et al., 2008). 
  
Figure 1.8. NEDD8 conjugation pathway. NEDD8 is conjugated to its substrates via 
the APP/BP1-UBA3 E1 activation enzyme, Ubc12 E2 conjugation enzyme and an E3 
ligase. Its best characterized target is the CRLs, E3 ligases that ubiquitylate and target 
proteins for their proteasomal degradation. The cell-cycle regulator β-catenin is an 
example of protein targeted for ubiquitylation by the CRL.  
 
The conjugation of NEDD8 to a protein is called neddylation and is reversible. 
The COP9 signalosome (CNS) is a protein of 8 subunits, highly similar to the lid 
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component of the 19S proteasome, which deneddylates proteins via a 
metalloproteinase activity (Wei and Deng, 2003). Moreover, as DUBs exist for 
Ub, deneddylating enzymes have been found, such as NEDP1 (Shen et al., 
2005). Furthermore, NEDD8 is regulated by NUB1, which targets NEDD8 and 
its conjugates for proteasomal degradation (Kamitani et al., 2001) 
 
1.4.1.2. NEDD8 targets  
The primary function of NEDD8 is to regulate the activity and degradation of 
proteins. Through the regulation of cullins, Mdm2/p53 and BCA3/NF-κB, 
NEDD8 is directly or indirectly involved in numerous pathways, including 
modulation of the cell cycle, DNA repair, tumor progression and proteasomal 
degradation. 
The cullin subunit. Contrary to Ub, the first role discovered for NEDD8 
conjugation is to regulate protein function. The first and best characterised 
target protein for neddylation is the cullin subunit of the cullin-RING E3 
ubiquitin-ligases (CRLs). The CRLs are the largest Ub E3 ligase family, involved 
in the regulation of numerous cellular processes, including gene transcription, 
cell signalling and cell cycle progression. The cullin proteins serve as a scaffold 
for different CRLs, for example cullin 1 (CUL1) in the SCF (Skp1-Cullin-F-box) 
complex. Neddylation of CUL1 induces the activation of the SCF, which, in turn, 
induces the degradation of numerous cell cycle activators. In the SCF, CUL1 
binds a RING finger protein Rbx at its C-terminus, a docking site for E2 
conjugating enzymes, while its N-terminus interacts with the Skp1/F-box 
complex, necessary for substrate recognition. It thereby brings the Ub on the 
Rbx E2 in close proximity to the substrate within the Ub CRL. Therefore, the 
Rbx plays a double role, it promotes the neddylation of cullins, but also binds 
the Ub E2 conjugating enzyme (Merlet et al., 2009). The SCF is a well known 
E3 ligase for the NF-κB inhibitor IκB, necessary for its ubiquitination and 
degradation. Therefore, by promoting the CUL1 activity, NEDD8 positively 
modulates NF-κB transcriptional activities. However, a new target for NEDD8 is 
the protein BCA3 (involved in breast cancer) which, upon neddylation, inhibits 
NF-κB transcriptional activities. Thus, NEDD8 could also downregulate NF-κB 
(Gao et al, 2006).  
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The other cullin family members are specific scaffold proteins of different E3 Ub 
ligase complexes (Merlet et al., 2009). Interestingly, NEDD8 conjugation is 
necessary for cullins to be fully functional and recognise E2 enzymes. 
Furthermore, neddylation can also prevent the inhibition of cullins by the cullin-
associated and neddylation dissociated-1 (CAND-1). Indeed, CAND-1 normally 
disrupts the association between Skp1 and CUL1, thus preventing the formation 
of the SCF, but neddylation of the CUL1 inhibits CAND-1-mediated dissociation 
of CUL1 with Skp1 (Liu J et al., 2002). 
Other targets. Another interesting target for neddylation is the Mdm2/p53 
complex. Upon stress, p53 is activated resulting in the transcription/translation 
of several proteins involved in cell growth arrest and apoptosis. The oncogene 
Mdm2 is an E3 ligase that directly interacts with p53 and promotes its 
ubiquitylation and degradation. Recently, Mdm2 has been shown to induce 
neddylation of both p53 and itself, which stabilises Mdm2 and inhibits the 
transcriptional activity of p53 (Xirodimas et al., 2004; Xirodimas, 2008; Watson 
et al., 2011).  
NEDD8 also targets both the C99 fragment and the AICD of APP. These 
findings directly implicate neddylation in APP processing and function.  
NEDD8 in neurodegeneration. NEDD8 has been detected in numerous 
inclusions in neurodegenerative diseases, including NFTs and senile plaques in 
AD, Lewy bodies in PD, and Pick bodies in PiD (Dil Kuazi et al., 2003). 
Neddylation of the C99 and AICD fragments of APP blocks AICD interaction 
with Fe65 and AICD transcriptional activity (Lee MR et al., 2008). Although the 
role of AICD is not fully understood, AICD is thought to form a complex with 
Fe65 and TiP60 and to regulate gene expression, including p53, GSK3β and 
caspases 3 and 6. Thus, AICD has been shown to induce apoptosis in cells, 
and to be involved in synaptic plasticity and cytoskeleton dynamics (Muller et 
al., 2008) 
Neddylation is activated by the APP-BP1/Uba3 E1 enzyme. APP-BP1 interacts 
directly with the C-terminal domain of APP and downregulates Aβ42 formation 
probably via promoting the degradation of the C-terminal fragment of the PS 
component of the APP γ-secretase (Chen et al., 2007). APP-BP1 is also 
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implicated in cell-cycle regulation. Indeed, APP-BP1 depletion in fetal neural 
cells blocks the cells in G1 phase, and in neurons mediates the S-M phase 
transition and promotes apoptosis (Joo et al, 2010; Chen et al., 2000). NEDD8, 
through regulation of the CRL, is also involved in cell-cycle regulation, 
downregulating several targets of the SCF. Indeed, homozygous mutation of 
Uba3, that lacks the catalytic subunit of the NEDD8 activating enzyme, was 
lethal in mice. Embryo analysis showed that cells could not enter the S-phase, 
exhibited upregulation of cyclin E and p57, and accumulation of β-catenin, a 
well known target of SCF (Tateishi et al., 2001). Notably, β-catenin is the 
downstream effector of GSK3β in the canonical Wnt signalling pathway, 
modulation of which is central to the GSK3β hypothesis that links Aβ and tau 
neurotoxicity. In summary, cell cycle dysregulation is a pathological feature of 
AD, and the NEDD8 pathway could be an integral part of this dysregulation. 
 
1.4.2. The ubiquitin-like modifier  FAT10 
The F-adjacent transcript 10 (FAT10) is an 18 kDa ULM. It is a small protein of 
165 aa, composed of 2 UBL domains joined in a head-to-tail fashion separated 
by a short linker, which originally gave it the name of Ubiquitin D or di-ubiquitin 
like protein. Unlike NEDD8 and other ULM, the FAT10 conjugates and enzymes 
are not fully known. The E1 activating enzyme for FAT10 is UBA6, followed by 
the UBA6-specific E2 enzyme (USE1) as an E2 conjugating enzyme. 
Interestingly, USE1 is auto-FAT10ylated (Aichem et al., 2010). Another potential 
E1 activating enzyme for FAT10 is E1-L2, which is found to activate both Ub 
and FAT10 (Chiu et al., 2007).  
FAT10 expression and function. FAT10 is constitutively active in mature B cells 
and can be induced by interferon-γ or tumour necrosis factor-α (Liu YC et al., 
1999). Interestingly, FAT10 can directly interact with the 26S proteasome, via its 
UBL domains (Schmidtke et al., 2006). Like NEDD8, NUB1 binds FAT10 and 
accelerates its degradation by the proteasome (Hipp et al., 2004). Moreover, 
NUB1 is necessary for FAT10 degradation by the proteasome (Schmidtke et al., 
2009). Thus, along with NEDD8, FAT10 is a new marker of Ub-independent 
proteasomal degradation via the recruitment of NUB1. 
Although its functions are not fully understood, FAT10 is upregulated in various 
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cancers and it can induce apoptosis. FAT10 interacts with MAD2, a spindle-
assembly checkpoint protein, and the FAT10 levels are cell-cycle dependent. 
FAT10 is therefore probably involved in cell cycle regulation (Raasi et al., 2001; 
Lim et al., 2006). Moreover, FAT10 is downregulated by the tumor suppressor 
p53 (Zhang et al., 2006). However, its relationship with p53 is unclear, as a 
recent study by Li et al, 2011, showed that p53 is FAT10ylated, which modifies 
p53 transcriptional activity. Another potential target for FAT10 is NF-κB. Gong 
et al, 2010, suggests that FAT10 mediates the TNFα-dependent activation of 
NF-κB reducing its transcriptional activities. 
Recently, FAT10 has been shown to interact with HDAC6, a protein involved in 
aggresome formation and activation of autophagy, following inhibition of the 
proteasome. Moreover, FAT10 co-localised with the aggresomes, thus 
suggesting that FAT10 is a regulator of protein aggregation/degradation 
(Kalveram et al., 2006). This correlates with a new study by Nagashima et al, 
2011, who found that FAT10 deficiency in cells enhanced the aggregation of 
polyQ proteins. Therefore, accumulation of FAT10 in aggresomes upon 
proteasome inhibition and interactions with polyQ proteins reveals new 
regulatory functions for FAT10/NUB1.  
 
1.4.3. NUB1 
The NEDD8 ultimate buster 1 (NUB1) targets NEDD8 and FAT10 as well as 
neddylated and FAT10ylated proteins for proteasomal degradation. 
NUB1 structure. The 601 aa protein has one UBL domain at the N-terminus, 
and two UBA domains at the C-terminus as an integral part of its structure. A 
naturally occurring longer splicing isoform, NUB1L, contains an insertion of 14 
aa that completes the C-terminal half of a second UBA domain in NUB1L 
(Figure 1.9). Moreover, NUB1 has one PEST domain at the C-terminus, and a 
bipartite nuclear localisation signal (NLS) between residues 414-431 (Figure 
1.9).  
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Figure 1.9. NUB1 and NUB1L structure. NUB1/NUB1L have a UBL domain at the N-
terminus. With an insertion of 14 aa, NUB1L exhibits one extra UBA than NUB1 at the 
C-terminus. The predictive NLS (from aa 414 to 431) overlaps with the second UBA 
domain in NUB1L. 
 
 
Although the UBA domains are necessary to bind FAT10, NUB1 interacts with 
NEDD8 via the PEST domain, between residues 536 and 584 (Schmidtke et al., 
2006; Kamitani et al., 2001). No major functional differences between NUB1 
and NUB1L have been detected, with the exception that NUB1L interacts more 
strongly with NEDD8 compared to NUB1 (Tanaka et al., 2003). Interestingly, 
NUB1 and NUB1L have a greater affinity for FAT10 than NEDD8 (Hipp et al., 
2004). 
NUB1 belongs to the UBL/UBA family proteins. Although not much is known 
about the UBL and UBA domains of NUB1, the UBA and UBL domains, by 
definition, are closely related to the UPS system, and more generally to the 
regulation of protein homeostasis. 
 
1.4.3.1. The ubiquitin-associated domain 
The ubiquitin-binding domains (UBD) encompass a vast number of interacting 
motifs for Ub, that occur in a large diversity of proteins, which are involved in a 
variety of processes including proteasomal degradation, deubiquitylation, 
endocytosis, signalling and DNA repair. The UBA domain was one of the first 
UBD to be discovered, using bioinformatic methods, in proteins that bind mono 
or polyUb (Hicke et al., 2005). The UBA is a small domain of about 40 aa, 
formed by 3 α-helices. It is very similar to another UBD, the coupling of Ub 
conjugation to endoplasmic reticulum degradation domain (CUE) (Buchberger, 
2002; Dikic et al., 2009). Multiple UBA domains can be found within a protein, 
and the UBA domain often occurs in association with other UBDs or the UBL 
domain (Hicke et al., 2005). The UBA domains are very variable in their 
interaction with Ub, and have led to a suggested classification of UBA domains: 
selective interaction with K48 (class I) or with K63 (class II) polyUb, no 
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interaction with Ub (class III) or interaction with polyUb with no linkage 
preference (class IV) (Raasi et al., 2005; Hurley et al., 2006).  
UBA domain proteins and neurodegeneration. Several proteins with a UBA 
domain are important in neurodegenerative disorders. The protein E2-25K is a 
small E2 conjugating enzyme (25 kDa) that can interact with huntingtin (htt), 
and is therefore also called huntingtin interacting protein 2 (Wilson et al., 2009). 
In cells expressing the htt polyQ mutant, E2-25K enhances aggregate formation 
and cell death (de Pril et al., 2007). The function of the UBA domain is not fully 
understood, but probably contributes to the formation of the Ub binding surface 
(Wilson et al., 2009). E2-25K is highly expressed in the brain, and has been 
associated with AD. The UBA domain seems to be involved in E2-25K 
interaction with the UBB+1 Ub mutant, which accumulates in AD. Indeed, E2-
25K triggers the capping of unanchored polyUb chains with the UBB+1 mutant, 
which inhibits the proteasome activity (Chadwick et al., 2012; Song and Jung, 
2004). Moreover, E2-25K is upregulated in AD and in neurons exposed to Aβ 
peptide, where E2-25K would enhance Aβ toxicity (Song et al., 2003). 
P62 or sequestosome 1 (SQSTM1) is a 440 aa protein that encompasses a 
UBA domain at its C-terminus and several other domains, including a PB1 and 
TBS domain that are implicated in signal transduction. P62 is involved in the 
regulation of protein homeostasis through proteasomal degradation and 
autophagy induction. P62 selectively binds K63 polyubiquitylated proteins via its 
UBA domain, and interacts with the proteasome via its N-terminus to target 
proteins for proteasomal degradation (Geetha and Wooten, 2002; Salminen et 
al., 2012). P62 decorates numerous inclusion bodies in neurodegenerative 
diseases, including PiD, PD, Frontotemporal lobar degeneration with TDP43 
positives inclusions (FTDP-TDP43), spinocerebellar ataxias, AD and ALS 
(Kuusisto et al., 2001; Mizuno et al., 2006). In a mouse model of HD, p62 levels 
are increased and related to an early activation of autophagy (Heng et al., 
2010). Interestingly, p62 KO mice exhibit accumulation of hyperphosphorylated 
tau and NFTs that lead to synaptic dysfunction, neuron loss and deficiency of 
working memory (Wooten et al., 2008). Moreover, p62 loss clearly increased 
the levels of GSK3β, Akt and MAPK. Indeed, p62 seems necessary for the 
proteasomal degradation of tau, and tau aggregates in p62 deficient mice are 
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K63 polyubiquitylated (Babu et al., 2005; Wooten et al., 2008).  
 
1.4.3.2. The ubiquitin-like domain   
Along with UBDs, another motif, the UBL domain, is commonly found in 
numerous proteins. Proteins with a UBL, called UBL-domain proteins (UDPs), 
are implicated in diverse cellular functions, including degradation, 
deubiquitination, transcription and dephosphorylation (Hartmann-Petersen and 
Gordon, 2004).  
In contrast to the UBA domain, the UBL domain is less well characterised. The 
UDPs also often possess a UBD. One of the characteristics of the UBL domain 
is to directly bind the proteasome. A proteasome interacting motif (PIM) can be 
found in a group of UDPs (such as Parkin), but other UDPs that can bind the 
proteasome do not exhibit a PIM (including Rad23). UDP functions, however 
numerous, are mostly related to the proteasome and protein homeostasis 
(Hartmann-Petersen and Gordon, 2004). Thus, through their role in the 
regulation of protein levels, several UDPs have been implicated in 
neurodegenerative disorders, including Bag-1, Parkin and Sacsin. 
UBL domain proteins and neurodegeneration: Bag1. The Bcl-2-associated 
athanogene 1 (Bag1) is an HSC70/HSP70 co-chaperone (Hartmann-Petersen 
and Gordon, 2004). Bag1 can bind the proteasome via a UBL domain at the N-
terminus, and a BAG domain at the C-terminus is important for its interaction 
with HSC70/HSP70. Bag1 stimulates the release of substrate from 
HSC70/HSP70 and associates with the E3 ligase CHIP (Demand et al., 2001). 
Bag1 therefore links the protein folding chaperone system with the protein 
degradation system. Bag1 is involved in neuronal differentiation and 
neurodegenerative diseases including HD and AD (Kermer et al., 2002; Sroka 
et al., 2009, Elliott et al., 2009). In HD, Bag1 accumulates in inclusion bodies 
and is protective against htt toxicity in vitro (Jana and Nukina, 2005). In AD, 
Bag-1 co-localises and co-immunoprecipitates with tau and APP (Elliott et al., 
2009). Moreover, the Bag1-M isoform is upregulated in AD patients compared 
to control patients. Interestingly, although Bag-1 has been shown to assist 
proteasomal degradation of misfolded proteins, in cells, Bag1 seems to inhibit 
tau proteasomal degradation via its association with HSC70/HSP70 (Elliott et 
  Chapter 1 - Introduction 
  57 
al., 2007).  
Parkin. Parkin is a UDP protein mostly known for its role in PD. Mutation of 
Parkin causes AR-JP. Parkin exhibits a UBL at the N-terminus and a RING-
finger box at the C-terminus. The UBL domain of Parkin binds the PSDM4 
subunit of the proteasome and is important for auto-regulation of its own levels 
(Safadi et al., 2011; Sakata et al., 2003; Finney et al., 2003). Interestingly, some 
mutations of Parkin that cause AR-JP are found in the UBL domain itself, and 
disrupt the interaction with the proteasome. As an E3 ligase, Parkin 
ubiquitinates several proteins, including a modified form of α-synuclein and itself 
(Shimura et al., 2001). Parkin is involved in synaptic function and mitochondrial 
regulation (Finsterer, 2011). Parkin targets the degradation of mitochondria by 
autophagy (mitophagy) via the recruitment of p62 and HDAC6 (Lee, JY et al., 
2010; Plowey and Chu, 2011). Interestingly, in cells, Parkin has been shown to 
interact with Aβ, reduce its levels, reverse the inhibition of the proteasome and 
therefore promote cell survival (Burns et al., 2009; Rosen et al., 2010).  
Sacsin. Sacsin is a large protein of 4579 aa, containing a UBL domain at the N-
terminus and a J-domain at the C-terminus. Sacsin mutations cause the 
neurodegenerative disorder autosomal recessive spastic ataxia of Charlevoix-
Saguenay (ARSACS). The UBL domain of Sacsin binds the proteasome and 
Sacsin has been shown to reduce ataxin-1 aggregation (Parfitt et al., 2009).  
 
1.4.3.3. UBL/UBA domain proteins and neurodegeneration 
UBL/UBA proteins were first described in yeast, as proteasome substrate 
carriers. The yeast proteins Rad23 and Dsk2 interact with the 26S proteasome 
via their UBL domain, and more precisely with the Rpn10 (PSMD4 in human) 
subunit of the 19S proteasome (Hartmann-Petersen and Gordon, 2004). The 
equivalent human proteins hHR23A and B for Rad23 and Ubiquilin-2/PLIC-2 for 
Dsk2 also interact with the proteasome, and surprisingly with each other (Figure 
1.10) (Kang et al., 2007).  
hHR23A and B. The hHR23A/B proteins possess a UBL domain at the N-
terminus, and two UBA domains at the C-terminus. The UBA domains interact 
with monoUb and polyUb with different affinity and preference. Besides protein 
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degradation, hHR23A/B has been implicated in DNA nucleotide excision repair 
(Chen and Madura, 2006). Recently, the proteins hHR23A/B have been shown 
to interact with the wild-type and mutant protein ataxin-3 (atx-3). Aggregation of 
atx-3 via an expanded polyQ tail causes the neurodegenerative disorder 
spinocerebellar ataxia type 3 (SCA-3).  
 
Figure 1.10. UBL/UBA proteins. The three proteins hHR23A/B, Ubiquilin-1/2 and 
NUB1/NUB1L possess a N-terminal UBL domain and one or several C-terminal UBA 
domains, that predict a role in proteasomal degradation. Ubiquilin-1/2 and hHR23A/B 
also exhibit one or two STI domains, characteristic of co-chaperone proteins, which 
interact with HSPs. PEST: regions rich in proline, glutamate, serine, and threonine; ZZ: 
zinc finger domain; TB: TRAF6 bindng domain; LIR: LC3 interacting region. 
 
In cells, hHR23A/B both interact with atx-3 via their UBL domains, and hHR23A 
co-localises with aggregated atx-3 (Wang et al., 2000; Reina et al., 2010). 
Ubiquilin protein family. The study of Ubiquilin-2 (PLIC-2 or UBQLN2) led to the 
discovery of another isoform, Ubiquilin-1 (also called PLIC-1 or UBQLN1), both 
of which are involved in neurodegeneration. A third isoform, Ubiquilin-3 (or 
UBQLN3), seems to be expressed only in the testis (Conklin et al., 2000). The 
Ubiquilins have one N-terminal UBL domain and one C-terminal UBA domain. 
Both Ubiquilin-1 and -2 can interact with the proteasome via their UBL domain, 
and with Ub via their UBA domain. Therefore, a potential role for these proteins 
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is the shuttling of ubiquitylated proteins to the proteasome (Kleijnen et al., 2000; 
Ko et al., 2004).  
Another role of Ubiquilins is to regulate autophagy. Upon starvation, cells with 
depletion of Ubiquilins are sensitized to cell death (N’Diaye et al., 2009). Both 
Ubiquilins have been shown to regulate receptors, but not in the same 
pathways. Ubiquilin-1, via its UBA domain, interacts with the GABAA receptor 
and regulates its trafficking through the ER (Saliba et al., 2008). On the other 
hand, Ubiquilin-2, via its UBL and UBA domains, downregulates the 
endocytosis of G-protein coupled receptors (N’Diaye et al., 2008). In addition, 
both Ubiquilin-1 and -2 are implicated in aggresome formation and 
neurodegeneration, although not always for the same disorders. For instance, 
they have both been shown to accumulate with polyQ inclusions in a cell model 
and mouse model of HD (Doi et al., 2004). However, if Ubiquilin-1 has been 
shown to be involved in AD, Ubiquilin-2 has mostly been implicated in ALS. 
Several studies links Ubiquilin-1 and AD, via the regulation of both PS and APP. 
A yeast-two hybrid analysis demonstrated that Ubiquilin-1 interacts with both 
PS1 and PS2 (Mah et al., 2000). Interestingly, overexpression of Ubiquilin-1 in 
cells induces PS2 accumulation, probably by facilitating protein synthesis (Mah 
et la., 2000). Similarly, ectopic expression of Ubiquilin-1 has been shown to 
increase the high molecular weight form of PS1 and to trigger its accumulation 
in aggresomes, without altering the γ-secretases activity (Wiswanathan et al., 
2011). In this study, they propose that Ubiquilin-1 targets ubiquitinated PS1 
either for proteasomal degradation or aggresome accumulation. Moreover, 
Ubiquilin-1 downregulation in cells increased the maturation of APP, its 
trafficking to the plasma membrane, the secretion of sAPP (α and β) and the 
formation of Aβ40 and Aβ42. As the down-regulation of Ubiquilin-1 did not affect 
the activity of α, β and γ-secretases activity, they suggest that Ubiquilin-1 is a 
“gate-keeper,” a trafficking factor which, in co-operation with PS for instance, 
might regulate the APP secretory pathway (Hiltunen et al., 2006). In addition, 
NFTs from AD patients and Lewy bodies from PD patients were both positive 
for Ubiquilin-1 (Mah et al., 2000). Following these results, a single nucleotide 
polymorphism (SNP) in the UBQLN1 gene that resulted in an alternative 
splicing of the gene lacking the exon 8 was suggested to be a risk factor for late 
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onset AD (Bertram et al., 2005). However, this hypothesis remains controversial 
(Slifer et al., 2006). Apart from AD, Ubiquilin-1 may be implicated in ALS. The 
UBA domain of Ubiquilin-1 were suggested to be involved in recruitment of 
TDP-43 to aggresomes and activation of autophagy, while a mutant form of 
TDP-43 asociated with sporadic ALS was no longer able to bind Ubiquilin-1, 
which reduced their association in aggregates (Kim et al., 2009). 
Besides its potential involvement in polyQ diseases, Ubiquilin-2 interacts with 
and recruits Eps15 to aggresomes via its UBL domain (Regan-Klapisz et al., 
2005). However, Ubiquilin-2 is mostly known for its role in ALS. Indeed, recent 
studies have demonstrated that mutations in the Ubiquilin-2 gene cause ALS 
(Deng HX et al., 2011). A total of about 2% of cases of familial ALS (FALS) 
harbored a mutation in the C-terminus of Ubiquilin-2, but none were in the UBA 
or in the UBL domain. Ubiquilin-2 positive inclusions were found in the spinal 
cord of FALS patients but also in patients with sporadic ALS. Furthermore, 
Ubiquilin-2 positive inclusions were found in the hippocampus of ALS patients 
with dementia, but not in patients without dementia. Although further studies are 
necessary, Ubiquilin-2 is probably an important new factor in ALS and dementia 
(Deng HX et al., 2011; Daoud and Rouleau, 2011). Recently, inclusions from 
various neurodegenerative disorders were positive for Ubiquilin-2, including 
Lewy bodies in PD and dementia with Lewy bodies, and in six different polyQ-
associated pathologies, which suggests a wider role for Ubiquilin-2 in 
neurodegeneration (Mori et al, 2012). 
 
1.4.3.4. The UBL/UBA domain protein NUB1  
NUB1/NUB1L is an interesting UBL/UBA protein. Indeed, the necessity for its 
UBL domain in proteasome binding is controversial, and its UBA domains are 
not always involved in target recognition (Tanji et al., 2005; Rani et al., 2012). 
For instance, the UBA domains are necessary for NUB1/NUB1L to bind FAT10 
and UbC1, but NEDD8 interacts with NUB1 at its C-terminus near the PEST 
domain. However, the UBA2 domain of NUB1L can also interact with NEDD8 
(Tanaka et al., 2003; Schmidtke et al., 2006). Nonetheless, NUB1 has been 
shown to promote proteasomal degradation of proteins, and to be involved in 
apoptosis, cell cycle regulation, cell signalling and neurodegeneration. 
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The primary function of NUB1/NUB1L is shuttling proteins for proteasomal 
degradation. Indeed, NUB1/NUB1L can directly bind the PSMD4 subunit of the 
19S proteasome, although probably not via its UBL domain (Tanji et al., 2005). 
The best characterised targets for NUB1/NUB1L mediated proteasomal 
degradation are the ULM NEDD8 and FAT10 as well as their conjugates. NUB1 
also interacts with the Ub precursor UbC1, and together with an Ub C-terminal 
hydrolase mediates the C-terminal hydrolysis of UbC1, thus resulting in the 
release of Ub monomers consequently available for the polyubiquitination of 
target proteins. Therefore, NUB1 may play a role in regulating the availability of 
Ub monomers for conjugation (Tanaka et al., 2004).  
NUB1 may also directly modulate cell-cycle activity and cell proliferation. NUB1 
interacts with p53 in a NEDD8-dependent manner, thereby increasing p53 
ubiquitylation and translocation to the cytoplasm, and inhibiting p53 
transcriptional activity (Liu and Xirodimas, 2010). NUB1 overexpression has 
recently been shown to be anti-proliferative in renal carcinoma cells. Indeed, 
NUB1 overexpression downregulated NEDD8 levels, and induced apoptosis 
and cell cycle arrest in the S-phase (Hosono et al., 2010).  
NUB1 function has been implicated in neurodegeneration. NUB1 interacts with 
the aryl hydrocarbon receptor interacting protein-like 1 (AIPL1). Mutations in 
AIPL1 cause Leber congenital amaurosis (LCA) leading to the early and severe 
neurodegeneration of the retinal photoreceptors causing early-onset  blindness. 
AIPL1 induces a cytoplasmic translocation of NUB1 from the nucleus, and 
consequently probably regulates NUB1 functions (van der Spuy et al., 2004). 
Indeed, wild-type AIPL1 inhibits the NUB1-dependent degradation of FAT10 
and its conjugates, whereas AIPL1 mutants that cause LCA are unable to delay 
FAT10 degradation. Thus, NUB1-dependent degradation of FAT10 and FAT10 
conjugated proteins might be an important underlying mechanism of AIPL1 
associated retinal degeneration (Bett et al., 2012). 
An intriguing role for NUB1 is its capacity to interact with synphilin-1, a protein 
that accumulates in Lewy bodies in various neurodegenerative diseases, 
including PD. NUB1 interacts directly with synphilin-1 via the same region that 
interacts with NEDD8, thereby promoting synphilin-1 proteasomal degradation 
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and reducing synphilin-1 positive inclusions (Tanji et al., 2006). Moreover, 
NUB1 is detected in Lewy bodies in PD and in dementia with Lewy bodies, and 
accumulates in presynaptic neurites along with protein kinase (PK)-resistant α-
synuclein (Tanji et al., 2007; Tanji et al., 2011). 
In conclusion, there is a lot of evidence to support a role for the ULM NEDD8 
and the NEDD8 ultimate buster 1, NUB1, in neurodegeneration. In particular, 
NEDD8 appears to have an important role in AD, exemplified by its 
accumulation in NFTs and senile plaques. Furthermore, the downregulation of 
NEDD8 expression and direct targeting of synphilin-1 by NUB1 emphasizes the 
importance of NUB1 in protein homeostasis and in neurodegenerative 
disorders. Thus, the NUB1 pathway might play an important regulatory role in 
pathogenic mechanisms of AD.  
 
1.5. Aims of this study 
This study set out to test the hypothesis that NUB1 may have an important 
function in neurons and in neuropathogenic mechanisms in AD.  
The first aim was to examine the expression and localisation of endogenous 
NUB1 and the ULM regulated by NUB1 in brain sections of AD patients. 
Moreover, the localisation of NUB1, tau and GSK3β was also explored in 
primary rat cortical neurons.  
The second objective was to assess the role of NUB1 in the modulation of tau in 
neuroblastoma cells. Therefore, the formation of inclusions of wild type tau in 
the presence of GSK3β and proteasome inhibitors was assessed, and the 
influence of NUB1, NUB1L and NUB1L UBL/UBA mutants on tau aggregation 
was investigated. 
The third aim was to analyse the potential interactions between NUB1, GSK3β 
and tau in neuroblastoma cells. Moreover, the effect of NUB1, NUB1L and 
NUB1L UBL/UBA mutants on the levels of total and phosphorylated tau and on 
the turnover of GSK3β was examined. 
Finally, the fourth aim was to explore the functional implications of the findings 
for the endogenous complex. In particular, the affect of the downregulation of 
endogenous NUB1 by RNA interference on the turnover of endogenousGSK3β 
was investigated. 
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Chapter 2  
Materials and Methods  
 
2.1. Reagents 
The source and catalogue number of all reagents are listed in appendix A. All 
the solution compositions are listed in appendix B.  
2.2. Molecular techniques  
2.2.1. Plasmids  
All the plasmids used for this study are listed in table 2.1. 
Table 2.1. Plasmids. 
Vector cDNA insert Source Tag Tag location Resistance 
Tau 0N4R 
isoform 
Utton et al., 
2005 
NUB1 
pEGFP-C1 
 
Empty 
van der Spuy 
et al., 2004 
GFP N-terminus Kanamycin (50 µg/ml) 
pCMV-DsRed Tau 0N4R isoform 
Dr Diane 
Hanger DsRed N-terminus 
Kanamycin 
(50 µg/ml) 
NUB1 
Constructed 
in the 
laboratory pCMV-Tag3B 
Empty Sigma 
c-Myc N-terminus Kanamycin (50 µg/ml) 
pCMV14/3xFLAG NUB1 Bett et al., 2012 FLAG C-terminus 
Ampicillin 
(100 µg/ml) 
NUB1 
NUB1L 
NUB1LΔUBL 
pCDNA3.1 
NUB1LΔUBA1-3 
Schmidtke et 
al., 2006 HA N-terminus 
Ampicillin 
(100 µg/ml) 
pMT2 GSK3β Lovestone et al., 1994  HA N-terminus 
Ampicillin 
(100 µg/ml) 
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2.2.2. Amplification of plasmids  
Plasmids were amplified by bacterial transformation. Briefly, 50 ng of plasmid 
was incubated with 25 µl of JM09 competent cells on ice for 10 min, followed by 
a heat-shock (42°C, 45 sec) and incubation on ice for 2 min. After adding 975 µl 
of warm (37°C) Luria-Bertani broth (LB), cells were left to grow for 1 h at 37°C 
with agitation (300 rpm). A volume of 50 µl of cells was plated on LB/agarose 
containing antibiotics (Table 2.1), and incubated at 37°C for 18 h. A single 
colony of bacteria was inoculated in 2 ml of LB with antibiotics for 7 h at 37°C 
with agitation. The starter culture was diluted at 1:1000 in 50 ml of LB with 
antibiotics and incubated overnight (O/N) at 37°C with agitation before plasmid 
extraction. 
 
2.2.3. Plasmid extraction and purification 
Plasmid DNA was extracted using the HISpeed Plasmid Midi kit according to 
the manufacturer’s protocol. After precipitation with isopropanol, the DNA was 
washed with ethanol, eluted in 0.8 ml of water, and stored at -20°C. DNA 
concentration was measured using a ND-1000 Nanodrop spectrophotometer 
(Labtech international, East Sussex, UK).  
2.2.4. NUB1 siRNA 
The ON-TARGETplus Specificity-Enhanced small interfering RNA (siRNA) 
against NUB1 was obtained from Dharmacon. In addition, a non-targeting 
siRNA was used as a negative control. Sequences are shown in table 2.2. 
Table 2.2. SiRNA sequences. 
 
2.2.5. NUB1 antibody 
To generate the NUB1 antibody (AB), a rabbit polyclonal anti-serum was raised 
against a C-terminal polypeptide (LSYVENRKSATKKN, from residues 588 and 
601 included) of human NUB1 protein, conjugated to keyhole limpet 
siRNA Sequence Reference 
NUB1 5’-CGAUGGUGCUUGAACUAAAUU-3’ Tanji et al, 2006 
Non-targeting 5’-UAGCGACUAAACACAUCAA-3’ Evans et al, 2010 
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hemocyanin (van der Spuy et al, 2003) (Genosys Biotechnology, Cambridge, 
UK).  
 
2.3. Cell culture 
2.3.1. Culture of adherent cells  
The origin of all cells cultured is presented in table 2.3. 
 
2.3.1.1. Immortalised neuroblastoma cells 
Human SK-N-SH and SH-SY5Y neuroblastoma cells were grown at 37°C and 
5% CO2 in complete media, i.e. Dulbecco’s Modified Eagle's Medium (DMEM), 
supplemented with 10% foetal bovine serum (FBS) and penicillin (100 U/ml), 
streptomycin (100 µg/ml) in a T75 flask. For propagation, every 2-3 days, cells 
were washed with Hank's Balanced Salt Solution (HBSS), trypsinised with 
trypsin-ethylenediaminetetraacetic acid (Trypsin-EDTA, 0.05%), and diluted in 
15 ml of complete media at 1:5 for SK-N-SH and 1:4 for SH-SY5Y cells in a T75 
flask to grow at 37°C. 
 
2.3.1.2. Primary neurons  
The extraction of primary cortical neurons was performed by authorised 
personnel in Dr. Diane Hanger’s laboratory, at the Institute of Psychiatry, 
London, UK (Pooler et al., 2012). Primary cortical neurons were extracted from 
Sprague Dawley rat embryos (stage E18) and incubated at 37°C and 5% CO2 in 
complete rich media, i.e. in Neurobasal medium, supplemented with 2% B27, 
penicillin (100 U/ml), streptomycin (100 µg/ml) and 0.5 mM L-glutamine.  
Table 2.3. Origin of cell lines. 
Cell line Species Tissue Origin Morphology Reference 
SK-N-SH Human Bone Marrow 
Neurobla-
stoma Epithelial 
Biedler et al, 
1973 
SH-SY5Y Human Bone Marrow 
SK-N-SH 
cells Epithelial 
Biedler et al, 
1978 
Rat cortical 
neurons  Rat Brain 
Sprague 
Dawley ® 
strain 
Primary 
neurons 
Pooler et al, 
2012 
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2.3.2. Transient transfection of neuroblastoma cells 
2.3.2.1. Plating of cells 
Cells were plated in preparation for transfection as described in table 2.4.  
 
Table 2.4. Number of cells plated for transfection. 
Cell line Dish Type of transfection 
Number of 
cells/well 
Volume of 
media/well 
Time before 
transfection 
6-well plate Plasmid 5x105 2 ml 24 h 
SK-N-SH 8-well 
chamber slide Plasmid 5x10
4 0.25 ml 24 h 
Plasmid 6.5x105 2 ml 24 h 
6-well plate 
siRNA 2x105 2 ml 24 h SH-SY5Y 
8-well 
chamber slide Plasmid 6.5x10
4 0.25 ml 24 h 
6-well plate Plasmid 1x106 2 ml 5 days Rat cortical 
neurons  12-well plate Plasmid 0.5x106 1 ml 5 days 
 
2.3.2.2. Transient transfection of plasmid DNA 
SK-N-SH and SH-SY5Y cells were plated at the density described (Table 2.4) 
with complete media. Cells were transfected 24 h after plating, using 
lipofectamine and Plus reagent in DMEM free of serum and antibiotics (serum 
free media, SF) as described by the manufacturer (Invitrogen, Paisley, UK). The 
total quantity of DNA per transfection was equalised by the addition of an empty 
vector if necessary. Untransfected cells and mock transfected cells, which were 
treated with lipofectamine and Plus reagent in the absence of DNA, were used 
as controls. 
In a 6-well plate. A total of 2.4 µg of DNA per well (amount of each plasmid 
detailed in table 2.5) diluted in 100 µl of SF was incubated with 8 µl of Plus 
reagent for 15 min at room temperature (RT). 4 µl of lipofectamine per well was 
diluted in 800 µl of SF. A final volume of 804 µl of SF/lipofectamine was added 
to the DNA/Plus mix and incubated for 15 min at RT. Cells were washed three 
times with SF, and incubated with 900 µl of the final DNA mix for 3 h at 37°C. 
Finally, 900 µl of DMEM supplemented with 20% FBS and 2% of antibiotics was 
added to each well, and cells were left to grow for at least 24 h.  
 Chapter 2 - Materials and Methods 
  67 
In an 8-well Permanox chamber slide. A total of 0.3 µg of DNA (amount of each 
plasmid detailed in table 2.5) was mixed with 1 µl of Plus reagent and SF to a 
final volume of 12.5 µl, and incubated at RT for 15 min. 0.5 µl of lipofectamine 
was incubated with 100 µl of SF per well. The SF/lipofectamine mix was added 
to the DNA/Plus mix and incubated at RT for a further 15 min. A total volume of 
112 µl of final mix per well was added to the cells for 3 h, before adding 112 µl 
of DMEM supplemented with 20% FBS and 2% antibiotics. Cells were left to 
grow for at least 24 h. 
 
Table 2.5. Amount of each plasmid transfected in 6-well plates and 8-well chamber 
slides. N/A: non applicable. 
Amount of DNA per well 
Plasmid  Protein expressed 
6-well plate 8-well chamber slide 
pEGFP-0N4R GFP-tau 0.4 µg 0.05 µg 
pDsRed-tau DsRed-tau 0.4 µg N/A 
pEGFP-NUB1 GFP-NUB1 0.8 µg 0.1 µg 
pCMV-Tag3-NUB1 c-Myc-NUB1 0.8 µg 0.1 µg 
pCMV14-NUB1 NUB1-FLAG 0.8 µg 0.1 µg 
pCDNA3.1-NUB1 HA-NUB1 0.8 µg 0.1 µg 
pCDNA3.1-NUB1L HA-NUB1L 0.8 µg 0.1 µg 
pCDNA3.1-NUB1LΔUBL HA-NUB1LΔUBL 0.8 µg 0.1 µg 
pCDNA3.1-NUB1L ΔUBA1-3 HA-NUB1LΔUBA1-3 0.8 µg 0.1 µg 
pMT2-GSK3β HA-GSK3β 1.2 µg 0.15 µg 
 
Optimisation of relative amounts of plasmids. Cells were plated in 8-well 
chamber slides as described in table 2.4. Transient transfection was performed 
as described above with increasing amounts of pMT2-GSK3β while that of 
pEGFP-0N4R remained constant at either 25 ng, 50 ng or 100 ng (Table 2.6.) 
The total amount of DNA transfected was 0.2 µg, equalized by the addition of 
empty plasmid where necessary.  
 
 
 Chapter 2 - Materials and Methods 
  68 
Table 2.6. Quantity of plasmids transfected for the optimisation of tau inclusions in the 
presence of GSK3β. 
Plasmid Quantity of plasmid transfected (ng) 
pEGFP-0N4R  25 25 25 25 50 50 50 50 100 100 100 100 
pMT2-GSK3β 25 50 100 150 25 50 100 150 25 50 75 100 
Ratio  
tau:GSK3β 1:1 1:2 1:4 1:6 1:0.5 1:1 1:2 1:3 1:0.25 1:0.5 1:0.75 1:1 
 
Titration of NUB1 plasmids. Cells were plated in 8-well chamber slides as 
described in table 2.4. Transient transfection was performed as described 
above. A total amount of 0.3 µg plasmid DNA, equalized by the addition of 
empty vector where necessary, was transfected as listed in table 2.7.  
 
Table 2.7. Quantity of plasmid transfected for the effect of NUB1, NUB1L or NUB1L 
mutants on tau inclusions. 
 Plasmid Quantity of plasmid transfected (ng) 
pEGFP-0N4R  50 50 50 50 50 50 50 50 
pMT2-GSK3β N/A N/A N/A N/A 150 150 150 150 
pCDNA3.1 NUB1  
or pCDNA3.1 NUB1L  
or pCDNA3.1 NUB1LΔUBL  
or pCDNA3.1 NUB1LΔUBA1-3 
25 50 75 100 25 50 75 100 
Ratio NUB1:tau  1:0.5 1:1 1:1.5 1.2 1:0.5 1:1 1:1.5 1.2 
 
With the exception of the optimisation of relative amounts of plasmids and the 
titration of NUB1 plasmids described above, SK-N-SH cells were transfected as 
described as listed in table 2.5. 
 
2.3.2.3. Transient transfection of siRNA 
Cells were plated in a six well plate in preparation for transfection as described 
in table 2.4, in serum rich media without antibiotics (SR). All siRNA were 
transfected using DharmaFECT according to the manufacturer’s protocol 
(Dharmacon, Thermo Scientific, Northumberland, UK). Briefly, 24 h after plating, 
100 µl of 200 nM siRNA were mixed with 100 µl of SR and left to incubate for 5 
min at RT. 2 µl of Dharmafect reagent 1 was mixed with 198 µl of SR. The 
siRNA/SR and Dharmafect/SR were mixed together and incubated for 15 min at 
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RT. 1.6 ml of SR was added to the final mix, and 2 ml of the solution was added 
to the cells for 72 h at 37°C if not said otherwise.   
 
2.3.3. Transient transfection of rat primary cortical neurons 
All biochemical analysis of proteins were performed in 6-well plates, and 
immunodetection of proteins in 12-well plates, with a glass coverslip added to 
the bottom of the well before plating cells at the density described in table 2.4. 
Cells were transfected after 5 days in vitro (DIV) culture using lipofectamine 
2000 in Opti-MEM according to manufacturer’s instructions (Invitrogen, Paisley, 
UK). 3 µg of either pEGFP-C1 or pEGFP-C1-NUB1 was mixed with 200 µl of 
Opti-MEM and 7 µl of lipofectamine 2000 per well, and incubated for 20 min at 
RT. The media was removed from the cells and retained at 37°C, and replaced 
by the addition of 1 ml of Opti-MEM to the cells. 0.8 ml of Opti-MEM was added 
to the DNA/lipofectamine solution. The Opti-MEM was removed from the cells 
which were then incubated with 1 ml of the final DNA mix for 5 h at 37°C. After 
removing the transfection solution, 1 ml of the previously retained complete 
media and 1 ml of fresh complete media were added to the cells.  
 
2.3.4. Treatment of cells with proteasome inhibitors 
All drugs and vehicles were diluted in serum rich media, and treatments were 
performed at least 24 h after transfection (table 2.8). 
Cells were transfected as described in chapter 2.3.2. Cells were treated with a 
vehicle (NT), epoxomicin (EPO), lactacystin (LAC), Z-Leu-Leu-Leu-al (MG132), 
or a combination of two (LAC+MG132, EPO+MG132 and LAC+EPO) for 2, 4 
and 6 h (Table 2.8). In subsequent experiments, cells were treated with MG132 
or a vehicle for 4 h, 30 h after transfection.  
Table 2.8. Drug treatments. Ki: inhibition constant, obtained from the manufacturer’s 
data sheet.  
Drug Concentration Vehicle Potency Treatment 
Lactacystin 10 µM Water Ki = 4 nM 2, 4 or 6 h 
Epoxomicin 10 µM 
Dimethyl 
Sulfoxide 
(DMSO) 
IC50 = 4 nM 2, 4 or 6 h 
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MG132 50 µM DMSO Ki = 4 nM 2, 4 or 6 h 
 
2.4. Protein localisation  
2.4.1. Immunohistochemistry  
Immunohistochemistry (IHC) of proteins in brain sections was performed with 
the LSAB Dakocytomation kit. All the paraformaldehyde (PFA) fixed, paraffin 
embedded brain sections (8 µm) were provided by the London Brain Bank. 
Sections were dewaxed in three changes of xylene for 10 min each with 
agitation. Sections were then rehydrated in two changes of 100% and one 
change of 95% industrial methylated spirit (IMS) for 5 min each.  
Tau, Ub, FAT10 and NEDD8 detection. To block endogenous peroxidase 
activity, sections were incubated in 0.5% hydrogen peroxidase (H2O2)/methanol 
for 30 min, and washed in water for 10 min. Sections were treated with 0.01 M 
citric acid, pH6, and boiled in a microwave oven for 4x2.5 min for antigen 
retrieval. Twenty minutes after the antigen retrieval, sections were washed in 
water for 10 min and in phosphate buffered saline (PBS) for 3x5 min with 
agitation, and blocked in 10% normal swine serum/2% bovine serum albumin 
(BSA)/PBS for 1 h at RT. After washing 3x5 min in PBS, sections were 
incubated with primary antibodies (table 2.9) in 0.1% BSA/PBS at 4°C O/N with 
gentle agitation. Sections were washed 3x5 min in PBS, and incubated for 30 
min with the swine multilink secondary antibody (LSAB Dakocytomation kit, 
table 2.10) for 30 min or with the swine anti-rabbit polyclonal antibody in 0.1% 
BSA/PBS for FAT10 staining for 45 min at RT. Sections were washed as 
described above and incubated with peroxidase solution (Dakocytomation kit) 
for 30 min at RT. Sections were washed 3x10 min in PBS, incubated with 3,3-
diaminobenzidine tetrahydrochloride (DAB, from the LSAB Dakocytomation kit) 
for 30 sec to 1 min and immediately washed in water for 10 min with agitation. 
Sections were dehydrated with one change of 70% and 95% IMS and three 
changes of 100% IMS. Finally, sections were cleared with three changes of 
xylene for 10 minutes each and mounted with DPX mounting media.  
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Table 2.9. Primary antibodies. 
Name Specificity Host species WB ICC IHC IP 
Anti-tau Total human tau protein Rabbit 1:40 000 1:2000 N/A 1:1000 
Anti-
pS396 
Tau phosphorylated on 
S396 Rabbit 1:5000 1:500 N/A N/A 
AT8 Tau phosphorylated on S199, S202 and T205 Mouse 1:1000 1:250 1:1500 N/A 
Anti        
c-Myc c-Myc tagged proteins Mouse 1:5000 1:1000 N/A 1:500 
Anti-GFP GFP tagged proteins Mouse 1:2000 N/A N/A N/A 
Anti-
GSK3β GSK3β Rabbit 1:2000 1:100 N/A 1:100   
Anti-
FLAG FLAG tagged proteins Mouse 1:5000 N/A N/A 1:500 
Mouse 1:5000 1:500 N/A 1:500 
Anti-HA HA tagged proteins 
Rabbit 1:2000 1:250 N/A N/A 
Anti-
FAT10 
FAT10 and FAT10 
conjugates Rabbit N/A N/A 1:500 N/A 
Anti-
NEDD8 
NEDD8 and NEDD8 
conjugates Rabbit N/A N/A 1:500 N/A 
Anti-
NUB1 
NUB1, NUB1L and NUB1L 
mutant proteins Rabbit 1:20000 N/A 1:1500 N/A 
Anti-Ub Ub and Ub-conjugated proteins Rabbit N/A N/A 1:500 N/A 
Anti-
GAPDH 
Glyceraldehyde 3-
phosphate dehydrogenase Mouse 1:20000 N/A N/A N/A 
Anti-Actin Actin Rabbit 1:2000 N/A N/A N/A 
Anti-
tubulin β-tubulin subunit Mouse 1:2000 1:150 N/A N/A 
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Table 2.10. Secondary antibodies. 
Name Raised 
against 
WB/IP ICC IHC Colour 
emitted 
GαM HRP Mouse 1:30 000 N/A N/A N/A 
GαR HRP Rabbit 1:30 000 N/A N/A N/A 
Swine multilink 
biotinylated 
Rabbit, 
Mouse, goat 
N/A N/A 
From LSAB 
Dakocytomation 
kit, few drops 
N/A 
Swine biotinylated Rabbit N/A N/A 1:300 N/A 
Alexa Fluor® 488 goat  Mouse N/A 1:1000 N/A Green 
Alexa Fluor® 488 goat  Rabbit N/A 1:1000 N/A Green 
Alexa Fluor® 594 goat  Mouse N/A 1:1000 N/A Red 
Alexa Fluor® 594 goat  Rabbit N/A 1:1000 N/A Red 
Alexa Fluor® 647 goat  Mouse N/A 1:1000 N/A Purple 
Alexa Fluor® 647 goat  Rabbit N/A 1:1000 N/A Purple 
 
NUB1 detection. NUB1 immunostaining followed the same steps as described 
above with a number of changes. To block endogenous peroxidase activity, 
sections are incubated in 3% H2O2/methanol for 30 min, and for antigen 
retrieval sections were boiled in Mc Ilvane’s citrate buffer. Anti-NUB1 (table 2.9) 
and swine anti-rabbit were used as the primary and a secondary antibody 
respectively. To verify the NUB1 AB specificity, NUB1 AB was incubated for 1 h 
at RT with the polypeptide (30 µg/ml) against which it was raised (Chapter 
2.2.5), before incubation with the brain sections. 
Localisation of NUB1 and NEDD8. The subcellular localisation of NEDD8 and 
NUB1 in the CA1-2 and CA4 areas of the hippocampus was observed, and 
divided into three categories: strictly nuclear (N), nuclear and cytoplasmic (N/C) 
and strictly cytoplasmic (C). To calculate the percentage of cells with nuclear or 
cytoplasmic NUB1 and NEDD8 localisation, at least 100 cells were counted for 
each region. Statistical significances were determined using the unpaired 
Student’s t-test.  
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2.4.2. Fixation and permeabilisation of cells  
Fixation and permeabilisation of SK-N-SH and SH-SY5Y cells. To detect the 
localisation of proteins by immunofluorescent laser scanning confocal 
microscopy, cells were plated and transfected as described in chapter 2.3.2 in 
an 8-well Permanox chamber slide. After treatment with MG132 or a vehicle for 
4 h, cells were rinsed once with warm (37°C) PBS and once with warm (37°C) 
Pipes/ Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
(EGTA)/Magnesium chloride (MgCl2) buffer (PEM), fixed and permeabilised with 
0.3% glutaraldehyde/0.5% Nonidet P-40 for 10 min. All fixations were performed 
at 37°C to preserve microtubule structures and associated proteins. All the 
subsequent steps were done at RT. Cells were rinsed with PBS, and treated 
with sodium borohydride (NaBH4) for 7 min. After a wash with PBS, cells were 
incubated with 0.1 M glycine for 20 min to reduce background. Alternatively, in 
order to count cell inclusions, cells were fixed with 100% methanol for 10 min at 
-20°C and permeabilised with 0.1% Triton X-100 for 5 min at RT. Protein 
immunocytochemistry (ICC) was performed as described in chapter 2.4.3.  
Fixation of primary neurons. Cells were plated and transfected as described in 
chapter 2.3.1.2 and 2.3.3 in a 12-well plate with glass coverslips. Cells were 
treated with MG132 or a vehicle for 4 h. Coverslips were washed 3x with warm 
PBS (37°C) and fixed with 4% PFA for 10 min at 37°C. Cells were rinsed with 
PBS, and permeabilised with 0.1% Triton X-100 for 5 min at RT. Protein 
immunodetection was performed as described in chapter 2.4.3. 
 
2.4.3. Immunocytochemistry  
After fixation and permeabilisation of cells, all the subsequent steps were done 
at RT. Cells were rinsed with PBS (5 min) and blocked with block solution (3% 
BSA/goat normal serum) for 1 h. Cells were incubated with primary antibody 
(table 2.9) diluted in block solution for 1 h. After 3x5 min washes with PBS, cells 
were incubated with an AlexaFluor secondary antibody (table 2.10) diluted in 
block solution for 45 min at RT. Cells were washed 2x5 min with PBS, and 
incubated with 4',6-diamidino-2-phenylindole (DAPI) (2 mg/ml diluted 1:5000 in 
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Nuclear (N) (%) = (Nuclear intensity/Whole cell intensity) x 100 
Cytoplasmic (C) (%) = 100 – (N)  
 
PBS) for 5 min. Cells were washed 1x5 min with PBS and mounted with Dako 
mounting medium. All images were taken with a Carl Zeiss LSM700 confocal 
microscope (Carl Zeiss Ltd, Hertfordshire, UK). 
 
2.4.4. Analysis of NUB1 localisation  
NUB1 localisation. The localisation of NUB1 in at least 100 cells was analysed 
in cells transfected with GFP-NUB1 in the presence or absence of MG132. 
Total Fluorescence intensity in the nucleus and in whole cells was measured 
using the ImageJ software (Image Processing and Analyse in Java, 
http://rsbweb.nih.gov/ij/). The ratio of nuclear fluorescence intensity was 
calculated as a percentage of the whole cell fluorescence intensity:  
  
The cytoplasmic fluorescence intensity was deducted from there: 
  
The error bars were the standard error of the mean. 
NUB1 recruitment to tau. Pearson’s and Mander’s coefficients were measured 
to determine the co-recruitment of GFP-NUB1 and DsRed-tau to microtubules 
and DsRed-tau inclusions. The Pearson’s coefficient (PC) and Mander’s 
coefficient (M) were calculated using the Just Another Colocalization plugin 
(JACoP, http://rsbweb.nih.gov/ij/plugins/track/jacop.html, Bolte and Cordelieres, 
2006) in ImageJ. At least 3 different cells for DsRed-tau and GFP-NUB1 co-
localisation were analysed and the PC and MC calculated. Pearson’s coefficient 
(PC) indicates the degree of overlap and scores between (-)1 and (+)1, where (-
)1 indicates total exclusion, (+)1 a perfect image registration and (0) a random 
localisation. The Pearson’s coefficient takes into account the shape and the 
intensity, but is affected by the presence of non-overlapping data, i.e. a signal 
present only in one channel. On the other hand, the Mander’s coefficient 
indicates when the Red and Green channel are overlapping, and will give a 
number between 0 and 1 which is calculated from the contribution of the Green 
(GFP-NUB, M1) or the Red (DsRed-tau, M2) to the co-localising area, 
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independently of the intensity. However, this coefficient is very sensitive to 
background, therefore a threshold was set before calculation. 
The mean and standard error of the mean were calculated using Excel and 
statistical significances were determined using the unpaired Student’s-t test. 
 
2.4.5. Quantitation of tau inclusions  
To calculate the percentage (%) of cells expressing GFP-tau, at least 4 fields of 
100 cells were counted. To calculate the percentage (%) of GFP-tau inclusions 
in GFP-tau transfected cells, at least 4 fields of 100 cells transfected with GFP-
tau were counted and scored for the presence of inclusions. The percentage of 
GFP-tau inclusions in GFP-tau transfected cells was counted blind to 
experimental status. Statistical analysis was performed using an unpaired 
Student’s t-test. 
 
2.5. Protein levels and interactions 
All protein analyses were performed in 6-well plates. 
 
2.5.1. Sample preparation for western blotting 
SK-N-SH and SH-SY5Y cells. Cells were plated in 6-well plates and transiently 
transfected as described in chapter 2.3.1.1 and 2.3.2.2 respectively. Cells were 
lysed with 200 µl of RIPA buffer supplemented with 2% protease inhibitor 
cocktail (PIC) and 1% phosphatase inhibitor cocktail (PhIC) for 5 min on ice. 
Cells were dislodged from the wells using a sterile cell scraper, collected and 
sonicated for 10 sec on ice (continuous pulse, 22.5 kHz, Amplitude 5) using a 
Misonix Ultrasonic Liquid Processor XL-2000 (Misonix Incorporated, 
Farmingale, NY). 20 µl of the sample was removed for protein quantification as 
described in chapter 2.5.2. After adding 60 µl of 4x loading buffer, samples were 
boiled for 3 min, and centrifuged for a few seconds at 12 000 rpm before 
resolving the proteins by denaturing sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) (Chapter 2.5.3). If not said otherwise, 10 µg of 
proteins were resolved on a 10% polyacrylamide gel and analysed by western 
blotting (WB) as described in chapter 2.5.3 and 2.5.4. 
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Rat cortical neurons. Cells were plated in 6-well plates and transiently 
transfected as described in chapter 2.3.1.2 and 2.3.3 respectively. Cells were 
lysed with 1xLaemli buffer without dye, supplemented with 2% PIC and 1% 
PhIC for 5 min on ice. Cells were scraped together and after adding the 
bromophenol blue dye, cells were boiled for 15 min and centrifuged for a few 
seconds at 12 000 rpm. A total of 25 µg of proteins were resolved on a 10% 
polyacrylamide gel and analysed by WB as described in chapter 2.5.3 and 
2.5.4. 
2.5.2. Quantification of proteins  
Protein concentration from cell lysates was determined using the bicinchonitic 
acid (BCA) Protein Assay kit. The BCA reagents A and B were mixed at a ratio 
50:1, and 200 µl of the A/B mix was added to 10 µl of cell lysates in duplicate. In 
parallel, a standard curve was determined by adding 200 µl of the A/B mix to 10 
µl of known amounts of BSA diluted in the same buffer used to lyse the cells 
giving a standard concentration ranging from 200 ng/ml to 2 000 ng/ml The test 
and standard samples were prepared in duplicate. The samples were incubated 
for 30 min at 37°C. The absorbance was measured at 562 nm with a 
spectrophotometer (Safire, Tecan, Reading, UK). The concentration of proteins 
from cell lysates was calculated by interpolation from the BSA standard curve, 
which was plotted using Excel software.  
 
2.5.3. SDS-PAGE  
The SDS-PAGE gels were prepared and ran using the Bio-Rad Protean II 
system (Bio-Rad, Hertfordshire, UK). For all the assays using WB analysis, a 
10% polyacrylamide resolving gel was poured, followed by a 3% polyacrylamide 
stacking gel. Protein samples and a protein ladder were applied to the wells in 
the stacking gel, proteins were resolved by electrophoresis at 150 V until the 
bromophenol blue dye left the stacking gel and at 200 V until the dye reached 
the bottom of the gel. Molecular weights were determined using the Compute 
pl/Mw tool from the ExPASy website (www.expasy.org). 
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2.5.4. Western blotting 
Resolved proteins were transferred to a nitrocellulose membrane for 22 min at 
0.4 Amp, 15 V using a Transblot semi-dry transfer cell (Bio-Rad, Hertfordshire, 
UK). Transferred proteins were detected with Ponceau red dye. Membranes 
were blocked O/N at 4°C in 5% non-fat dried milk in PBS-Tween 20 (PBS-T). 
Proteins were detected with a specific primary antibody (table 2.9) diluted in 1% 
non-fat dried milk in PBS-T for 1 h at RT, with agitation. Membranes were 
washed 3x5 min and 1x15 min with PBS-T before incubation with a specific 
secondary antibody conjugated to horseradish peroxidase (HRP) (table 2.10) 
diluted in 1% dried milk in PBS-T for 45 min at RT, with agitation. After 3x5 min 
and 1x15 min wash in PBS-T, membranes were incubated for 5 min with the 
ECL Plus reagent. The peroxidase activity was revealed by chemiluminescence 
and visualised by autoradiography on Super RX X-Ray Fuji film.  
 
2.5.5. Quantitative protein assay 
Cells were plated and transiently transfected as described in chapter 2.3.1.1 
and 2.3.2.2 respectively. Cells were treated with MG132 or a vehicle 28 h after 
transfection as described in chapter 2.3.4. Cells were lysed with 200 µl of 0.1% 
SDS buffer supplemented with 2% PIC and 1% PhIC for 5 min on ice. A 
nitrocellulose membrane was pre-equilibrated with three washes of 0.1% SDS 
buffer on a dot-blot apparatus (Bio-Rad, Hertfordshire, UK). After 10 sec of 
sonication (as described in chapter 2.5.1), 20 µl of cell lysates were removed for 
protein quantification, as described in chapter 2.5.2. The remaining volume of 
cell lysate was appropriately diluted (final volume: 100 µl per sample) in 0.1% 
SDS buffer, loaded in quadruplicate onto the nitrocellulose membrane on the 
dot-blot apparatus and allowed to bind for 20 min. The nitrocellulose membrane 
was washed twice with 0.1% SDS buffer. Proteins were detected by 
immunoblotting as described in chapter 2.5.4. Each experiment was performed 
at least twice. 
Standard curve. A standard curve for the anti-tau and anti-pS396 antibodies 
that detect the total and phosphorylated tau levels respectively was established. 
A serial dilution of samples from cells transfected with GFP-tau or with GFP-tau 
and HA-GSK3β for detection with anti-tau and anti-pS396-tau antibodies 
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respectively was performed. Each dilution, from 1:20 to 1:5000, was applied to 
a nitrocellulose membrane in quadruplicate as described above and total or 
phosphorylated tau levels were detected by immunoblotting using the anti-tau 
and anti-pS396 antibodies (Chapter 2.5.4). 
Quantitation. In each experiment, WB with the same exposure time were 
scanned in black and white and protein levels were analysed using the ImageJ 
software. The mean grey value of each spot was measured. The average 
intensity of the quadruplicate spots from the same sample was calculated along 
with the standard error of the mean using Excel software, and normalised to 
protein concentration. Statistical significance was determined using an unpaired 
Student’s t-test. All values were normalised to a reference intensity. For 
comparison of changes in total tau levels, values were normalised to that of 
total tau in the absence of GSK3β or proteasome inhibition. For comparison of 
changes in phosphorylated tau levels, values were normalised to that of tau 
phosphorylated in the presence of GSK3β and in the absence of proteasome 
inhibition. 
 
2.5.6. Immunoprecipitation  
All the immunoprecipitations (IP) and co-immunoprecipitations (co-IP) were 
performed using magnetic dynabeads on a magnetic rack (Invitrogen, Paisley, 
UK). Before immunoprecipitation, magnetic beads were washed three times 
with RIPA-T buffer and blocked overnight with BSA–T blocking buffer to avoid 
non-specific attachment of proteins to the beads. Cells were plated and 
transiently transfected as described in chapter 2.3.1.1 and 2.3.2.2 respectively. 
Cells were treated with MG132 or vehicle, 28 h post-transfection. Cells were 
lysed with 200 µl of RIPA buffer supplemented with 5% PIC and 1% PhIC for 5 
min on ice. After 10 sec of sonication as described previously, 30 µl of cell 
lysates were removed, mixed with 10 µl of 4x loading buffer and kept at 4°C for 
the input fraction. The remaining supernatant was incubated with 25 µl of 
magnetic dynabeads pre-washed in RIPA-T buffer with specific primary 
antibodies (table 2.9), O/N at 4°C. Alternatively, as controls, samples were 
incubated with a non-specific primary antibody (but raised in the same species, 
IgG), or with the beads only (BO) (table 2.11). The supernatant was removed 
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and the dynabeads were washed three times with RIPA-T buffer. Proteins were 
eluted in 40 µl of 4x loading buffer, and boiled for 3 min. After a quick spin at 12 
000 rpm, 5 µl of inputs, 5 µl of IP product and 10 µl of co-IP product were 
loaded on a polyacrylamide gel and analysed by WB as described in chapter 
2.5.3 and chapter 2.5.4.  
Table 2.11. Antibodies used as controls in IP and co-IP. 
Protein IP Protein co-IP Primary Antibody Non-specific primary antibody 
NUB1-FLAG Rabbit anti-HA 
GFP-tau 
HA-GSK3β 
Rabbit anti-pan tau 
Rabbit anti-flag 
GFP-tau  
HA-GSK3β 
NUB1-FLAG 
Mouse anti-HA Mouse anti-c-Myc 
GFP-tau 
NUB1-FLAG 
HA-GSK3β 
Mouse anti-FLAG Mouse anti-c-Myc 
 
In each experiment, WB with the same exposure time were scanned in black 
and white and protein levels were analysed using the ImageJ software. 
The mean grey value of each band of protein co-immunoprecipitated was 
measured and compared to the same protein band in the input fraction. Twice 
as much co-IP product (10 µl) was resolved compared to the input and IP 
samples (5 µl), and the concentration in the final co-IP samples was 4x higher 
than in the inputs (undiluted). Therefore, the following equations were used to 
calculate the percentage of total protein immunoprecipitated and co-
immunoprecipitated: 
 
 
 
2.5.7. Cycloheximide assays  
Cells were plated and transfected as described in chapter 2.3.1.1 and chapter 
2.3.2.2 respectively. 28 h after transfection, cells were treated with 
cycloheximide (CHX) for 2 h, 4 h or 6 h. Four hours before the end of the CHX 
treatment, cells were also treated with MG132 or vehicle for 4 h. Preparation of 
(%) of protein IP = 100 x (Intensity of co-IP / (Intensity of inputs x 4)) 
(%) of protein co-IP = 100 x (Intensity of co-IP / (Intensity of inputs x 8)) 
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the samples for WB and quantification of proteins were described in chapter 
2.5.1. and 2.5.2. Samples were loaded three times on the same polyacylamide 
gel (10%), and electrophoresis and WB were carried out as described in 
chapter 2.5.3 and 2.5.4. Each experiment was performed at least twice. 
Quantitation. In each experiment, WB with the same exposure time were 
scanned in black and white and protein levels were analysed using the ImageJ 
software. Average values and standard errors of the mean were calculated 
using Excel software. Statistical significance was determined using an unpaired 
Student’s t-test. For determination of changes in the overall levels of GSK3β, all 
values were normalised to GSK3β in the absence of NUB1, proteasome 
inhibition or CHX treatment. For determination of the degradation rate, GSK3β 
levels after 2, 4 and 6 h of CHX treatment were calculated as a percentage of 
the initial GSK3β levels (0 h CHX treatment). Similarly, NUB1 levels were 
measured and were calculated as a percentage of the initial NUB1 levels (0 h 
CHX treatment) in the absence of MG132. 
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Chapter 3 
Localisation of NUB1  
 
3.1. Introduction 
The NFTs in AD are composed of PHF, twisted tangles of protofilaments of 
hyperphosphorylated tau (Martin et al., 2011; Braak and Braak, 1991). NFTs 
are only seen in neurons, and are described as either flame shaped or rounded 
(globose). After the death of the neuron, NFTs remain as ghost tangles. The 
progressive accumulation of NFTs throughout the brain has led to the 
description of 6 main stages of AD called Braak stages (Figure 3.1). First, NFTs 
accumulate in the entorhinal cortex, an important memory centre (Braak stage I 
and II). Subsequently, NFTs spread to the pyramidal layer of the hippocampus 
(Braak stages III and IV), a part of the limbic system involved in long-term 
memory and spatial navigation. Finally, NFTs reach layers III and IV of the 
neocortex (Braak stages V and VI), a part of the cerebral cortex implicated in 
sensory perception, language and the generation of motor commands (Figure 
3.1) (Braak and Braak, 1991; Duyckaerts et al., 2009). Braak stages correlate 
with the seriousness of the disease. Tau fibrils also appear in dendrites as NT, 
in dystrophic neurites (either dendrites or axons), and in the corona of the senile 
plaques. 
NFTs are argyrophilic, and can therefore be detected using silver-staining 
techniques. The fluorescent dye Thioflavin S can also label NFTs and Aβ 
deposits, as it binds to the β-sheet structures of fibrillar aggregates. Different 
antibodies for tau aggregation in AD are used to label NFTs. The Alz50 primary 
antibody, for example, requires tau to be misconformed as it recognises two 
discontinuous epitopes (Duyckaerts et al., 2009). The PHF-1 antibody 
specifically detects tau phosphorylated on two residues, Ser396 and Ser404. 
The AT8 antibody has been found to be one of the most consistent over the 
years of tau studies to label NFTs and NTs. AT8 has been used extensively to 
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detect PHF-tau in NFTs in samples from AD patients. AT8 is cross-reactive for 
3 epitopes, it specifically recognises PHF-tau doubly phosphorylated on Ser199 
and Ser202, Ser202 and Thr205, and Thr205 and Ser208 (Porzig et al., 2007). 
 
Figure 3.1. Limbic system and NFT progression in AD. (A) The limbic system is 
composed of the limbic lobe (grey shadow) and deep-lying structures such as the 
hippocampus and amygdala. (B) Braak stage I and II are characterised by lesions 
confined to the transentorhinal cortex. NFTs progress to the limbic system in stage II 
and IV, and finally spread to the isocortex in stage V to VI. The darker the colour, the 
greater the severity of NFT lesions.  
 
A range of different proteins accumulate in NFTs. Often, but not always, Ub 
accumulates in NFTs and in the neuritic plaques. Ub accumulation in NFTs 
appears to correlate with the progression of AD, and is therefore considered a 
late event of NFT formation (He et al., 1993). A recent study by Garcia-Sierra et 
al. (2011) showed that 30% of NFTs are ubiquitinated, and that Ub labelling is 
associated with phosphorylated tau and tau truncated by caspase 3.  
NFTs are also positive for the ULM NEDD8 (Chen et al., 2003; Mori et al., 
2005). NEDD8 accumulates in different inclusions such as Lewy bodies in PD, 
and NFTs in AD. Interestingly, NEDD8 labelling appears to be related to Ub. 
Indeed, Mori et al., (2005) showed that Ub-negative inclusions, including NFTs 
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in corticobasal degeneration and progressive supranuclear palsy, and Pick 
bodies in PiD, are also NEDD8-negative. Interestingly, as a regulator of 
NEDD8, NUB1 localisation has been studied and shown to co-localise with 
Lewy bodies in PD, but not with NFTs (Tanji et al., 2007).  
The accumulation of tau in PHFs and NFTs occurs only when tau is 
hyperphosphorylated by several kinases such as GSK3. In non-pathological 
conditions, tau localisation is mostly axonal in neurons, although tau can be 
found in the dendrites and the soma, but not in the nucleus (Dehmelt and 
Halpain, 2005). The tau kinase GSK3 is a cytosolic protein, however studies 
suggest that it is also activated in mitochondria and the nucleus (Bijur and Jope, 
2003).  
The aims of the following experiments were to determine the subcellular 
distribution of NUB1 and the ULM proteins in vivo in brain sections provided by 
the London Brain Bank, from AD patients and age-matched control patients, 
and to examine their correlation with the progression of tau aggregation and 
NFT formation.  
Moreover, the localisation of GFP-NUB1 in rat cortical primary neurons was 
examined and compared to that of endogenous tau, microtubules and GSK3β. 
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3.2. Results 
3.2.1. Tau accumulates in NTs and NFTs 
Formalin fixed, paraffin embedded sections (8 µm) from the entorhinal cortex 
and hippocampus of a Braak stage VI AD patient were labelled with AT8, an 
antibody specific to hyperphosphorylated tau accumulated in PHFs and NFTs 
(Braak and Braak 1995; Duyckaerts et al., 2009). Figure 3.2, A illustrates the 
accumulation of tau in the entorhinal cortex and from the CA1 to the CA4 areas 
of the hippocampus. As described by Braak and Braak (1991), tau first 
aggregates in the entorhinal cortex and then spreads to the neurons of the 
pyramidal layers (CA1 to CA4) of the hippocampus.  
Tau localisation was analysed in detail in the entorhinal cortex, and in the CA2 
and CA4 areas of the hippocampus of a Braak stage VI AD or age-matched 
control patient (Figure 3.2, B). Hyperphosphorylated tau (p-tau) accumulated in 
globose (long arrows) and flame-shaped (short arrows) NFTs in neurons, and in 
NT (small arrowheads) in dendrites. As tau aggregation is not cleared after cell 
death, p-tau was also detected in dystrophic neurites (large arrowheads).  
A stronger AT8 background and greater number of globose NFTs and NTs were 
detected in the entorhinal cortex of the AD patient (Figure 3.2, B, a) compared 
to the control patient (Figure 3.2, B, d). In the CA2 (Figure 3.2, B, b and e) and 
CA4 (Figure 3.2, B, c and f) areas of the hippocampus, p-tau aggregation was 
detected in NFTs in the pyramidal neurons, and in NTs in both the AD (Figure 
3.2, B, b and c) and control patient (Figure 3.2, B, e and f). However, a larger 
number of NFT and NTs were detected in the AD patient than the control 
patient in both the CA2 and CA4 areas. Moreover, dystrophic neurites were only 
detected in the AD patient. Overall, although p-tau could be detected in 
aggregates in age-matched control patients, a higher number of NTs, NFTs and 
dystrophic neurites were detected in the Braak stage VI AD patient. Moreover, 
the presence of NFTs in the control patient was sporadic in the entorhinal cortex 
and the CA4 area of the hippocampus, while they were widely spread in the AD 
patient and led to the detection of tau in dystrophic neurites. 
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Figure 3.2. Subcellular localisation of hyperphosphorylated tau in the entorhinal cortex 
and hippocampus of an AD patient and an age-matched control patient. 
Hyperphosphorylated tau was detected by immunohistochemistry using the 
DAB/peroxidase method following the incubation of brain sections with the AT8 primary 
antibody. Nuclei were labeled with hematoxylin reagent (purple). (A) Composite of 
images taken from the entorhinal cortex and hippocampus from an AD patient. The 
arrows represent the dissemination of tau throughout the hippocampus, from the CA1 
to the CA4 pyramidal layer of neurons. (B) The localisation of hyperphosphorylated tau 
was examined in the entorhinal cortex (a, d), CA2 (b, e) and CA4 (c, f) area of the 
hippocampus. Globose NFT (long arrows), flame-shaped NFT (short arrows), NTs 
(small arrowheads) and dystrophic neurites (large arrowheads) are demarcated. Scale 
bars = 25 µm. 
 Chapter 3 - Localisation of NUB1 
  86 
 
3.2.2. Ubiquitin, FAT10, NEDD8 and NUB1 distribution in the 
entorhinal cortex and hippocampus of AD and control patients 
The localisation of Ub, NEDD8, FAT10 and NUB1 was examined in a Braak 
stage VI AD patient and an age-matched control by immunohistochemical 
detection in brain sections.  
Ub was detected in the entorhinal cortex and hippocampus in a non-affected 
and a Braak stage VI AD patient (Figure 3.3). Both in the control (Figure 3.3, D, 
E and F) and the AD patient (Figure 3.3, A, B and C), Ub accumulated in NFTs 
(arrows). However, Ub appeared to label NTs (small arrowheads) and 
extracellular structures, which could be either dystrophic neurites (large 
arrowheads) or senile plaques or both, only in the AD patient. 
FAT10 localisation was analysed in an age-matched non-demented and a 
Braak stage VI AD patient (Figure 3.4). In both the entorhinal cortex and the 
hippocampus, FAT10 in the control appeared to be restricted to few cells 
(Figure 3.4, D, E and F, arrows), whereas it was more widespread in the AD 
patient. In the AD patient, FAT10 appeared to accumulate in extracellular 
structures similar to dystrophic neurites (Figure 3.4, A and B, arrowheads) and 
in individual cells (Figure 3.4, C, arrow). The subcellular localisation of FAT10 in 
cells in both the control and AD patient was mostly cytoplasmic. 
NEDD8 was detected in the entorhinal cortex and hippocampus of a non-
affected and a Braak stage VI AD patient (Figure 3.5). In these brain sections, 
NEDD8 was detected primarily in cells (Figure 3.5, arrows), and did not appear 
to accumulate in any extracellular structures. Noticeably, NEDD8 was detected 
in the majority of pyramidal neurons in the hippocampus (Figure 3.5, B, C, E, F, 
arrows), where NFTs accumulate, in both the control and the AD patient. 
NEDD8 subcellular localisation was mostly cytoplasmic in the CA2 and CA4 
areas of the hippocampus whereas it was more nuclear in the entorhinal cortex 
(Figure 3.5, A and D, arrows). 
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Figure 3.3. Subcellular localisation of Ub in the entorhinal cortex and hippocampus of 
an AD patient and an age-matched control patient. Ub was detected in brain sections 
by immunohistochemistry using the anti-Ub antibody and the DAB/peroxidase method. 
Nuclei were labeled with hematoxylin reagent (purple). Ub was detected in the 
entorhinal cortex (A, D), CA2 (B, E) and CA4 (C, F) area of the hippocampus of the AD 
patient (A, B, C) and the control (D, E, F). NTs (small arrowheads), NFTs (arrows) and 
dystrophic neurites (large arrowheads) are demarcated. Scale bars = 25 µm.  
 
Figure 3.4. Subcellular localisation of FAT10 in the entorhinal cortex and hippocampus 
of an AD patient and an age-matched control patient. FAT10 localisation was detected 
in brain sections by immunohistochemistry using the anti-FAT10 antibody and the 
DAB/peroxidase method. Nuclei were labeled with hematoxylin reagent (purple). The 
FAT10 specific detection is depicted with arrowheads (extracellular localisation) and 
arrows (intracellular localisation) in the entorhinal cortex (A, D), CA2 (B, E) and CA4 
(C, F) area of the hippocampus of the AD patient (A, B, C) and the control (D, E, F). 
Scale bars = 25 µm. 
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Figure 3.5. Subcellular localisation of NEDD8 in the entorhinal cortex and 
hippocampus of an AD patient and an age-matched control patient.  NEDD8 
localisation was examined by immunohistochemistry in brain sections using a primary 
antibody specific to NEDD8 and the DAB/peroxidase method. Nuclei were labelled with 
hematoxylin reagent (purple). The NEDD8 specific detection is shown with arrows in 
the AD patient (A, B, C) and in the control (D, E, F) in the entorhinal cortex (A, D), and 
the CA2 (B, E) and CA4 (C, F) areas of the hippocampus. Scale bars = 25 µm. 
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The NUB1 subcellular localisation was observed in a non-demented and a 
Braak stage VI AD patient. The NUB1 antibody is a peptide-directed antibody 
previously developed and characterised in our laboratory (van der Spuy et al., 
2003), therefore the specificity of the NUB1 immunodetection in the brain 
sections was first assessed by peptide competition and by comparison with the 
pre-immune serum in a Braak stage VI AD patient (Figure 3.6). Pre-incubation 
of the primary antiserum with the NUB1 peptide (30 µg/ml) against which the 
antibody was raised significantly reduced the immunodetection of NUB1 in brain 
sections (Figure 3.6, D, E and F), and no specific NUB1 immunostaining was 
detected with the pre-immune serum (not shown). Therefore, the NUB1 
detection was specific, and the localisation of NUB1 was compared in the 
entorhinal cortex and hippocampus of an age-matched non-demented and 
Braak stage VI AD patient (Figure 3.7). Noticeably, the NUB1 localisation was 
similar to that of NEDD8 (Figure 3.5). In both the AD patient and the control, 
NUB1 distribution was mostly cytoplasmic throughout the neurons in the 
entorhinal cortex and hippocampus, and did not appear to label extracellular 
structures. However, NUB1 was also detected in the nucleus in some cells of 
the entorhinal cortex, but only in the control patient. Interestingly, similar to 
NEDD8, NUB1 was detected in the pyramidal neurons of the hippocampus, in 
both the CA2 and CA4 areas of the AD patient and control, where NFTs are 
known to accumulate. 
In conclusion, as previously described by Braak and Braak (1991), 
hyperphosphorylated tau accumulated in NTs, NFTs and dystrophic neurites in 
the entorhinal cortex and hippocampus of AD patients. Although tau 
aggregation was detected in a non-demented control, the NFTs in the control 
were only found sporadically in the entorhinal cortex and CA2 area of the 
hippocampus. The accumulation of tau in the NFTs has been shown to be co-
labelled with Ub and NEDD8 and in the dystrophic neurites with Ub (Mori et al., 
2005, Duyckaerts et al., 2009).  
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Figure 3.6. Analysis of NUB1 detection in the entorhinal cortex and hippocampus of an 
AD patient.  NUB1 was detected in the entorhinal cortex (A, D), CA2 (B, E) and CA4 
(C, F) areas of the hippocampus by immunohistochemistry using a primary antibody 
specific to NUB1 and the DAB/peroxidase method. The NUB1 antibody was pre-
incubated for 1 h at RT either without peptide (A, B, C) or with peptide (30 µg/ml) (D, E, 
F) prior to  labelling the brain sections. Nuclei were labelled with hematoxylin reagent 
(purple). Scale bars = 25 µm. 
Figure 3.7. Subcellular localisation of NUB1 in the entorhinal cortex and hippocampus 
of an AD patient and an age-matched control patient. The localisation of NUB1 in brain 
sections was detected by immunohistochemistry using a primary antibody specific to 
NUB1 and the DAB/peroxidase method. Nuclei were labelled with hematoxylin reagent 
(purple). The NUB1 specific detection (arrows) is shown in the entorhinal cortex (A, D), 
and CA2 (B, E) and CA4 (C, F) areas of the hippocampus in the AD patient (A, B, C) 
and in the control (D, E, F). Scale bars = 25 µm. 
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Ub was detected in both control and AD patients, but was detected in 
extracellular dystrophic structures only in the AD patients. NEDD8 was also 
detected in control and demented patients, and was localised in the pyramidal 
layer neurons of the hippocampus, where NFT aggregation is most prominent in 
the late stages of AD. Interestingly, another ULM, FAT10, was expressed in the 
pyramidal neurons of the hippocampus, and appeared to localise in dystrophic 
neurites. Finally, NUB1, which specifically downregulates both the NEDD8 and 
FAT10 ULM, was specifically detected in the hippocampus and the entorhinal 
cortex of both control and AD patients, with a distribution very similar to that of 
NEDD8. Thus, NUB1 might regulate the degradation of neddylated and 
FAT10ylated proteins in neurons. 
 
3.2.3. Comparison of NEDD8 and NUB1 distribution in the entorhinal 
cortex and hippocampus of AD and control patients 
Chen et al. (2003) immunostained the hippocampus in five cases of AD and five 
age-matched controls with rabbit anti-NEDD8. In four out of five AD cases 
examined, NEDD8 was located primarily in the cytoplasm in hippocampal 
neurons. In contrast, in four out of five control cases, NEDD8 was located 
primarily in the nucleus in hippocampal neurons, showing a shift from a 
neuronal to a cytoplasmic localisation in affected regions of AD brain. However, 
we did not detect a similar shift in NEDD8 subcellular distribution (Table 3.1 and 
3.2). Indeed, the subcellular distribution of NEDD8 in the AD patient and control 
was similar; NEDD8 was more nuclear in the entorhinal cortex, and more 
cytoplasmic in CA2 and CA4 areas of the hippocampus (Figure 3.5). Moreover, 
the localisation of NUB1 was similar to that of NEDD8 (Figure 3.7). Therefore, 
the localisation of NEDD8 and NUB1 was compared in 5 different control (Table 
3.1) and 6 different AD patients (Table 3.2). The subcellular localisation of 
NEDD8 and NUB1 in the CA1-2 and CA4 areas of the hippocampus was 
observed, and divided into three categories: strictly nuclear (N), nuclear and 
cytoplasmic (N/C) and strictly cytoplasmic (C).  
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In the CA1-2 area of the non-demented controls (Table 3.1),  only patient III 
showed any strictly nuclear (N) localisation of NEDD8 in 20% of cells counted.  
If this control is excluded, NEDD8 localisation was strictly cytoplasmic (C) in 
63±2.4% of cells and both nuclear and cytoplasmic (N/C) in 37±2.4% of cells 
counted. Similarly, NUB1 distribution in the CA1-2 area was cytoplasmic (C) in 
60±4.1% and both nuclear and cytoplasmic in 40±4.1% of cells counted. In the 
CA4 area of the hippocampus, NEDD8 localisation was cytoplasmic (C) in 
68±4.0% and both nuclear and cytoplasmic (N/C) in 33±4.0% of cells counted. 
NUB1 distribution in the CA4 area was mostly cytoplasmic (C) (63±3.2%). In 
conclusion, in the hippocampus of the controls, the distribution of both NEDD8 
and NUB1 was similar, and in most cells was localised predominantly in the 
cytoplasm. 
In the AD patients (Table 3.2), only patient X showed a strictly nuclear 
localisation (N) for NEDD8 in both the CA1-2 and CA4 areas for 46% and 11% 
of cells counted respectively. With the exclusion of patient X, NEDD8 was on 
average predominantly localised in the cytoplasm (C) in 59.75±4.66% of 
hippocampal cells/neurons in the CA1-2 area, which was not significantly 
different from the percentage of strictly cytoplasmic localisation in the group of 
controls (63±2.4%, p-value = 0.401 using an unpaired Student’s t-test). 
In the CA4 area, NEDD8 was again mostly distributed in the cytoplasm 
(69±4.5%), which was not significantly different from that in the controls 
(68±4.1%, p-value = 0.478 using an unpaired Student’s t-test). Similarly, NUB1 
distribution in AD patients was predominantly cytoplasmic (C) in both the CA1-2 
and the CA4 areas of the hippocampus (55±1.5% and 62±3.9% respectively), 
and was not significantly different from the cytoplasmic localisation in controls 
(60±4.1%, p-value = 0.056 and 63±3.2%, p-value = 0.769 using an unpaired 
Student’s t-test in CA1-2 and CA4 respectively). However, NEDD8 had a 
significantly higher strictly cytoplasmic localisation (C) in the CA4 area 
compared to the CA1-2 area (69.29±4.51% and 59.75±4.66% respectively, p-
value = 0.026) in the AD patients. Similarly, NUB1 distribution was significantly 
more strictly cytoplasmic (C) in the CA4 area than in the CA1-2 area 
(62.08±3.94 and 54.81±1.48 respectively, p-value = 0.005) in the AD patients.
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Table 3.1. Subcellular distribution of NEDD8 and NUB1 in the hippocampus of non-demented controls. NEDD8 and NUB1 localisation was 
categorised as cytoplasmic (C), nuclear (N), or both nuclear and cytoplasmic (N/C) in hippocampal neurons.  
Localisation (%) 
NEDD8 NUB1 
Patient 
 
Age (y) 
 
Sex 
 
PM delay 
(h) 
 
Pathology 
 N C N/C N C N/C 
Area 
 
I 86 M 6   64 36  61 39 CA1-2 
        
Normal adult brain 
    67 33  65 35 CA4 
II 81 M 18   69 31  65 35 CA1-2 
    
Control- old cerebral 
infarct 
(BraakI)   72 28  59 41 CA4 
III 80 M 11 20 47 33  55 45 CA1-2 
        
Normal adult brain 
   65 35  66 34 CA4 
IV 82 F 43   57 43 N/A N/A N/A CA1-2 
        
Normal adult brain 
    63 37 N/A N/A N/A CA4 
V 92 F 17 N/A N/A N/A  58 42 CA1-2 
        
Normal adult brain 
  N/A N/A N/A  62 38 CA4 
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Table 3.2. Subcellular distribution of NEDD8 and NUB1 in the hippocampus of AD patients. NEDD8 and NUB1 localisation was categorised as 
cytoplasmic (C), nuclear (N), or both (N/C) in hippocampal neurons. 
 Localisation (%)  
Patients Age (y) Sex 
PM 
Delay (h) Pathology NEDD8 NUB1 Area 
     N C N/C N C N/C   
VI 88 M 22  63 37  56 44 CA1-2 
    
AD braak stage V/VI 
 69 31  66 34 CA4 
VII 103 F 12  59 41  54 46 CA1-2 
    
AD modified Braak 
stage V/VI with mild 
focal amyloid 
angiopathy  65 35  56 44 CA4 
VIII 80 M 15  64 36  57 43 CA1-2 
    
AD Braak stage VI 
 75 25  65 35 CA4 
IX 71 F 21  53 47  54 46 CA1-2 
    
AD 
 68 32  62 38 CA4 
X 67 F 56 46 1 53 N/A N/A N/A CA1-2 
    
AD Braak stage VI 
11 45 44 N/A N/A N/A CA4 
XI 88 M 5 N/A N/A N/A  53 47 CA1-2 
        
AD Braak stage VI 
with amyloid 
angiopathy N/A N/A N/A  64 36 CA4 
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In conclusion, in the controls, both NEDD8 and NUB1 were predominantly 
cytoplasmic in both the CA1-2 and CA4 areas. In the AD patients, NEDD8 and 
NUB1 distributions were similar, with a predominant cytoplasmic localisation in 
the CA1-2 and CA4 areas. However, in AD patients, the NUB1 and NEDD8 
distributions were more evenly distributed in the nucleus and cytoplasm in the 
CA1-2 areas, whereas it was more strictly cytoplasmic in the CA4 area. 
 
3.2.4. Expression of endogenous NUB1 in rat cortical primary 
neurons. 
NUB1 was detected in neurons of the hippocampus, where tau is known to 
accumulate in AD. Thus, to investigate the influence of NUB1 on endogenous 
tau, the localisation and expression of GFP-NUB1, endogenous NUB1, tau and 
GSK3β were explored in rat cortical primary neurons.  
Primary cortical neurons were isolated from Sprague Dawley rat embryos on 
day 18 of gestation (E18). Between 5 to 7 days in vitro (DIV) culture, cells were 
transfected with GFP or GFP-NUB1 and treated with vehicle (PBS), or the 
pharmacological inhibitor of GSK3 activity, lithium chloride (LiCl) (10 mM, 2 h) 
(Ryves and Harwood, 2001; Tajes et al., 2008). The expression of GFP, GFP-
NUB1, tau and GSK3β was analysed by WB analysis (Figure 3.8). 
Although six different isoforms of tau are expressed in the adult brain, only the 
0N3R isoform is expressed in foetal brain (Buee et al., 2000). Therefore, in 
embryonic rat primary cortical neurons, endogenous tau was detected as a 
prominent band of ~50kDa (Figure 3.8, A). The inhibition of GSK3β activity and 
consequent reduced phosphorylation of tau in the presence of LiCl, resulted in 
an increased mobility of tau to a lower molecular weight. Moreover, tau 
expression appeared unchanged in the presence of GFP or GFP-NUB1. 
Endogenous GSK3β (Figure 3.8, B) was detected as a single band of ~47kDa, 
and the LiCl treatment reduced GSK3β levels. Similar to tau, GSK3β levels 
were similar in the presence of GFP-NUB1 compared to GFP alone. 
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Figure 3.8. Expression of tau, GSK3β and GFP-NUB1 in primary neurons. Rat primary 
neurons were transfected with GFP or GFP-NUB1 plasmids. Twenty-four hours after 
transfection, cells were treated with vehicle (PBS) or LiCl (10 mM, 2 h). Samples were 
resolved on a polyacrylamide gel (10%) and proteins were detected by WB, using anti-
tau (A), anti-GSK3β (B) or anti-GFP(C). 
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The detection of GFP and GFP-NUB1 in primary neurons with the anti-GFP 
antibody is shown in Figure 3.8, C. GFP was detected at ~27kDa, while GFP-
NUB1 was detected at ~100kDa, similar to the predicted molecular weight 
(96kDa). GFP-NUB1 levels were reduced compared to GFP, possibly due to 
differences in transfection efficiency or protein expression in the neuronal cells, 
or both. Neither GFP nor GFP-NUB1 levels were affected by treatment with 
LiCl.  
The expression of GFP-NUB1 was also detected with an antibody specific to 
NUB1 (Figure 3.9). This antibody is a peptide-directed antibody raised against a 
sequence derived from the C-terminus of human NUB1 (van der Spuy et al., 
2003). GFP-NUB1 was detected by the NUB1 antibody (Figure 3.9, A). 
Surprisingly, a second band of ~66kDa, the putative molecular weight of 
endogenous rat NUB1, was also detected. In order to assess if the ~66kDa 
band was indeed endogenous rat NUB1, the NUB1 antibody was pre-incubated 
with the NUB1 peptide against which it was raised and which competes with 
NUB1 antibody antigen recognition. The immunodetection of both the ~66 kDa 
band and the GFP-NUB1 was lost when the NUB1 antibody was first pre-
incubated with the NUB1 peptide (30 µg/ml, 1 h). Thus, the NUB1 antibody can 
specifically detect endogenous NUB1 in rat primary neurons. The levels of 
endogenous NUB1 and GFP-NUB1 were similar. LiCl treatment did not 
significantly alter the levels of endogenous NUB1.  
In conclusion, the exogenous expression of GFP-NUB1 or GFP did not alter the 
expression of either tau or GSK3β. However, the low relative expression levels 
of exogenous GFP-NUB1, similar to that of endogenous NUB1, and the poor 
transfection efficiency of exogenous NUB1 (less than 6%) might explain the 
absence of any effect on endogenous tau and GSK3β levels. Indeed, the levels 
of endogenous tau and GSK3β in the cells that are not transfected with 
exogenous NUB1 could mask the influence of GFP-NUB1 in transfected cells. 
Endogenous NUB1 is expressed in rat primary neurons and was specifically 
detected with the human peptide-directed NUB1 antibody. 
 
  
 Chapter 3 - Localisation of NUB1 
  98 
 
 
 
Figure 3.9. Expression of GFP-NUB1 and endogenous NUB1. Rat primary neurons 
were transfected with GFP or GFP-NUB1 plasmids. Twenty-four hours after 
transfection, cells were treated with vehicle (PBS) or LiCl (10 mM, 2 h). Samples were 
resolved on a polyacrylamide gel (10%) and endogenous NUB1 and GFP-NUB1 were 
detected using a rabbit anti-NUB1 primary antibody (A), or following the pre-incubation 
of the anti-NUB1 antibody with the NUB1 peptide (30 µg/ml) for 1 h (B).  
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3.2.5. Localisation of GFP-NUB1 in rat primary cortical neurons 
The NUB1 peptide-directed antibody detected the expression of endogenous 
NUB1 in rat primary cortical neurons by WB analysis. However, it has been 
established in our laboratory that the NUB1 peptide-directed antibody is not 
suitable for immunocytochemical localisation. Therefore, primary cortical 
neurons were transfected with GFP-NUB1 in order to assess the subcellular 
localisation of GFP-NUB1 in these cells. 
Rat primary cortical neurons were collected at embryonic day 18 (E18) and 
cultured in vitro for 5 days (5 DIV) prior to transfection. GFP-NUB1 and GFP 
plasmids were transfected by lipofection, and cells were fixed with 
paraformaldehyde (4%) 24 h after transfection. The percentage of total cells 
expressing GFP-NUB1 was ~5.6±0.7% while the GFP transfection efficiency 
was ~13.5±1.1%. The subcellular localisation of GFP-NUB1 and GFP alone is 
shown in Figure 3.10. GFP-NUB1 distribution (Figure 3.10, top row) was 
prominently nuclear, in accordance with the presence of a NLS in the C-terminal 
domain of the NUB1 sequence between residues 414 and 431. GFP-NUB1 was 
also observed in the neurites (axons and dendrites), and appeared prominently 
in the axonal varicosities (Figure 3.10, top row, white arrows). GFP, on the other 
hand, was expressed ubiquitously throughout the neurons, including the cell 
body, axons and dendrites.  
 
3.2.6. GFP-NUB1 co-localisation with endogenous tau, GSK3β and 
β-tubulin in rat primary cortical neurons 
In order to analyse the distribution of GFP-NUB1 compared to that of 
endogenous tau, microtubules and GSK3β, rat primary cortical neurons were 
transfected with GFP-NUB1 and labelled for tau, β-tubulin and GSK3β. 
Endogenous tau (Figure 3.11, red) was detected prominently in the axons and 
dendrites, in accordance with the role of tau as a microtubule associated protein 
implicated in neuron growth (Buee et al., 2000; Gendron and Petrucelli, 2009). 
GFP-NUB1 (Figure 3.11, green) was detected in the nucleus, cell body and 
primary neurites. In the magnified image of the cell body, low levels of tau were  
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Figure 3.10. Localisation of GFP-NUB1 and GFP in rat primary neurons. Rat primary 
cortical neurons were transfected with GFP or GFP-NUB1 plasmids. Twenty-four hours 
after transfection, cells were fixed with paraformaldehyde (4%, 10 min, 37°C), and 
treated with DAPI to detect nuclei (blue). Images were acquired with a laser scanning 
confocal microscope (Zeiss LSM 700). White arrows show the varicosities. Scale bars 
= 10 µm. 
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Figure 3.11. Distribution of GFP-NUB1 and endogenous tau in rat primary neurons. 
Rat primary cortical neurons were transfected with GFP-NUB1 plasmid. Twenty-four 
hours after transfection, cells were fixed with paraformaldehyde (4%, 10 min at 37°C). 
Cells were labelled with the anti-tau primary antibody in conjunction with the AlexaFluor 
594 secondary antibody and treated with DAPI to detect nuclei (blue). Images were 
acquired with a laser scanning confocal microscope (Zeiss LSM 700). The white 
squares I and II demarcate the magnification of the cell body (soma, I) and neurites (II). 
The varicosities are highlighted by white arrows. Scale bars = 10 µm. 
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detected in the soma and no tau expression was detected in the nucleus 
(Figure 3.11, I, red). In contrast, GFP-NUB1 was predominantly detected in the 
nucleus with comparatively lower levels detected in the cell soma (Figure 3.11, 
I, green). Therefore, GFP-NUB1 and endogenous tau did not co-localise in the 
nucleus but both were detected in the soma. Moreover, GFP-NUB1 co-localised 
with tau in the primary neurites (Figure 3.11, II, merge) and in the varicosities 
(Figure 3.11, II, merge, arrowheads).  
The microtubules, labelled with an antibody specific to β-tubulin, were detected 
in the dendrites and axons (Figure 3.12, red) similar to the distribution of tau. In 
the magnified image of the cell body, the microtubules (Figure 3.12, I, red) 
appeared to surround the cell body and were not detected in the nucleus. GFP-
NUB1 (Figure 3.12, I, green) was detected prominently in the nucleus and also 
in the cytoplasm. Both GFP-NUB1 and β-tubulin were detected in the primary 
neurites (Figure 3.12, I and II). However a partial co-localisation of their 
distribution in these structures was evident, with the microtubules appearing to 
surround the GFP-NUB1 in the axon more than to co-localise with it (Figure 
3.12, I). Interestingly, in the magnified image of the neurites (Figure 3.12, II, 
merge), it can be seen that GFP-NUB1 and β-tubulin seemed to inter-digitise 
with one another, with the microtubules surrounding the GFP-NUB1 in the 
varicosities (white arrows). 
GSK3β localisation in rat primary neurons (Figure 3.13, red) was mostly 
detected in the cytoplasm of the cell body and in the primary neurites, although 
very low levels could be detected in the nucleus. In the magnified image of the 
soma (Figure 3.13, I, merge), the detection of GSK3β and GFP-NUB1 
overlapped in the cytoplasm and the proximal part of the primary axon, resulting 
in a partial co-localisation with one another in the cytoplasm and axon. In the 
magnified image of the primary neurites (Figure 3.13, II), both GSK3β and GFP-
NUB1 were detected, but GSK3β did not accumulate in the varicosities (white 
arrow), as GFP-NUB1 did.  
In conclusion, GFP-NUB1 co-localised with endogenous tau in the primary 
neurites and varicosities, and with endogenous GSK3β in the cytoplasm and 
primary axon of the cell soma.  
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Figure 3.12. Distribution of GFP-NUB1 and endogenous microtubules in rat primary 
neurons.  Rat primary cortical neurons were transfected with GFP-NUB1 plasmid. 
Twenty-four hours after transfection, cells were fixed with paraformaldehyde (4%, 10 
min at 37°C). Cells were labelled with the anti-β-tub primary antibody in conjunction 
with the AlexaFluor 594 secondary antibody and treated with DAPI to detect nuclei 
(blue). Images were acquired with a laser scanning confocal microscope (Zeiss LSM 
700). The white squares I and II demarcate the magnification of the cell body (soma, I) 
and neurites (II). The varicosities are highlighted by white arrows. Scale bars = 10 µm. 
 
 Chapter 3 - Localisation of NUB1 
  104 
 
 
 
Figure 3.13. Distribution of GFP-NUB1 and endogenous GSK3β in rat primary 
neurons.  Rat primary cortical neurons were transfected with GFP-NUB1 plasmid. 
Twenty-four hours after transfection, cells were fixed with paraformaldehyde (4%, 10 
min at 37°C). Cells were labelled with the anti-GSK3β primary antibody in conjunction 
with the AlexaFluor 594 secondary antibody and treated with DAPI to detect nuclei 
(blue). Images were acquired with a laser scanning confocal microscope (Zeiss LSM 
700). The white squares I and II demarcate the magnification of the cell body (soma, I) 
and neurites (II). The varicosities are highlighted by white arrows. Scale bars = 10 µm. 
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3.3. Discussion 
As thoroughly described in previous studies, tau accumulates in NT, NFTs and 
the corona of neuritic plaques in AD patients. These inclusions are positive for 
hyperphosphorylated tau, and numerous other proteins including Ub and 
NEDD8.  
In this chapter, detection of tau with the AT8 antibody, specific for 
hyperphosphorylated tau, in the entorhinal cortex and hippocampus of Braak 
stage V and VI patients validated the staging of the brain sections and the 
diagnosis. Although AT8 positive cells and tau aggregations could be detected 
in a control, the number of cells with NFTs and the quantity of NTs were far less 
abundant in the age-matched control compared to the AD patient. Moreover, no 
labelling of dystrophic neurites could be found in the control. The presence of 
NFTs and AT8 labelling in non-demented adults has been reported before. The 
difference with AD lies in the load and localisation of NFTs and NTs, twice less 
abundant in the hippocampus of controls than in demented adults (Shin et al., 
1991). A recent study by Braak et al, (2011) on 2332 brain sections from 
patients aged from 1 to 100 years reported that AT8-positive neurons could be 
found in the brain of adults as young as 20 years old. The AT8 immunoreactivity 
was present in cells that contained pretangle tau, i.e. non-argyrophilic 
hyperphosphorylated tau that could not be detected using silver-staining 
techniques. Interestingly, they showed that the presence of 
hyperphosphorylated tau was inevitable after 40 years of age and that the vast 
majority of adults aged 70 or more had NFTs and NTs at least in the 
transentorhinal region. However, even in adults aged more than 90, the 
progression of NFTs was restricted to Braak stage I and II. Braak stage V and 
VI pathology was detected in 9.5 % of the total cases, and in 24.4% of people 
aged more than 80 years. Moreover, a marker of AD is brain shrinkage, 
particularly obvious in cortical regions, due to neuronal loss. The progression of 
NFTs is closely related to the seriousness of the disease, and the pattern and 
regions of NFT load matches the neuron loss. However, cell death within a 
region exceeds the number of NFTs. Furthermore, NFTs in cells can persist for 
decades before becoming ghost tangles, suggesting that tangle-bearing 
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neurons could still be functional and that the formation of NFTs is a 
neuroprotective mechanism. This might explain why not all patients with NFTs 
develop dementia. In fact, NFT formation could be a very slow process spread 
over decades, and the development of sporadic AD might occur only in 
individuals predisposed to pathogenic mechanisms because of environmental 
and genetic factors (Mattson and Magnus, 2006). The present study first 
confirmed the overload of AT8 positive inclusions in the hippocampus and 
entorhinal cortex of a Braak stage VI patient compared to a control patient, in 
order to correlate the subsequent findings with AD pathology. 
One of the known pathogenic mechanisms in AD is the dysregulation of the 
UPS. NFTs and neuritic plaques are decorated with Ub, PHFs and Aβ peptides 
negatively influence the proteasome activity and impairment of the proteasome 
activity has been reported in AD (Oddo, 2008). In this study, Ub accumulated in 
pyramidal neurons of Braak stage VI patients, in structures similar to NFTs. Like 
AT8-specific tau labelling, Ub could be seen in NFT-shaped structures in AD 
patients and less frequently in age-matched control adults. Moreover, no 
extracellular structures (NTs and dystrophic neurites) exhibited strong Ub 
immunoreactivity in control patients compared to AD patients. Therefore the 
Braak stage VI AD patient had more Ub-positive depositions than the control 
patient. Normally, Ub is recycled after targeting a protein for proteasomal 
degradation. The accumulation of Ub in AD lesions suggests that UPS 
degradation mechanisms are impaired or overwhelmed and unable to trigger 
the clearance of aggregating polypeptides. Therefore Ub is sequestered to the 
aggregates.  
The presence of both ULM FAT10 and NEDD8 in the hippocampus was 
revealed. Although NEDD8 has been reported to accumulate in NFTs in AD 
patients, it is the first time that FAT10 has been described in the hippocampus 
and entorhinal cortex of a control and AD patient. However, the detection of 
FAT10 and Ub in only one AD patient and one control cannot lead to thorough 
conclusions. Nonetheless, the fact that FAT10 immunoreactivity was more 
ubiquitously distributed in AD brain sections might be the result of increased 
neuroinflammation in AD, as inflammatory cytokines induce FAT10 expression 
(Lukasiak et al., 2008). Interestingly, FAT10, similarly to Ub, labelled 
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extracellular structures that were probably dystrophic neurites only in the AD 
patient. However, NFT-like structures were decorated with FAT10 in both AD 
patient and control. A role for FAT10 in proteasomal degradation has been 
described (Hipp et al., 2004). This suggests that FAT10 might target tau or a 
conformational population of tau for proteasomal degradation in a Ub-
independent manner.  
NEDD8 is thought to be a predominantly nuclear protein that is involved in 
proteasomal degradation and therefore the regulation of protein activity (Dil 
Kuazi et al., 2003). Several studies have linked NEDD8 to Ub-positive 
inclusions in neurodegenerative disorders such as NFTs and senile plaques in 
AD (Chen et al., 2003; Dil Kuazi et al., 2003; Mori et al., 2005). In this study, 
analysis of NEDD8 immunoreactivity in an AD Braak stage VI and control 
yielded interesting results. In fact, no major difference in NEDD8 
immunoreactivity could be observed between the control and AD patient, while 
Chen et al (2003) showed than in the hippocampus of AD patients NEDD8 was 
shifted from a nuclear to a cytoplasmic localisation compared to control 
patients. This was suggested to occur as a consequence of cell cycle 
dysregulation in AD. In our study, NEDD8 staining was mostly nuclear in 
entorhinal cortical cells, and was predominantly cytoplasmic in the CA1 and 
CA4 areas of the hippocampus in both the control and AD patient. Contrary to 
the study by Mori et al., 2005, no typical AD inclusion bodies, such as NFTs or 
senile plaques, were found to be NEDD8 positive. However, NEDD8 was 
detected in most pyramidal neurons in the CA2 and CA4 areas of the 
hippocampus, where NFT formation occurs.  
As NEDD8 and Ub have been shown to decorate NFTs in AD, double labelling 
with AT8 was performed to unequivocally determine the recruitment to NFT and 
other tau aggregations, but the autofluorescence of the brain sections could not 
be overcome despite the application of various techniques. 
NUB1 can target NEDD8, FAT10 and their conjugated proteins for proteasomal 
degradation (Kamitani et al., 2001; Hipp et al., 2004). Moreover, NUB1 reduces 
synphilin-1 positive inclusions in a model of PD (Tanji et al., 2006). Hence, the 
immunoreactivity of NUB1 was also explored in a Braak stage VI AD patient 
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compared to an age-matched control. However, a previous study from Tanji et 
al, 2007, found no NUB1 immunoreactivity in AD patients. Therefore, the 
specificity of NUB1 antibody was verified. The detection of NUB1 was strongly 
reduced when the NUB1 antibody was pre-incubated with the NUB1 peptide 
and no specific immunoreactivity was detected with the pre-immune serum, 
thus validating the specificity of this antibody. This major difference in our 
findings from those of Tanji et al., (2007) could be explained in many ways, 
including the use of a different NUB1 antibody, variation in the methods used for 
antigen retrieval and antigen detection by immunohistochemistry, or 
characteristics of the brain sections themselves. Indeed, the post-mortem 
fixation delay and the type of embedment are factors that could influence the 
detection of proteins. Nonetheless, examination of NUB1 immunoreactivity was 
interestingly very similar to that of NEDD8. Notably, despite the presence of an 
NLS, NUB1 immunoreactivity was mostly cytoplasmic throughout the neurons in 
the entorhinal cortex and hippocampus of the AD patient and control, and in 
contrast to NEDD8 was also detected in the nucleus in some cells of the 
entorhinal cortex in the control patient only. 
To verify these observations, the localisation of NEDD8 and NUB1 was directly 
compared in a panel of AD patients and controls. The localisation of NEDD8 
and NUB1 in the pyramidal neurons of the CA1/2 and CA4 areas of the 
hippocampus was analysed. No major differences in NEDD8 and NUB1 
immunoreactivity were observed between the control and AD patients, and the 
similarities between NUB1 and NEDD8 were confirmed with their localisation 
more cytoplasmic. This suggests that NUB1 and NEDD8 might cooperate in the 
cytoplasm of the cells in the hippocampus to modulate proteasomal 
degradation. The fact that both NEDD8 and NUB1 were more cytoplasmic in the 
CA4 area than in the CA1/2 area in the AD patient perhaps suggests a 
progressive redistribution of these proteins that correlates with the progression 
of disease severity. As NFTs spread from the entorhinal cortex, where NEDD8 
and NUB1 were found to be more nuclear, to the dentate gyrus, NUB1 and 
NEDD8 relocate to the cytoplasm. It would therefore be interesting to analyse 
NUB1 and NEDD8 in other parts of the brain affected by AD, in order to assess 
if a similar shift could be observed. 
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The expression and localisation of NUB1 was compared to that of endogenous 
tau and GSK3β in rat primary cortical neurons. Lithium treatment clearly 
impaired GSK3β activity, both reducing the levels of endogenous GSK3β and 
decreasing the GSK3β-mediated phosphorylation of endogenous tau. However, 
LiCl had no effect on either GFP-NUB1 or GFP levels. Moreover, transiently 
overexpressed GFP-NUB1 did not have a significant effect on either 
endogenous tau or GSK3β levels. However, transiently expressed levels of 
GFP-NUB1 were dramatically inferior to those of GFP and similar to those of 
endogenous NUB1; therefore, GFP-NUB1 overexpression was probably not 
sufficient to have significantly affected endogenous tau and GSK3β.  
An interesting discovery was that the NUB1 antibody could also specifically 
cross-react with endogenous rat NUB1 that shares 85.7% identity with human 
NUB1 (and 64,3% identity in the NUB1 epitope). Therefore, inhibiting 
endogenous expression of NUB1 by siRNA might be more informative than the 
overexpression of NUB1 in rat cortical neurons.   
Analysis of GFP-NUB1 localisation with endogenous tau, GSK3β and 
microtubules showed interesting findings. As expected, NUB1 was mostly 
nuclear due to its C-terminal NLS. However, all cells expressing GFP-NUB1 
also exhibited diffuse GFP-NUB1 in the cytoplasm and in the neurites. 
Therefore, although predominantly nuclear, NUB1 is also cytoplasmic and might 
participate in protein regulation, for example as a shuttle for proteasomal 
degradation as shown for synphilin-1 (Tanji et al., 2006). Neither β-tubulin, tau 
nor GSK3β were seen in the nucleus, even with GFP-NUB1 expression. In the 
cytoplasm of the cell body, GFP-NUB1 localisation overlapped with that of 
GSK3β. In the neurites, GFP-NUB1 localisation appeared to overlap with that of 
endogenous tau, yet to be enclosed by microtubules rather than to co-localise 
with them. Interestingly, GFP-NUB1 accumulated in what appeared to be 
varicosities. Endogenous tau, but not β-tubulin or GSK3β was also detected in 
these swellings. Indeed, β-tubulin and GFP-NUB1 expression in these swelling 
was mutually exclusive, as though the microtubules enclosed them. 
Varicosities, also called presynaptic boutons, are thought to be swellings of the 
axons rich in neurotransmitter substances and involved in intercellular signal 
transduction. This raises the interesting possibility that NUB1 and tau could 
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cooperate in either neurotransmitter trafficking, or regulation of signal 
transduction at synapses. Indeed, NFT bearing neurons in AD seem to have 
reduced synaptic proteins such as synaptophysin compared to NFT-free 
neurons (Callahan et al., 1995). Moreover, a study of AD synaptosomes 
showed that Aβ peptides were found to aggregate in the synaptosomes which 
were also decorated with phosphorylated tau (Sokolow et al., 2011). Thus, tau 
is probably involved in synaptic signalling through regulation of the 
cytoskeleton. Whether the GFP-NUB1 positive varicosities are synaptic 
structures could be tested by staining for specific synaptic markers, such as the 
glutamatergic presynaptic terminal marker, vesicular glutamate transporter 1 
(Lin et al., 2010). 
The analysis of NUB1 and the ULMs NEDD8 and FAT10 in Braak stage VI AD 
patients has shown that these proteins can be detected in areas of the brain 
that are vulnerable to degeneration in AD, where they may be involved in 
protein turnover. Moreover, NUB1 expression in rat cortical neurons revealed 
that NUB1 co-localised with endogenous tau in the neurites and varicosities, 
and with GSK3β in the cytoplasm of the cell body. Thus, NUB1 could interact 
functionally with them. Furthermore, the predominantly nuclear localisation of 
NUB1 implies that NUB1 might have an independent role in cell regulatory 
functions such as cell signalling. The localisation of NUB1 with tau in the 
neurites and varicosities, an important platform for signal transduction, suggests 
that NUB1 and tau might have a role in the regulation of neurotransmitter 
trafficking or release. 
The next chapter will focus on the capacity of NUB1 to modulate the formation 
of tau inclusions in a cell model of tau phosphorylation and aggregation. 
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Chapter 4  
NUB1 reduces tau aggregation 
 
4.1. Introduction 
The cytoskeletal microtubules are an essential support network for neuronal 
activity. Microtubules are composed of α and β dimers that polymerise in 
protofilaments. The flexibility and remodelling of microtubules are essential for 
the growth of neuronal processes. Wide and long microtubule filaments in the 
axon provide tracks for the dynamic transport of proteins. Therefore, the stability 
of microtubules, but not the rigidity, is crucial for the normal function of neurons. 
The MAP tau is involved in microtubule polymerisation and stability, and binds 
to the microtubules via its MBD domain composed of 3 or 4 repeat regions. The 
presence of 4 repeat regions in the MBD of the 4R isoforms enhances the 
strength of tau interaction with the microtubules and the ability of tau to promote 
microtubule assembly and stabilisation compared to the 3R isoforms. More 
precisely, it is a particular motif, KVQIINKK, located between the repeat regions 
R1 and R2 that confers the high affinity for microtubules to the 4R isoforms 
(Panda et al., 1995). Indeed, in mammalian cells, tau overexpression promotes 
microtubule bundling. Tau co-localises with microtubule bundles, the shapes of 
which vary from one cell type to another (Bruijn et al, 2004; Lovestone et al., 
1996).  
Tau phosphorylation regulates its binding to the microtubules and aggregation. 
Phosphorylation in the MBD (between residues 244-368) has the strongest 
influence on tau interaction with the microtubules. For instance, the residues 
Ser262 and Ser356 alone, if phosphorylated, inhibit tau interaction with the 
microtubules and are crucial for the outgrowth of neuronal processes (Biernat 
and Mandelkow, 1999; Fischer et al., 2009). The phosphorylation of Thr231 and 
Ser214, in the proline-rich domain, also reduce the ability of tau to bind 
microtubules (Sengupta et al., 1998; Cho and Johnson, 2003). Interestingly, in 
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cell models mimicking tau phosphorylation, the phosphorylation of tau at the N-
terminus (before residue 208) inhibited tau aggregation, while phosphorylation 
at the C-terminus (from residue 396) induced tau aggregation (Abraha et al., 
2000; Haase et al., 2004). 
The formation of NFTs in AD is not linked to a mutation in the tau sequence but 
rather to post-translational modification such as its hyperphosphorylation. This 
would occur as a result of the combined upregulation of kinases (GSK3, cdk5, 
CK1) and downregulation of phosphatases (PP2A, PP5) (Hanger et al., 2009; 
Martin et al., 2011). In vitro, tau phosphorylated at specific sites (S396, S404, 
S422) is prone to aggregate (Liu F et al., 2007) and tau phosphorylated on 
Ser396 (pS396-tau) has been detected in PHF (Otvos et al., 1994). GSK3 is a 
major kinase for tau phosphorylation in AD as it can phosphorylate tau on many 
residues recognized by the antibodies Alz50, PHF-1, AT8, AT100 and AT180, 
antibodies specifically used to detect PHFs and NFTs in AD. Moreover, it has 
been shown that GSK3 activity is increased in AD brain, which is likely to be 
responsible for tau hyperphosphorylation (Hooper et al., 2008). The 
GSK3β isoform is highly expressed in the brain and neurons and co-localises 
with the microtubules (Johnson and Stoothoff, 2004; Hanger et al., 2009). 
Furthermore, in vitro, tau phosphorylation by GSK3β has been shown to trigger 
the formation of tangle-like structures (Rankin et al., 2008).  
A consequence of the hyperphosphorylation of tau is a shift in its molecular 
weight detected on WB. Although the normal six isoforms of tau have a 
molecular weight distribution of between 50 kDa to 65 kDa, 
hyperphosphorylated tau in AD is seen as 3 prominent bands of 55, 64, and 69 
kDa and a less prominent band of 74 kDa that represents the 
hyperphosphorylation of the 6 different tau isoforms. On the other hand, due to 
the overexpression of the 4R tau isoforms in PSP, CBD and FTDP-17 with 
mutations affecting tau splicing, only 2 prominent bands of 64 and 69 kDa and a 
smaller one at 74 kDa are detected (Lee et al., 2001; Buee et al., 2000). 
As noted previously, NUB1 and NUB1L are UBL/UBA proteins that target the 
ULM NEDD8 and FAT10, and their conjugates, for proteasomal degradation. As 
seen in chapter 3, both NEDD8 and NUB1 are expressed in the pyramidal 
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neurons of the hippocampus in control and AD patients, suggesting that both 
NUB1 and NEDD8 have a functional role in this region of the brain.  
NUB1 has been shown to reduce synphilin-1 positive inclusions in a cell model 
of PD (Tanji et al., 2006). Interestingly, the C-terminus of NUB1 was essential 
for direct interaction with synphilin-1, which might suggest that neddylation or 
FAT10ylation is not always necessary for NUB1 activity.  
This chapter focused on the optimisation of a cell model for tau aggregation. 
Human neuroblastoma SK-N-SH cells, lacking detectable levels of endogenous 
tau protein, were transfected with the 0N4R isoform of tau fused with GFP at its 
N-terminus. In addition, GSK3β was overexpressed to induce the 
phosphorylation of tau, and the proteasome was inhibited to promote tau 
aggregation as proteasome failure is a feature of AD. The influence of NUB1 
co-expression on tau aggregation was analysed. Furthermore, the effect of 
NUB1L and NUB1L mutants, lacking the UBL domain or the three UBA 
domains, on tau inclusion formation was assessed. 
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4.2. Results 
4.2.1. Expression and localisation of GFP-tau 
To analyse the expression and localisation of tau, GFP-tau was transiently 
overexpressed in SK-N-SH neuroblastoma cells (Figure 4.1) 
Twenty-four hours after transfection, cells were harvested and 10 µg of total 
protein was resolved on a polyacrylamide gel (10%). Tau protein was detected 
by WB, using an antibody specific to total tau (anti-tau) or to the GFP tag (anti-
GFP) (Figure 4.1, A). Although the six isoforms of tau are normally expressed in 
human adult brain (Buee et al., 2000), endogenous tau protein could not be 
detected in SK-N-SH cells (Figure 4.1, A), even with longer exposures and 
increased amounts of protein. However, GFP-tau was detected with both the 
anti-tau and the anti-GFP antibodies as a single band of ~91kDa. Because of 
the absence of detectable endogenous tau protein, the SK-N-SH 
neuroblastoma cell line was considered a very useful tool to control the 
expression and the aggregation of exogenous tau protein.  
The subcellular distribution of GFP-tau was examined in SK-N-SH cells, 
following a 4 h treatment of cells with a vehicle (DMSO) or with MG132 (50 µM) 
24 h after transfection. The inhibition of the proteasome has been shown to 
induce the formation of GFP-tau inclusions (Goldbaum et al., 2003), and 
impairment of the proteasome in AD has been reported to be an underlying 
pathogenic mechanism exacerbating the aggregation of tau and formation of 
NFTs (Keck et al, 2003). Subsequently, cells were fixed with 0.3% 
glutaraldehyde for 10 min at 37°C. The endogenous microtubule network was 
labelled using the anti-β-tubulin (anti-β-tub) primary antibody in conjunction with 
the AlexaFluor 594 secondary antibody. In Figure 4.1, B, GFP-tau (green) was 
detected in the cytoplasm, in a prominent microtubule network co-labelled by 
anti-β-tub (red). GFP-tau overexpression induced the formation of microtubule 
bundles (arrows), (Lewis et al., 1989; Bruijn et al., 2004). Following inhibition of 
the proteasome (Figure 4.1, B, bottom row), GFP-tau was detected in protein 
aggregates (arrowhead). However, these inclusions were not microtubule 
positive.  
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Figure 4.1. Expression and localisation of GFP-tau in SK-N-SH cells. (A) Cells were 
transfected with with 50 ng of GFP-tau plasmid. Twenty-four hours after transfection, 
cell lysates (10 µg of total cellular protein) were resolved on a polyacrylamide gel (10%) 
and proteins were detected by WB, using the anti-tau or anti-GFP antibody. (B) Cells 
were transfected with 50 ng of GFP-tau. Twenty-four hours after transfection, cells 
were treated with a vehicle (DMSO) or with MG132 (50 µM) for 4 h. Cells were fixed 
with 0.3% glutaraldehyde for 10 min at 37°C. The microtubules (red) were detected 
using the anti-β-tub antibody and the AlexaFluor 594 secondary antibody. Nuclei were 
detected with DAPI (blue). GFP-tau (green) was detected in microtubule bundles 
(arrows) and protein aggregates (arrowheads). Images were acquired with a laser 
scanning confocal microscope (Zeiss LSM 700). Scale bars = 10 µm.  
 Chapter 4 - NUB1 reduces tau aggregation 
  116 
Thus, GFP-tau was normally associated with the microtubules, but upon 
inhibition of the proteasome, detached from the microtubule network and 
formed inclusions. 
 
4.2.2. Expression and localisation of HA-GSK3β 
In AD, tau aggregation occurs following its hyperphosphorylation by several 
kinases such as GSK3β  (Buee et al., 2000; Hanger et al., 2009). Therefore, the 
expression of endogenous GSK3β and transiently expressed HA-GSK3β was 
analysed in SK-N-SH cells (Figure 4.2). 
Twenty-four hours after transfection, 10 µg of  total cellular protein was resolved 
on a 10% polyacrylamide gel and proteins were detected by WB using the anti-
GSK3β or the anti-HA antibody (Figure 4.2, A). The endogenous GSK3β was 
detected in SK-N-SH cells as a single band of ~47 kDa, but at very low levels 
compared to the exogenous HA-GSK3β, even with long exposures and 
significantly increased amounts of protein. The recombinant protein HA-GSK3β 
was specifically detected by both the anti-GSK3β and the anti-HA antibodies as 
a single band of ~50 kDa. 
To analyse the subcellular localisation of GSK3β in SK-N-SH neuroblastoma 
cells, HA-GSK3β was detected with the anti-HA primary and the AlexaFluor 594 
secondary antibody (Figure 4.2, B). HA-GSK3β was localised ubiquitously 
throughout the cytoplasm, both with and without proteasome inhibition. 
However, following proteasome inhibition, the appearance of HA-GSK3β was 
more particulate in the cytoplasm and HA-GSK3β was also detected in the 
nucleus.  
 
4.2.3. HA-GSK3β induces GFP-tau inclusion formation 
The anomalous hyperphosphorylation of tau by GSK3β is an important 
pathogenic mechanism of tau aggregation in AD (Balaraman et al, 2006; Giese, 
2009). Moreover, the failure of the UPS system to clear tau inclusions has been 
described to enhance the formation of NFTs (Oddo, 2008). Therefore, both the 
co-transfection of HA-GSK3β with GFP-tau and the inhibition of the proteasome 
were optimised in SK-N-SH cells to induce GFP-tau aggregation. 
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Figure 4.2. Expression and localisation of HA-GSK3β in SK-N-SH cells. (A) Cells were 
transfected with a control plasmid (-) or with 150 ng of HA-GSK3β (+).Twenty-four 
hours after transfection, cell lysates (10 µg total cellular protein) were resolved on a 
polyacrylamide gel (10%) and proteins were detected by WB, using the anti-GSK3β or 
anti-HA antibody. (B) Cells were transfected with 150 ng of HA-GSK3β 
plasmid. Twenty-four hours after transfection, cells were treated with a vehicle (DMSO) 
or with MG132 (50 µM) for 4 h. Cells were fixed with 0.3% glutaraldehyde for 10 min at 
37°C. HA-GSK3β (red) was detected using the anti-HA antibody and the AlexaFluor 
594 secondary antibody. Nuclei were detected with DAPI (blue). Images were acquired 
with a laser scanning confocal microscope (Zeiss LSM 700). Scale bars = 10 µm. 
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To confirm that HA-GSK3β could phosphorylate exogenous GFP-tau, cells were 
transfected with GFP-tau alone or with HA-GSK3β, and the detection of two 
phosphorylable epitopes of tau, Ser396 and AT8 epitopes, was analysed by WB 
(Figure 4.3, A). 
Tau residue S396 and the AT8 epitopes are two targets for GSK3β-dependent 
phosphorylation (Plattner et al., 2006, Hanger et al., 2009; Qian et al., 2010). In 
the absence of HA-GSK3β, a basal level of tau phosphorylated on S396 could 
be detected in SK-N-SH cells, whereas phosphorylation of tau on the AT8 
epitopes could not be observed. Phosphorylation of tau on the AT8 epitopes 
was only detected in the presence of HA-GSK3β. An increase in 
phosphorylation of GFP-tau S396 was seen with HA-GSK3β co-expression, as 
well as a shift in GFP-tau molecular weight. Indeed, with the two antibodies anti-
tau and anti-pS396, a second higher molecular weight band was observed as a 
result of hyperphosphorylation of GFP-tau in the presence of exogenous 
GSK3β. 
To detect and define GFP-tau inclusions, cells were transfected with GFP-tau 
and HA-GSK3β. Twenty-four hours after transfection, cells were treated with a 
vehicle (DMSO) or with MG132 (50 µM) for 4 h. Subsequently, cells were fixed 
with 0.3% glutaraldehyde for 10 min at 37°C, and GFP-tau inclusions were 
labelled with the AT8 antibody. The AT8 antibody does not normally detect tau 
unless it is abnormally phosphorylated (Figure 4.3, A) (Braak and Braak, 1995). 
Figure 4.3, B, shows that, in addition to the microtubule bundles, GFP-tau 
(green) was also diffusely localised in the cytoplasm both in the absence (top 
row) and the presence (bottom row) of proteasome inhibition with HA-GSK3β 
co-transfection compared to GFP-tau alone (Figure 4.1). Moreover, GFP-tau 
inclusions that were AT8 positive were detected (arrows). In the presence of 
MG132 (Figure 4.3, B, bottom row), GFP-tau was noticeably detected diffusely 
in the cytoplasm and AT8 also detected some of the GFP-tau labelled 
microtubule bundles. Therefore, AT8 co-labelling confirmed the formation of 
GSK3β-dependent GFP-tau inclusions in SK-N-SH cells.  
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Figure 4.3. GSK3β-dependent GFP-tau phosphorylation and inclusion formation. (A) 
Cells were transfected with GFP-tau alone or in combination with HA-GSK3β plasmids. 
Twenty-four hours later, cells were lysed with RIPA buffer and samples (10 µg) were 
resolved on a polyacrylamide gel (10%). Proteins were detected by WB using the anti-
tau, anti-pS396, AT8 and anti-HA primary antibodies. (B) Cells were transfected with 
50 ng of GFP-tau and with 150 ng of HA-GSK3β plasmids. Twenty-four hours after 
transfection, cells were treated with a vehicle (DMSO) or with MG132 (50 µM) for 4 h. 
Cells were fixed with 0.3% glutaraldehyde for 10 min at 37°C, and 
immunocytochemistry performed with the AT8 primary antibody and AlexaFluor 594 
secondary antibody. GFP-tau inclusions (green) were AT8 positive (red) (arrows) or 
AT8 negative (arrowhead). Images were acquired with a laser scanning confocal 
microscope (Zeiss LSM 700). Scale bars = 10 µm. 
 Chapter 4 - NUB1 reduces tau aggregation 
  120 
 
HA-GSK3β was able to phosphorylate tau and induce tau inclusion formation. 
The optimal ratio between GFP-tau and HA-GSK3β  that would induce tau 
aggregation was explored in SK-N-SH cells. Cells were co-transfected with 
increasing amounts of GFP-tau and HA-GSK3β (Figure 4.4).   
Twenty-four hours after transfection, cells were treated with MG132 (50 µM) for 
4 h, and GFP-tau inclusions were detected using the AT8 antibody in 
conjunction with the AlexaFluor 594 secondary antibody (Figure 4.4). The data 
showed that with any given amount of GFP-tau, there was generally a 
proportionate increase in the number of cells with AT8 positive inclusions with 
increasing amounts of GSK3β. However, the same ratio from different relative 
amounts of GFP-tau and HA-GSK3β co-transfected gave different percentages 
of GFP-tau inclusions. For instance, the ratio GFP-tau:GSK3β = 1:1 with 25 ng, 
50 ng and 100 ng of each produced 13.3±0.3%, 8±1.9% and 15.5±2.3% of 
GFP-tau transfected cells with inclusions respectively. Therefore, the 
percentage of GFP-tau inclusions was dependent on both the absolute amounts 
of each and their relative ratio. The co-transfection of 50 ng of GFP-tau and 150 
ng of HA-GSK3β (GFP-tau:GSK3β  = 1:3) yielded the greatest percentage 
(22.7±1.7%) of GFP-tau inclusions and was used in all further experiments. 
 
4.2.4. Proteasome inhibition enhances GFP-tau inclusion formation 
In AD, impairment of the UPS has been implicated in the failure to clear tau 
aggregates (Upadhya and Hegde, 2007; Riederer et al., 2011). Moreover, the 
inhibition of the proteasome in cells has been shown to stabilise the formation of 
tau inclusions (Goldbaum et al., 2003). Therefore, the effect of proteasome 
inhibition on GFP-tau inclusion formation was examined in SK-N-SH cells. Cells 
were transiently transfected with 50 ng of GFP-tau and 24 h later treated with 
vehicle (DMSO) (NT) or five different combinations of proteasome inhibitors: 50 
µM MG132 (MG132), 10 µM lactacystin (LAC), 10 µM epoxomicin (EPO), 50 
µM MG132 + 10 µM lactacystin (MG132+LAC), 50 µM MG132 + 10 µM 
epoxomicin (MG132+EPO), or 10 µM lactacystin + 10 µM epoxomicin 
(LAC+EPO).  
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Figure 4.4. Optimisation of GSK3β-dependent GFP-tau inclusion formation. Cells were 
transfected with increasing amounts of GFP-tau and HA-GSK3β plasmids. Twenty-four 
hours after transfection, cells were treated with MG132 (50 µM) for 4 h, fixed with 100% 
methanol for 5 min at -20°C, and immunocytochemistry performed with AT8. At least 4 
groups of 100 GFP-tau transfected cells (total, either with or without inclusions) for 
each of the two replicate experiments were counted using the Nikon Eclipse80i 
epifluorescent microscope, and the percentage of GFP-tau transfected cells with 
inclusions calculated. The GFP-tau:GSK3β ratio is shown in brackets. Error bars 
represent the standard error of the mean (SEM). 
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Cells were fixed and the percentage of cells transfected (Figure 4.5, A) as well 
as the percentage of cells transfected with inclusions (Figure 4.5, B) was 
counted.  
With any given proteasome inhibition treatment, the percentage of transfected 
cells remained unchanged and was 34.3±0.8% (Figure 4.5, A). In the absence 
of proteasome inhibition, few GFP-tau inclusions were counted over time 
(Figure 4.5, B).  
However, in the presence of proteasome inhibition, irrespective of the 
proteasome inhibitor used or combination thereof, the percentage of GFP-tau 
transfected cells with inclusions increased over time, even without GSK3β co-
transfection. Therefore inhibition of the proteasome alone was sufficient to 
induce the formation of GFP-tau inclusions in SK-N-SH cells. After 4 h of 
treatment, lactacystin alone was the least effective proteasome inhibitor and did 
not induce more than ~11% of GFP-tau transfected cells with inclusions (Figure 
4.5, B). In comparison, after 4 h of treatment, the percentage of cells with GFP- 
tau inclusions did not differ significantly (p-value > 0.8) following treatment with 
MG132 alone (18.3±0.3%), MG132+lactacystin (MG132+LAC, 18.7±5%) or 
MG132+epoxomicin (MG132+EPO, 18.15±3.3%). A 4 h treatment with MG132 
alone was therefore suitable for the induction of inclusions. After 6 h of 
treatment, non-specific effects on cell survival were noted, and this duration of 
treatment was deemed too long. 
Subsequently, cells were transfected with both GFP-tau and HA-GSK3β and the 
percentage of GFP-tau transfected cells (Figure 4.6, A) and percentage of GFP-
tau transfected cells with inclusions (Figure 4.6, B) counted following 
proteasome inhibition over time. Similarly to the transfection of GFP-tau alone 
(Figure 4.5, A), proteasome inhibition did not affect the percentage of GFP-tau 
transfected cells (33.2±0.6%) in the presence of HA-GSK3β (Figure 4.6, A). 
Moreover, in the absence of proteasome inhibition, GFP-tau phosphorylation 
due to GSK3β co-transfection alone enhanced GFP-tau inclusion formation 
(6.8±3%, 0 h), but the percentage of inclusions did not significantly increase 
over time (8.3±2.4%, 6 h; p-value = 0.533, using an unpaired Student’s t-test) 
(Figure 4.6, B).  
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Figure 4.5. Effect of Proteasome inhibition on GFP-tau aggregation. SK-N-SH cells 
were transfected with 50 ng of GFP-tau plasmid, and 24 h post-transfection treated 
with a vehicle (NT), 50 µM MG132 (MG132), 10 µM lactacystin (LAC), 10 µM 
epoxomicin (EPO), 50 µM MG132 + 10 µM lactacystin (MG132+LAC), 50 µM MG132 + 
10 µM epoxomicin (MG132+EPO), or 10 µM lactacystin + 10 µM epoxomicin 
(LAC+EPO) for 0, 2, 4 or 6 h. Cells were fixed with 100% methanol for 5 min at –20°C. 
The expression of GFP-tau (A) and the percentage of GFP-tau transfected cells with 
inclusions (B) were counted blind to experimental status in at least four groups of more 
than 100 cells for each condition in two separate experiments using the Nikon 
Eclipse80i epifluorescent microscope. Error bars represent the SEM. 
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Figure 4.6. Effect of Proteasome inhibition on GFP-tau aggregation with HA-GSK3β 
co-expression. SK-N-SH cells were transfected with 50 ng of GFP-tau and 150 ng of 
GSK3β plasmids and 24 h post-transfection treated with a vehicle (NT), 50 µM MG132 
(MG132), 10 µM lactacystin (LAC), 10 µM epoxomicin (EPO), 50 µM MG132 + 10 µM 
lactacystin (MG132+LAC), 50 µM MG132 + 10 µM epoxomicin (MG132+EPO), or 10 
µM lactacystin + 10 µM epoxomicin (LAC+EPO) for 0, 2, 4 or 6 h. Cells were fixed with 
100% methanol for 5 min at –20°C. The expression of GFP-tau (A) and the percentage 
of GFP-tau transfected cells with inclusions (B) were counted blind to experimental 
status in at least four groups of more than 100 cells for each condition in two separate 
experiments using the Nikon Eclipse80i epifluorescent microscope. Error bars 
represent the SEM.  
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Therefore, GSK3β-mediated phosphorylation of GFP-tau alone in the absence 
of proteasome inhibition was sufficient to induce the formation of GFP-tau 
inclusions.  
The percentage of inclusions after 4 h of MG132 treatment was 18.3±0.3% in 
GFP-tau transfected cells and 24.3±1.3% in GFP-tau + HA-GSK3β transfected 
cells. MG132 treatment for 4 h after GFP-tau + HA-GSK3β transfection was 
therefore sufficient to observe GFP-tau inclusion formation. However, after a 
prolonged treatment of 6 h, proteasome inhibition may induce cell death, as 
many cells appeared abnormal with cell shrinkage and plasma membrane 
blebs, although the percentage of GFP-tau transfected cells remained 
unchanged. Therefore, all subsequent experiments were conducted following 
MG132 treatment for 4 h. 
In conclusion, the combination of MG132 proteasome inhibition and HA-GKS3β 
co-expression enhanced the percentage of GFP-tau inclusions in SK-N-SH 
neuroblastoma cells. 
 
4.2.5. HA-GSK3β is recruited to GFP-tau inclusions 
The subcellular distribution of HA-GSK3β and GFP-tau phosphorylated on S396 
was examined by immunocytochemistry (Figure 4.7). SK-N-SH cells were 
transfected with GFP-tau and HA-GSK3β, and 24 h post-transfection were 
treated with vehicle (DMSO) or MG132 (50 µM) for 4 h. Cells were fixed with 
0.3% glutaraldehyde and the distribution of HA-GSK3β (Figure 4.7, A) and 
GFP-tau phosphorylated on S396 (Figure 4.7, B) was examined using the anti-
HA or anti-pS396 antibody respectively.  
In the presence of GFP-tau, HA-GSK3β (red) was detected in the cytoplasm, 
both in the absence (Figure 4.7, A, top row) and in the presence of MG132 
(Figure 4.7, A, bottom row). Moreover, GSK3β was recruited to the GFP-tau 
inclusions (arrows) in both the absence and presence of MG132, and the  
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Figure 4.7. GFP-tau inclusions are GSK3β and pS396-tau positive. SK-N-SH cells 
were transfected with 50 ng of GFP-tau and 150 ng of HA-GSK3β plasmids, and 24 h 
post-transfection were treated with vehicle (DMSO) or 50 µM MG132. Cells were fixed 
with 0.3% glutaraldehyde for 10 min at 37°C. Subsequently, HA-GSK3β and pS396 
GFP-tau were detected by immunocytochemistry with anti-HA (A) or anti-pS396 (B) in 
conjunction with the secondary antibody AlexaFluor 594. GFP-tau inclusions co-
labelled with anti-HA or anti-pS396 are indicated by arrows, and GFP-tau inclusions 
negative for the anti-pS396 co-label are indicated by arrowheads. Images were 
acquired with a laser scanning confocal microscope (Zeiss LSM 700). Scale bars = 10 
µm.
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number of aggregates increased in the presence of MG132. In the presence of 
HA-GSK3β and MG132 (Figure 4.7, A, bottom row), in addition to the 
microtubule bundles, GFP-tau (green) was also diffusely co-localised with HA-
GSK3β  (red) in the cytoplasm.  
In the presence of HA-GSK3β, GFP-tau (green) phosphorylated on Ser396 
(pS396-tau, red) was detected both in the absence (Figure 4.7, B, top row) and 
in the presence (Figure 4.7, B, bottom row) of MG132. In contrast to AT8 which 
was mostly restricted to GFP-tau inclusions (Figure 4.3), pS396-tau co-localised 
with GFP-tau in the microtubule network. Moreover, the MG132 treatment 
increased the number of GFP-tau transfected cells with inclusions. However, 
some of the GFP-tau inclusions were pS396 positive (arrows), and some were 
not (arrowheads).  
Therefore, AT8 positive phosphorylated GFP-tau was specifically detected in 
the inclusions, while GFP-tau phosphorylated on S396 was detected in the 
microtubule network and inclusions.  
 
4.2.6. GFP-tau inclusion formation as a function of time 
To assess the impact of GFP-tau inclusion formation on cells, the percentage of 
GFP-tau transfected cells and the percentage of cells with inclusions were 
compared to the percentage of GFP transfected cells over time. Cells were 
transfected with GFP or with GFP-tau and with HA-GSK3β. Cells were fixed at 
3, 6, 12, 18, 24, 36, 48 and 72 h after transfection (Figure 4.8). The number of 
cells expressing GFP or GFP-tau (Figure 4.8, A) and the percentage of GFP-tau 
transfected cells with inclusions (Figure 4.8, B) was counted. Three hours after 
the beginning of transfection, less than 1% of cells were either GFP or GFP-tau 
positive.  
Figure 4.8, A shows that the number of cells expressing GFP and GFP-tau 
increased over time to reach a maximum of 42.9±4.3% 36 h and 35±1.6% 24 h 
after the beginning of transfection respectively.  
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Figure 4.8. GFP-tau expression and inclusion formation over time. Cells were 
transfected with 50 ng of GFP or GFP-tau and 150 ng of HA-GSK3β plasmids. Cells 
were fixed with 100% methanol for 5 min at -20°C after 3, 6, 12, 18, 24, 36, 48 and 72 
h after the beginning of transfection. Subsequently, cells were labelled with the AT8 
antibody in conjunction with the AlexaFluor 594 secondary antibody. At least four 
groups of more than 100 GFP-tau or GFP transfected cells were counted for each 
condition, using the Nikon Eclipse80i epifluorescent microscope. (A) Percentage of 
GFP and GFP-tau transfected cells over time. (B) Percentage of GFP-tau transfected 
cells with inclusions. Error bars are the SEM. 
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The percentage of cells expressing GFP or GFP-tau was similar for the first 24 
h (40.9±4.9% and 35.7±1.6% respectively, p-value > 0.05, using an unpaired 
Student’s t-test), but was significantly different 36 h after the beginning of 
transfection (42.9±4.3% and 31.54±4.5% respectively, p-value = 0.01, using an 
unpaired Student’s t-test). No inclusions could be detected in GFP transfected 
cells. The number of cells with GFP-tau inclusions increased over time with 
inclusions detected in 17.2±3.6% of GFP-tau transfected cells 36 h after 
transfection (Figure 4.8, B). Taken together, these results showed that a small 
significant change on the percentage of cells expressing GFP-tau compared to 
cells expressing GFP occurred with increased inclusion formation. Therefore, all 
experiments were conducted between 24 h and 36 h after the beginning of 
transfection.  
 
4.2.7. Expression and localisation of NUB1 in SK-N-SH cells 
NUB1 reduces synphilin-1 positive inclusions in an in vitro model of Parkinson’s 
disease (Tanji et al., 2006). NUB1 also downregulates the expression of 
NEDD8, a ULM that co-labels NFTs in AD (Mori et al., 2005). Therefore, the 
subcellular distribution of NUB1 in SK-N-SH cells and effect on GFP-tau 
aggregation were analysed. 
In order to examine the expression of NUB1 in SK-N-SH cells, the detection of 
endogenous NUB1 was compared to that of transiently transfected  NUB1 
protein fused with the GFP (GFP-NUB1), the Myc (Myc-NUB1) and the HA (HA-
NUB1) tags at the N-terminus or with the FLAG tag (NUB1-FLAG) at the C-
terminus. Twenty-four hours after transfection, cells were harvested and 10 µg 
of the total protein fraction was resolved on a 10% polyacrylamide gel. The 
expression of endogenous NUB1, GFP-NUB1, HA-NUB1, NUB1-FLAG and 
Myc-NUB1 was analysed by WB, using the anti-NUB1 antibody (Figure 4.9, A) 
or the tag-specific antibodies respectively (Figure 4.9, B). Endogenous NUB1 
could not be detected with the anti-NUB1 antibody, although anti-NUB1 
detected the four recombinant NUB1 proteins, GFP-NUB1, HA-NUB1, NUB1-
FLAG and Myc-NUB1 as a single band of ~96.6, ~70.5, ~71.6 and ~70.8 kDa 
respectively.  
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Figure 4.9. Detection of recombinant NUB1. SK-N-SH cells were transfected with a 
control plasmid (-) or with HA-NUB1, GFP-NUB1, NUB1-FLAG or Myc-NUB1 (+). 
Twenty-four hours after transfection, cells were harvested and 10 µg of proteins were 
resolved on a polyacrylamide gel (10%). Proteins were detected by WB using the anti-
NUB1 antibody (A), or the antibody specific to the respective NUB1 tags (B). 
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The NUB1 antibody specifically detects endogenous NUB1 in tissues by 
immunohistochemistry and different cell lines by WB, and the absence of 
detection of endogenous NUB1 in SK-N-SH neuroblastoma cells is due to the 
low levels of NUB1 expressed and detected in this cell line (van der Spuy et al., 
2003). In Figure 4.9 B, the anti-HA, anti-GFP, anti-FLAG and anti-Myc 
antibodies specifically detected the recombinant proteins HA-NUB1, GFP-
NUB1, NUB1-FLAG and Myc-NUB1  respectively at the correct predicted 
molecular weights as for the anti-NUB1 antibody. 
It has been established in our laboratory that the NUB1 peptide-directed 
antibody is not suitable for immunocytochemical localisation. Therefore, the 
localisation of exogenous GFP-NUB1 was analysed in SK-N-SH neuroblastoma 
cells. Twenty-four hours after transfection, cells were treated with a vehicle 
(DMSO) or the proteasome inhibitor MG132 (50 µM) for 4 h at 37°C. 
Subsequently, cells were fixed with 0.3% glutaraldehyde for 10 min at 37°C 
(Figure 4.10). GFP-NUB1 was predominantly detected in the nucleus, in 
accordance with its NLS, and its distribution in rat primary cortical neurons 
(Chapter 3.2.5) and in ocular tissues (van der Spuy et al., 2003). The 
distribution of GFP-NUB1 shifted from nuclear to cytoplasmic after MG132 
proteasome inhibition. To quantify this shift, the intensity of fluorescence of 
GFP-NUB1 in the nucleus versus the cytoplasm was measured in a hundred 
cells using ImageJ (Figure 4.10, B). Without proteasome inhibition, the nuclear 
fluorescence of GFP-NUB1 was 73±10% of the total intensity of GFP-NUB1 
fluorescence. However, with MG132 treatment, there was a decrease in the 
nuclear fluorescence intensity (from 73±10% to 52±12.5%) and a concomitant 
increase in the cytoplasmic fluorescence intensity (from 27±10% to 48±12.5%). 
Whether this mechanism involves a change in active translocation mechanisms 
or a relative proteasomal stabilisation of cytoplasmic NUB1 remains unclear. 
 
4.2.8. Myc-NUB1 reduces GFP-tau aggregation 
The formation of GFP-tau aggregates in SK-N-SH cells was exacerbated by 
GSK3β hyperphosphorylation and the inhibition of the proteasome. The effect of 
NUB1 co-expression on GFP-tau inclusions was subsequently examined in SK-
N-SH neuroblastoma cells.  
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Figure 4.10. Distribution of GFP-NUB1 in SK-N-SH cells. Cells were transfected with 
the GFP-NUB1 plasmid. Twenty-four hours after transfection, cells were treated with a 
vehicle (DMSO) or with MG132 (50 µM) for 4 h. Subsequently, cells were fixed with 
0.3% glutaraldehyde for 10 min at 37°C. (A) GFP-NUB1 localisation. Images were 
acquired with a laser scanning confocal microscope (Zeiss LSM 700). Nuclei were 
detected using DAPI. Scale bars = 10 µm. (B) GFP-NUB1 fluorescence intensity. 
Fluorescence intensity was measured in 100 cells blind to experimental status using 
ImageJ. 
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Figure 4.11. Effect of Myc-NUB1 on tau aggregation. SK-N-SH cells were transfected 
with 50 ng of GFP-tau and with 0 ng (1:0), 50 ng (1:1), 75 ng (1:1.5) and 100 ng (1:2) 
Myc-NUB1 plasmids, in the absence (A) or presence (B) of 150 ng of HA-GSK3β. 
Thirty hours after transfection, cells were treated with a vehicle (DMSO) or with MG132 
(50 µM) for 4 h. Subsequently, cells were fixed with methanol for 10 min at -20°C, and 
the number of GFP-transfected cells with inclusions was counted. At least four groups 
of more than 100 GFP-tau transfected cells were counted for each condition using the 
Nikon Eclipse80i epifluorescent microscope. Statistical significance compared to the 
1:0 for each condition was determined using an unpaired Student’s t-test. *p-
value<0.05, **p-value<0.01. Error bars represent the SEM. 
 Chapter 4 - NUB1 reduces tau aggregation 
  134 
Cells were transfected with 50 ng of GFP-tau alone and with 0 (1:0), 50 (1:1), 
75 (1:1.5) or 100 ng (1:2) of Myc-NUB1 (Figure 4.11, A). Thirty hours after 
transfection, cells were treated with the proteasome inhibitor MG132 (50 µM) or 
a vehicle (DMSO) for 4 h, and fixed with 100% methanol. At least four groups of 
100 cells were counted blind to experimental status for each condition. The 
percentage of GFP-tau transfected cells did not change significantly, and was 
~33.2±1.4%. Without HA-GSK3β co-expression (Figure 4.11, A), few inclusions 
were detected in GFP-tau transfected cells in the absence of proteasome 
inhibition. MG132 induced the formation of inclusions, and 12.1±2.8% of GFP-
tau transfected cells with inclusions was detected in the absence of NUB1 
(GFP-tau:NUB1 = 1:0). Although increasing amounts of Myc-NUB1 reduced the 
number of cells with inclusions, none of the ratios assessed reached 
significance.  
Cells were transfected with 50 ng of GFP-tau and with 0 (1:0), 50 (1:1), 75 
(1:1.5) or 100 ng (1:2) of Myc-NUB1, in the presence of 150 ng of HA-GSK3β 
(Figure 4.11, B). The percentage of GFP-tau transfected cells did not vary and 
was 35±2%. In the absence of MG132 and Myc-NUB1, the percentage of GFP-
tau transfected cells with inclusions increased to 19.6±2.3%.  
In the presence of Myc-NUB1 (50 ng; GFP-tau:NUB1 = 1:1), the percentage of 
GFP-tau transfected cells remained unchanged but the percentage of GFP-tau 
transfected cells with inclusions declined to 16.9±3%, although it did not reach 
significance. The presence of 75 ng (GFP-tau:Myc-NUB1 = 1:1.5) and 100 ng 
(GFP-tau:Myc-NUB1 = 1:2) of Myc-NUB1 significantly reduced the percentage 
of GFP-tau transfected cells with inclusions to 14.1±1% (p-value = 0.019) and 
12±1.4% (p-value = 0.008) respectively. 
In the presence of MG132 (Figure 4.11, B, right hand side), the percentage of 
GFP-tau transfected cells with inclusions increased to 25.3±2.2% in the 
absence of Myc-NUB1. Myc-NUB1 did not alter the percentage of GFP-tau 
transfected cells, but reduced the percentage of GFP-tau transfected cells with 
inclusions in a concentration-dependent manner. With a ratio of 1:1.5 and 1:2 
between GFP-tau and Myc-NUB1, the percentage of GFP-tau transfected cells 
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with inclusions was significantly reduced to 16.1±3.2% (p-value = 0.003) and 
16.3±1.7% (p-value = 0.001) respectively.  
Taken together, these results showed that the overexpression of Myc-NUB1 
reduced the number of GFP-transfected cells with inclusions. 
 
4.2.9. GFP-NUB1 is recruited to DsRed-tau inclusions 
Myc-NUB1 reduced the number of GFP-transfected cells with inclusions. The 
localisation of GFP-NUB1 and DsRed-tau was analysed in SK-N-SH cells 
(Figure 4.12). 
Cells were transfected with GFP-NUB1 and DsRed-tau, and 28 h post-
transfection were treated with a vehicle (DMSO) or MG132 (50 µM) for 4 h. 
Cells were fixed with glutaraldehyde (0.3%, 10 min) and the distribution of GFP-
NUB1 and DsRed-tau was examined (Figure 4.12, A). In the presence of 
DsRed-tau and without proteasome inhibition, GFP-NUB1 localisation was 
predominantly nuclear (Figure 4.12, A, top row, green) similar to the distribution 
of GFP-NUB1 on its own (Figure 4.10). However, unlike GFP-NUB1 on its own, 
in the presence of DsRed-tau GFP-NUB1 appeared to co-label the microtubule-
associated DsRed-tau (white arrows). No difference in DsRed-tau distribution 
could be detected in the presence or absence of GFP-NUB1. MG132 treatment 
(Figure 4.12, A, bottom row) enhanced the formation of DsRed-tau inclusions 
(white arrowheads) and induced a shift of GFP-NUB1 distribution from nuclear 
to cytoplasmic as before (Figure 4.10). GFP-NUB1 co-localised with both 
DsRed-tau inclusions and microtubule-associated DsRed-tau.  
The co-localisation of GFP-NUB1 and DsRed-tau in the microtubule bundles 
and inclusions was further examined using the JAcOP software to measure the 
Pearson’s and Mander’s coefficients (Chapter 2.4.4) (Figure 4.12, B).  
The Pearson’s coefficient in the microtubule bundles was 0.67±0.18 and 
0.60±0.02 in the absence or presence of MG132 respectively (Figure 4.12, B). 
This data indicated, therefore, that although GFP-NUB1 was localised diffusely 
throughout the cytoplasm, it co-localised with DsRed-tau in the cytoplasmic 
microtubule bundles, if only partially. 
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Figure 4.12. Localisation of GFP-NUB1 and DsRed-tau in SK-N-SH cells. Cells were 
transfected with 100 ng of GFP-NUB1 and 50 ng of DsRed-tau plasmids. Twenty-eight 
hours after transfection, cells were treated with a vehicle (DMSO) or with MG132 (50 
µM) for 4 h. Cells were fixed with 0.3% glutaraldehyde for 10 min at 37°C, nuclei (blue) 
were labeled with DAPI. (A) Images were acquired with a laser scanning confocal 
microscope (Zeiss LSM 700). Microtubule bundles and inclusions are indicated by the 
white arrows and arrowheads respectively. The magnified images in the top right hand 
corner are a 10 x magnification of the white rectangle or square. Scale bars = 10 µm. 
(B) The Pearson’s (PC) and Mander’s (M1 and M2) coefficients were calculated in the 
microtubule bundles (white rectangle) and in the inclusions (white square) of at least 
three different cells. M1 = Green over Red, M2 = Red over Green. Statistical 
significance was determined using an unpaired Student’s t-test. *p-value <0.05. Error 
bars represent the SEM.  
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The Mander’s coefficient measured the contribution of the green channel (GFP-
NUB1, M1) and the red channel ( DsRed-tau, M2) in the demarcated area of co-
localisation over their total respective intensities (Figure 4.12, B). In the 
absence of MG132, the M1 and M2 coefficient were 0.73±0.15 and 0.77±0.1 
respectively in the microtubule bundles, indicating that a large proportion but not 
all of the GFP-NUB1 and the DsRed-tau overlapped in microtubule bundles. In 
the presence of MG132, the M1 coefficient in the bundles was significantly 
lower (0.472±0.09, p-value = 0.04), indicating that the GFP-NUB1 was not only 
located in the bundles, but also in the surroundings. This might reflect the 
MG132-dependent increased fluorescence intensity of GFP-NUB1 in the 
cytoplasm and therefore a decrease in the proportion of the green signal 
coincident with a signal in the red channel over its total intensity in the Mander’s 
calculation. 
The M2 coefficient was higher in the microtubule bundles in the presence of 
MG132 (0.93±0.1) compared to in the absence of MG132 (0.77±0.1), but the 
difference was not significant. Overall, these data indicate that a portion of the 
cytoplasmic GFP-NUB1 was co-localised with DsRed-tau in the microtubule 
bundles. 
MG132 induced the formation of DsRed-tau inclusions. Pearson’s and Mander’s 
coefficients were used to measure the co-localisation of GFP-NUB1 and 
DsRed-tau in the inclusions (Figure 4.12, B). Both the PC, M1 and M2 
coefficients were very high (0.94±0.05, 0.95±0.05 and 0.91±0.14 respectively), 
indicating that GFP-NUB1 was recruited to DsRed-tau inclusions.  
 
4.2.10. GFP-NUB1 and HA-GSK3β co-localise  
Myc-NUB1 reduced the percentage of GFP-tau inclusions in GFP-tau 
transfected cells (Chapter 4.2.8) and GFP-NUB1 co-localised with DsRed-tau 
inclusions in SK-N-SH cells. HA-GSK3β was also recruited to tau aggregates 
(Chapter 4.2.5), therefore the localisations of NUB1 and GSK3β were 
examined (Figure 4.13). 
SK-N-SH cells were transfected with GFP-NUB1 and HA-GSKβ, and 28 h post-
transfection were treated with a vehicle (DMSO) or MG132 (50 µM) for 4 h.  
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Figure 4.13. Localisation of GFP-NUB1 and HA-GSK3β. SK-N-SH cells were 
transfected with 100 ng of GFP-NUB1 and 150 ng of HA-GSK3β plasmids. Twenty-
eight hours after transfection, cells were treated with a vehicle (DMSO) or with MG132 
(50 µM) for 4 h. Cells were fixed with 0.3% glutaraldehyde for 10 min at 37°C, nuclei 
(blue) were detected using DAPI. Subsequently, HA-GSK3β was detected by 
immunocytochemistry with the anti-HA antibody in conjunction with the secondary 
antibody AlexaFluor 594. Images were acquired with a laser scanning confocal 
microscope (Zeiss LSM 700). Scale bars = 10 µm.  
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Cells were fixed with glutaraldehyde (0.3%, 10 min) and the HA-GSK3β and 
GFP-NUB1 distribution were examined (Figure 4,13). In the presence of GSK3β 
and without proteasome inhibition, GFP-NUB1 localisation was predominantly 
nuclear (Figure 4.13, top row, green) similar to the distribution of GFP-NUB1 on 
its own (Figure 4.10). Therefore, the subcellular distribution of GFP-NUB1 
remained unchanged with HA-GSK3β co-expression. However, HA-
GSK3β (Figure 4.13, top row, red) was more readily detected in the nucleus in 
the presence of GFP-NUB1 compared to when it was expressed on its own 
(Figure 4.2). With MG132 treatment (Figure 4.13, bottom row), GFP-NUB1 
fluorescence intensity was increased in the cytoplasm and co-localised with HA-
GSK3β in this cellular locale. In the presence of GFP-NUB1, no change in the 
HA-GSK3β distribution was detected in the absence and presence of MG132, 
although it appeared more particulate in the cytoplasm in the presence of 
MG132 as before (Figure 4.2). Moreover, in the presence of GFP-NUB1, HA-
GSK3β appeared to be more nuclear than when it was expressed on its own, 
irrespective of proteasome inhibition.  
These results suggest that the distribution of GFP-NUB1 and HA-GSK3β 
overlap in SK-N-SH cells. 
 
4.2.11. HA-NUB1 reduces GFP-tau aggregation 
In order to investigate the importance of the UBL and UBA domains of NUB1 
and its longer splicing isoform NUB1L, the effect of NUB1L, NUB1LΔUBL and 
NUB1LΔUBA1-3 on tau aggregation was assessed in SK-N-SH cells.  
SK-N-SH cells were transfected with NUB1, NUB1L, NUB1LΔUBL or 
NUB1LΔUBA1-3 fused with the HA tag at the N-terminus (Figure 4.14, A). 
Twenty-four hours after transfection, 10 µg of total cellular proteins were 
resolved on a polyacrylamide gel (10%) and proteins were detected by WB 
using the anti-NUB1 (Figure 4.14, B) or the anti-HA antibody (Figure 4.14, C).  
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Figure 4.14. Expression of HA-NUB1, HA-NUB1L and HA-NUB1L mutants in SK-N-SH 
cells. (A) NUB1, NUB1L and NUB1L mutants. (B) and (C) Cells were transfected with 
100 ng of a control plasmid (-), HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL or HA-
NUB1LΔUBA1-3. Twenty-four hours after transfection, cell lysates (10 µg of total 
cellular protein) were resolved on a polyacrylamide gel (10% acrylamide) and proteins 
were detected by WB, using the anti-NUB1 (B) or anti-HA antibody (C). 
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No endogenous NUB1 was detected in SK-N-SH cells, although anti-NUB1 
specifically detected the four recombinant NUB1 proteins, HA-NUB1, HA-
NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 as single bands of ~70.5, 
~71.9, ~61.5 and ~54.5 kDa respectively (Figure 4.14, B). The anti-HA, 
antibody specifically detected HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and HA-
NUB1LΔUBA1-3 at the correct predicted molecular weights as for the anti-
NUB1 antibody (Figure 4.14, C). 
The effect of HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 
on tau aggregation was investigated in SK-N-SH cells (Figure 4.15). Cells were 
transfected with 50 ng of GFP-tau, 150 ng of HA-GSK3β and with 0, 50, 75 or 
100 ng of HA-NUB1 (Figure 4.15, A), HA-NUB1L (Figure 4.15, B), HA-
NUB1LΔUBL (Figure 4.15, C) or HA-NUB1LΔUBA1-3 (Figure 4.15, D). Thirty 
hours after transfection, cells were treated with MG132 (50 µM) or a vehicle 
(DMSO) for 4 h, and fixed with 100% methanol. The percentage of GFP-tau 
transfected cells with inclusions was counted blind to experimental status, and 
HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 were 
detected by WB using the anti-HA antibody.  
In the presence of HA-NUB1, with or without proteasome inhibition, the 
percentage of GFP-tau transfected cells did not vary significantly and was 
35.7±1.4%. The levels of HA-NUB1 increased with the amount of HA-NUB1 
transfected and were stabilised in the presence of MG132 (Figure 4.15, A).  
In the absence of MG132 and HA-NUB1, the percentage of GFP-tau 
transfected cells with inclusions was 15.1±1.2%. In the presence of increasing 
amounts of HA-NUB1, the percentage of GFP-tau transfected cells with 
inclusions decreased significantly to  10.7±1.2% at a ratio of GFP-tau to HA-
NUB1 of 1:2 (p-value = 0.008) (Figure 4.15, A). Inhibition of the proteasome 
increased the percentage of GFP-tau transfected cells with inclusions. In the 
presence of MG132 the percentage of GFP-tau transfected cells with inclusions 
increased to 22.4±2% in the absence of HA-NUB1 (Figure 4.15, A). HA-NUB1 
did not alter the percentage of GFP-tau transfected cells but reduced the 
percentage of GFP-tau transfected cells with inclusions in a concentration-
dependent manner.  
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Figure 4.15. Effect of HA-NUB1, HA-NUB1L and HA-NUB1L mutant on tau 
aggregation. SK-N-SH cells were transfected with 50 ng of GFP-tau and 150 ng of HA-
GSK3β and with 0 ng (1:0), 50 ng (1:1), 75 ng (1:1.5) and 100 ng (1:2) of HA-NUB1 
(A), HA-NUB1L (B), HA-NUB1LΔUBL (C) or HA-NUB1LΔUBA1-3 plasmids (D). Thirty 
hours after transfection, cells were treated with a vehicle (DMSO) or with MG132 (50 
µM) for 4 h. Subsequently, cells were fixed with methanol for 10 min at -20°C, and the 
number of GFP-transfected cells with inclusions was counted blind to experimental 
status. At least four groups of more than 100 GFP-tau transfected cells were counted 
for each condition using the Nikon Eclipse80i epifluorescent microscope. Statistical 
significance was determined using an unpaired Student’s t-test. *p-value<0.05, **p-
value<0.01, ***p-value<0.001. Error bars represent the SEM. Alternatively, cells were 
lysed and proteins (10 µg) were resolved on a 10% polyacrylamide gel. Proteins were 
detected by WB using the anti-HA antibody. 
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At a ratio of GFP-tau to HA-NUB1 of 1:2, the percentage of GFP-tau transfected 
cells with inclusions was significantly reduced to 16.5±1.6% (p-value = 0.004). 
Similar results were obtained with HA-NUB1L (Figure 4.15, B). The percentage 
of GFP-tau transfected cells did not vary significantly and was 34.8±1.2%. The 
levels of HA-NUB1L increased with increasing amounts of HA-NUB1L 
transfected. In the absence of HA-NUB1L and MG132 treatment, the 
percentage of GFP-tau transfected cells with inclusions was 15.2±0.8%. HA-
NUB1L decreased the percentage of GFP-tau transfected cells with inclusions 
in a concentration-dependent manner. At a ratio of GFP-tau to HA-NUB1L of 
1:1.5 and 1:2, the percentage of GFP-tau transfected cells with inclusions 
significantly declined to 11.1±2.2% (p-value = 0.013) and 10.9±0.5% (p-value = 
0.000) respectively (Figure 4.15, B). With proteasome inhibition, the percentage 
of GFP-tau transfected cells with inclusions increased to 21.5±1.4% in the 
absence of HA-NUB1L. A ratio of GFP-tau to HA-NUB1L of 1:1.5 and 1:2 
significantly reduced the percentage of GFP-tau transfected cells with inclusions 
to 18.1±1.9% (p-value = 0.03) and 15.4±2.1% (p-value = 0.003) respectively. 
Following the HA-NUB1L-mediated reduction of GFP-tau aggregation, the effect 
of HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 on GFP-tau inclusions was 
assessed.  
The co-expression of HA-NUB1LΔUBL or inhibition of the proteasome did not 
significantly affect the percentage of GFP-tau transfected cells (35±1.4%). The 
levels of HA-NUB1LΔUBL increased with the amount of HA-NUB1LΔUBL 
transfected (Figure 4.15, C). In the absence of MG132, the percentage of GFP-
tau transfected cells with inclusions was 15.9±1.5%. In the presence of 
increasing amounts of HA-NUB1LΔUBL, the percentage of GFP-tau transfected 
cells with inclusions decreased significantly to  12.2±0.8% (GFP-tau:HA-
NUB1LΔUBL = 1:1.15) (p-value=0.006) and to 12.4±1.2% (GFP-tau:HA-
NUB1LΔUBL = 1:2) (p-value=0.011). In the presence of MG132 the percentage 
of GFP-tau transfected cells with inclusions increased to 22±1% in the absence 
of HA-NUB1LΔUBL. HA-NUB1LΔUBL did not alter the percentage of GFP-tau 
transfected cells but reduced the percentage of GFP-tau transfected cells with 
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inclusions in a concentration-dependent manner. At a ratio of 1:1.5 and 1:2 
(GFP-tau:HA-NUB1LΔUBL), the percentage of GFP-tau transfected cells with 
inclusions was significantly reduced to 18.2±2.1% (p-value = 0.021) and 
16.8±1.8% (p-value = 0.002) respectively.  
In comparison to HA-NUB1, HA-NUB1L and HA-NUB1LΔUBL, the HA-
NUB1LΔUBA1-3 was unable to reduce the formation of inclusions. The 
percentage of GFP-tau transfected cells did not vary significantly (35.1±0.9%) in 
the presence of HA-NUB1LΔUBA1-3. The levels of HA-NUB1LΔUBA1-3 
increased with increasing amounts of HA-NUB1L transfected (Figure 4.15, D). 
In the absence of MG132, the percentage of GFP-tau transfected cells with 
inclusions was 15.2±0.8%. HA-NUB1LΔUBA1-3 did not decrease the number of 
GFP-tau transfected cells with inclusions, irrespective of the ratio between GFP-
tau and HA-NUB1LΔUBA1-3. The percentage of GFP-tau transfected cells with 
inclusions was 15.6±2.6, 16.1±1.3 and 16.7±19% at a ratio of 1:1, 1:1.5 and 1:2 
(GFP-tau:HA-NUB1LΔUBA1-3) respectively. Proteasome inhibition increased 
the percentage of GFP-tau transfected cells with inclusions (21.9±2.1%), and 
HA-NUB1LΔUBA1-3 did not significantly decrease the percentage of cells with 
inclusions. The percentage of GFP-tau transfected cells with inclusions was 
22.1±2.9% (p-value = 0.9) and 20.4±1% (p-value = 0.23) at a ratio of 1:1.5 and 
1:2 (GFP-tau:HA-NUB1LΔUBA1-3) respectively.  
In order to compare the effect of HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and 
HA-NUB1LΔUBA1-3 on GFP-tau aggregation to the same control, cells were 
transfected with 150 ng GSK3β, 50 ng GFP-tau and 100 ng HA-NUB1, HA-
NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 (Figure 4.16). The 
percentage of GFP-tau transfected cells did not vary significantly and was 
34.5±1.2%. Without proteasome inhibition, the percentage of GFP-transfected 
cells with inclusions was 16.1±2.3% (Figure 4.16, control). 
This percentage declined significantly to 10.8±1.4% (p-value = 0.008), 
11.7±1.3% (p-value = 0.017) and 11.4±1.4% (p-value = 0.013) with HA-NUB1, 
HA-NUB1L, and HA-NUB1LΔUBL respectively. In the presence of HA-
NUB1LΔUBA1-3, the percentage of GFP-tau transfected cells with inclusions 
(15.6±1.3%) did not decrease significantly compared to the control.  
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Figure 4.16. Comparative effect of HA-NUB1, HA-NUB1L and HA-NUBL1 mutants on 
tau aggregation. SK-N-SH cells were transfected with 50 ng of GFP-tau and 150 ng of 
HA-GSK3β (control) and with 100 ng of HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL or 
HA-NUB1LΔUBA1-3 plasmids. Thirty hours after transfection, cells were treated with a 
vehicle (DMSO) or with MG132 (50 µM) for 4 h. Subsequently, cells were fixed with 
methanol for 10 min at -20°C, and the number of GFP-transfected cells with inclusions 
was counted. At least 4 groups of 100 GFP-tau transfected cells (total, either with or 
without inclusions) was counted using the Nikon Eclipse80i epifluorescent microscope, 
and the percentage of GFP-tau transfected cells with inclusions calculated. Statistical 
significance was determined using an unpaired Student’s t-test. *p-value<0.05, **p-
value<0.01. Error bars represent the SEM.  
 Chapter 4 - NUB1 reduces tau aggregation 
  146 
With proteasome inhibition, the percentage of GFP-transfected cells with 
inclusions increased to 24.4±1.9% (Figure 4.16, control). This percentage was 
significantly decreased to 18.7±1.5% (p-value = 0.003), 17.5±2.7% (p-value = 
0.005) and 18.3±0.9% (p-value = 0.001) with HA-NUB1, HA-NUB1L, and HA-
NUB1LΔUBL. However, HA-NUB1LΔUBA1-3 failed to significantly decrease the 
percentage of GFP-tau transfected cells with inclusions (21.7±2.3%, p-value = 
0.11). 
 
Taken together, these results indicate that, irrespective of the tag (Myc or HA), 
NUB1 was able to reduce tau aggregation in SK-N-SH cells. Moreover, tau 
inclusions also declined in the presence of NUB1L and NUB1LΔUBL. However, 
NUB1LΔUBA1-3 failed to decrease tau aggregation. 
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4.3. Discussion 
This chapter focused on the optimisation of tau aggregation in neuroblastoma 
cells as a model for the aggregation of tau in AD. Therefore, the aggregation of 
wild type tau without sequence changes upon phosphorylation and consequent 
release from the microtubules was modelled in cells. Furthermore, the effect of 
a potential proteasome shuttle, NUB1, on tau aggregation was assessed. 
In mammalian cells, the ectopic expression of tau results in the formation of 
various types of microtubule bundles. The shapes and structures of 
microtubules differ in accordance with the type and role of the cells (Bruijn et al, 
2004). In neurons, tau is important for the formation of neuronal processes 
(Lovestone et al., 1996, Lee and Rook, 1992). Endogenous tau as well as 
overexpressed tau are recruited to the microtubules and influence their 
stabilisation. In SK-N-SH cells expressing GFP-tau, the microtubules were 
bundled in rounded circles, similar to what has been observed upon tau 
overexpression in CHO cells (Bruijn et al, 2004). Bundles were not present in 
the absence of ectopic tau, as SK-N-SH neuroblastoma cells do not express 
detectable levels of wild type tau. Moreover, these microtubule bundles were 
co-labelled with GFP-tau, suggesting that GFP-tau influences the microtubule 
organisation via a direct interaction. It would be interesting to measure what 
proportion of the GFP-tau population was recruited to the microtubule bundles 
and inclusions upon phosphorylation and proteasome inhibition. Weissman et 
al. (2009) used photoactivatable GFP-tau to measure the mobility of tau in the 
neurites of living primary cortical neurons. They demonstrated that 
experimentally induced inhibition of GSK3β-mediated hyperphosphorylation of 
tau increased the effective diffusion constant indicating a decreased binding to 
microtubules. Therefore, we used fluorescence recovery after photobleaching 
(FRAP) and live imaging to measure the mobility of GFP-tau in microtubule 
bundles in the presence and absence of HA-GSK3β. A decrease in GFP-tau 
bound to the microtubules could be observed in the presence of HA-GSK3β as 
well as an increase in GFP-tau sequestered to inclusions (Appendix C, 
Supplementary Figure 1). However, these observations did not correlate with 
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changes in the FRAP measurements, most likely as tau mobility in the bundles 
in SK-N-SH cells was too rapid to detect measurable differences using this 
technique. The co-expression of HA-GSK3β induced GFP-tau phosphorylation 
on AT8 and Ser396. In SK-N-SH cells, about 70±1.5% of GFP-tau transfected 
cells were AT8 positive. Importantly, no cells that were transfected with GFP-tau 
alone in the absence of GSK3β exhibited AT8 labelling, whereas a basal level 
of GFP-tau was phosphorylated on ser396 probably via the endogenous 
kinases. This was confirmed by WB analysis where detection of the AT8 
epitope was only possible in cells co-transfected with both GFP-tau and GSK3β. 
Several studies have demonstrated that phosphorylated tau has less affinity for 
the microtubules, and detaches from the protofilaments. It has been described 
before that GSK3β reduces tau binding with the microtubules in mammalian 
cells (Lovestone et al., 1996). Similarly, in our cell model, the overexpression of 
GSK3β reduced the recruitment of GFP-tau to the microtubule bundles and 
resulted in a diffuse distribution of GFP-tau in the cytoplasm, as shown in figure 
4.7. Moreover, GFP-tau positive inclusions were not labelled with β-tubulin, 
suggesting that aggregated tau did not bind the microtubules. 
Hyperphosphorylation has been shown to be an important step in tau 
aggregation. It is interesting that wild-type tau itself can form inclusions, if 
hyperphosphorylated. Indeed, upregulation of tau kinases has been described 
in AD. In SK-N-SH cells, with GSK3β co-expression, GFP-tau formed inclusions 
that were detected using the AT8 antibody, which recognises tau 
phosphorylated on several epitopes found in the NFTs. AT8 labelled GFP-tau 
inclusions, and sometimes also GFP-tau in microtubule bundles. The increase 
of GFP-tau phosphorylated on Ser396 might participate in the formation of 
inclusions, as reported before (Liu et al., 2007). However, the S396 antibody 
labelled some but not all the GFP-tau inclusions, GFP-tau inclusions were 
mostly small, and restricted to one or two per cell. Interestingly, GFP-tau 
inclusions were labelled with GSK3β. This was consistent with the fact that 
NFTs in AD are also GSK3β positive (Duyckaerts et al., 2009). Inclusions could 
be found near the nucleus, therefore suggesting the formation of an aggresome. 
However, co-labelling with a marker specific for the centrosome (e.g. 
pericentrin) or aggresomes (e.g. p62) would be necessary to confirm this 
possibility. 
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In the absence of proteasome inhibition, the formation of GFP-tau inclusions 
required the presence of GSK3β. The optimal ratio between GFP-tau and 
GSK3β was assessed. Surprisingly, the relationship between GFP-tau and 
GSK3β was far from linear. The same ratio between the two proteins gave 
different percentages of cells with inclusions. Therefore, inclusion formation was 
also dependent on the relative amount of GFP-tau and GSK3β. This could be 
explained by a balance between phosphorylation/dephosphorylation and protein 
degradation. For example, at low levels of GSK3β expressed relative to GFP-
tau, endogenous phosphatases could counteract GSK3β activity. The highest 
percentage of cells with inclusions was observed with 50 ng of GFP-tau and 
150 ng of GSK3β co-transfected, where GFP-tau is most likely not yet 
deleterious and GSK3β activity can no longer be counter-balanced by 
endogenous phosphatases. Indeed, these absolute relative amounts of GFP-
tau and GSK3β transfected also showed one of the highest percentages of 
GFP-tau transfected cells that was AT8 positive (77±3%). 
An impairment of the UPS has been reported in AD and is thought to participate 
in Aβ and tau aggregation. More precisely, although the quantity of 
proteasomes remains similar in demented and non-demented patients, the 
chymotrypsin-like activity is significantly reduced in AD patients (Cecarini et al., 
2007). Formation of GFP-tau inclusions in SK-N-SH cells was enhanced by 
proteasome inhibition. In fact, all proteasome inhibitors were able to induce the 
formation of GFP-tau inclusions, although at a low level for lactacystin. 
Lactacystin, MG132 and epoxomicin principally inhibit the chymotrypsin-like 
activity of the proteasome. The trypsin-like activity is also inhibited by 
lactacystin and epoxomicin, but to a lesser extent (Lee and Goldberg, 1998; 
Meng et al., 1999). Lactacystin and epoxomicin are considered more specific 
inhibitors of the proteasome than MG132. However, MG132 alone was able to 
maximally induce the aggregation of GFP-tau into inclusions before any 
cytotoxic effects became evident. The presence of exogenous GSK3β 
exacerbated the formation of inclusions upon proteasome inhibition. 
The formation of inclusions is a dynamic process. This chapter demonstrated 
that GFP-tau inclusion formation was time-dependent, and that although 
inclusions could be seen as soon as 12 h after transfection their number was 
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the greatest 36 h after transfection. This was correlated with the number of 
GFP-tau positive cells, which increased until 24 h after transfection. The 
decrease of both GFP-tau inclusions and the number of cells transfected with 
GFP-tau at 48 h after transfection is most likely related to the fact that the 
adherent cells begin to die, due to contact inhibition as they reached 
confluence. Interestingly, cells expressing GFP-tau started to drop off at a 
similar rate as cells expressing GFP, suggesting that GFP-tau expression and 
inclusion formation did not appear to be significantly more cytotoxic to the cells 
than GFP alone. It is thought that the insoluble oligomers rather than the 
inclusions are not the most toxic species of aggregation-prone proteins. 
Therefore, GFP-tau toxicity could be balanced by sequestering GFP-tau 
oligomers/small aggregates into bigger inclusions. Nonetheless, the number of 
cells expressing GFP-tau and the percentage of GFP-tau expressing cells with 
inclusions was greatest between 24 h and 36 h after transfection. 
Proteasome inhibition together with the co-transfection of both GFP-tau and 
GSK3β induced the highest percentage of GFP-tau expressing cells with 
inclusions (~25%). Attempts were made to chemically increase tau 
phosphorylation by treating cells with okadaic acid (OA) or calyculin A, which 
inhibit PP2A/B and both PP1 and PP2A respectively. OA had little effect on tau 
phosphorylation, probably because OA has been shown to increase the levels 
of the inactive form of GSK3β, phosphorylated on Ser9. On the other hand, 
calyculin A efficiently increased the phosphorylation of tau on Ser396 and the 
AT8 epitope, but was highly toxic for the cells, even at a low concentration. 
Nevertheless, the co-expression of a wild-type isoform of tau and GSK3β, 
combined with proteasome inhibition, induced the formation of inclusions that 
were AT8 positive and validated the use of SK-N-SH neuroblastoma cells as a 
good model to study tau aggregation.  
To assess the effect of NUB1 on tau aggregation, the localisation and 
expression of NUB1 were first investigated. The expression of endogenous 
NUB1 in SK-N-SH cells could not be detected. Indeed, the levels of NUB1 
protein detected in different cell lines have been shown to be highly variable. 
The localisation GFP-NUB1 was investigated in SK-N-SH neuroblastoma cells, 
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and was predominantly nuclear. However, proteasome inhibition induced a shift 
of GFP-NUB1 from mostly nuclear to nuclear and cytoplasmic. This was also 
observed when cells were transfected with c-Myc-NUB1 and HA-NUB1 (data 
not shown). Proteasome inhibition may have resulted in the stabilisation of 
NUB1 levels. The increased detection of NUB1 in the cytoplasm with 
proteasome inhibition reflects the fact that NUB1 localisation may be dynamic 
and that NUB1 is able to translocate from the nucleus to the cytoplasm. 
However, the underlying mechanisms of this redistribution with proteasome 
inhibition were not investigated further. Proteins cross the nuclear membrane 
through the nuclear-pore complex (NPC). Although small molecules less than 
about 60 kDa can passively translocate through the NPC, protein trafficking 
generally involves receptor-mediated transport pathways via the karyopherins 
(importin and exportin). Importins recognise proteins that possess a NLS, and 
exportins bind the nuclear export sequence (NES) of cargoes. 
Importins/exportins interact with the NPC and permit the translocation of 
targeted proteins, with the consumption of GTP. NUB1, with a C-terminal NLS, 
may be actively transported to the nucleus (Grunwald et al., 2011), since the 
molecular weight of NUB1, ~61 kDa, is at the limit of the cut-off size for passive 
transport. Leptomycin B inhibits the signal-mediated (via NES) nuclear export of 
proteins, and could be used to assess if NUB1 is passively or actively 
translocated to the cytoplasm (Kudo et al., 1998).  
Analysis of GFP-NUB1 localisation with DsRed-tau or HA-GSK3β yielded 
interesting results. Indeed, GFP-NUB1 was recruited to both DsRed-tau labelled 
microtubule bundles and to DsRed-tau inclusions. Both the Pearson’s and 
Mander’s coefficients were high for NUB1 and tau localisation in inclusions, 
indicating that both proteins were co-localised rather than and merely non-
specifically overlapping. Recruitment of NUB1 to tau inclusions suggests that 
tau may be a target for NUB1, and that the reduction of inclusions occurred as a 
result of a direct effect of NUB1 on tau. GFP-NUB1 localisation in the 
microtubule bundles was less obvious. Although GFP-NUB1 remained mostly 
nuclear, most of the cytoplasmic population of GFP-NUB1 appeared to co-
localise with tau in microtubule bundles. With proteasome inhibition, some, but 
not all, of the cytoplasmic GFP-NUB1 was localised in the bundles. 
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Interestingly, whereas HA-GSK3β was mostly cytoplasmic when expressed 
alone or with GFP-tau, GFP-NUB1 co-expression promoted a slightly increased 
detection of HA-GSK3β in the nucleus. Both proteins overlapped in the 
cytoplasm and the nucleus. Therefore, NUB1 might influence GSK3β activity in 
addition to tau. 
The ectopic expression of NUB1 reduced the number of GFP-tau transfected 
cells with inclusions both in the absence and presence of proteasome inhibition. 
Importantly, the number of cells expressing GFP-tau was unchanged. When the 
incidence of GFP-tau inclusions was maximally increased by the co-expression 
of both GFP-tau and GSK3β, NUB1 significantly reduced tau aggregation in a 
concentration-dependent manner. Interestingly, treatment with MG132 did not 
abolish the effect of NUB1 on tau aggregation in the presence of GSK3β. This 
does not exclude a proteasome dependent effect of NUB1, but rather that the 
affect of NUB1 on GFP-tau was initiated before the treatment with MG132. 
Indeed, the number of cells with inclusions increased with proteasome 
inhibition, in the presence or absence of NUB1.  
To investigate which NUB1 domains might be important for the NUB1-mediated 
reduction in tau inclusions, the affect of the longer isoform, NUB1L, and the 
NUB1L mutants, NUB1LΔUBL and NUB1LΔUBA1-3, on tau aggregation in the 
presence of GSK3β was assessed. The fact that HA-NUB1 could reduce the 
number of cells with GFP-tau inclusions in concentration-dependent manner 
confirmed that the effect of NUB1 was independent of the tag used. NUB1L has 
been reported to have the same effect on FAT10 and NEDD8 as NUB1, and 
even to be more efficient. As expected, HA-NUB1L was also able to reduce the 
number of cells with inclusions in a concentration-dependent manner. So was 
the mutant lacking the UBL domain, HA-NUB1LΔUBL. These findings suggest 
that if NUB1 regulation of tau is dependent on its ability to bind the proteasome, 
it is not via its UBL domain. Indeed, although most of the UBL/UBA proteins 
interact with the proteasome via their UBL domain, NUB1 has been reported to 
bind the proteasome via its C-terminus (Tanji et al., 2005). This is controversial, 
as Schmidtke et al, (2006) showed that NUB1LΔUBL mutant was no longer able 
to bind the proteasome and accelerate FAT10 degradation. Nonetheless, the 
UBL domain was not necessary for NUB1 to reduce tau inclusions. On the other 
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hand, the HA-NUB1LΔUBA1-3 mutant failed to show any effect on tau 
aggregation. Indeed, no decrease, and even a slight increase of the number of 
cells with inclusions was seen with increasing amounts of HA-NUB1LΔUBA1-3 
expressed. This suggests that the UBA domains of NUB1/NUB1L are 
necessary for the effect on tau inclusions. Whether the UBA domains are 
important for binding tau or GSK3β, either directly or following modification with 
a ULM, or the proteasome remains unclear. For instance, the UBA domains of 
NUB1L are essential for binding FAT10, but not for accelerating FAT10 
degradation. FAT10 itself can bind the proteasome, thus Schmidtke et al., 
(2006) propose that NUB1L interaction with the proteasome would induce a 
conformational change of the proteasome and facilitate FAT10 and 
FAT10ylated protein degradation independently of NUB1L interaction with 
FAT10 via its UBA domains. It could also simply be a conformational issue, in 
that the deletion of all the UBA domains might be too disruptive for the protein 
NUB1/NUB1L to fold correctly, and thus to be active. 
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Chapter 5  
NUB1 interacts with tau and GSK3 β  
 
5.1. Introduction 
GSK3 is a ubiquitous Ser/Thr kinase highly expressed in the hippocampus and 
cerebral cortex. Separate genes encode the two isoforms of GSK3, GSK3α and 
GSK3β, which share an overall 85% homology. The two isoforms, although they 
are able to target a shared group of substrates, are not redundant. Thus KO of 
GSK3β in mice embryos is lethal and is not compensated by GSK3α (Hur and 
Zhou, 2010; Lei et al, 2011). Indeed, studies on GSK3β expression levels in 
human tissue showed that GSK3β is expressed, on average, at higher levels 
than GSK3α (Lau et al., 1999). GSK3 can phosphorylate primed and non-
primed residues, although priming enhances GSK3 efficiency. The consensus 
sequence for GSK3 phosphorylation is Ser/Thr (target residue)-X-X-X-(primed 
residue) Ser/Thr, where X is any amino acid residue (Jope and Johnson, 2004). 
GSK3 is thought to be a stable protein with a half-life of 48 h, and to be 
degraded by the proteasome (Hongisto et al, 2008). A recent study has 
demonstrated that GSK3β is also recruited to multi-vesicular bodies, an 
upstream event of lysosomal degradation, upon Wnt signalling (Taelman et al., 
2010). 
Both isoforms of GSK3 have been shown to phosphorylate tau and be 
overexpressed in AD. Indeed, mice with conditional overexpression of GSK3β 
showed a reduction of β-catenin levels and an increase of both tau 
phosphorylation and neuron loss in brains that led to spatial learning deficits 
(Lucas et al., 2001; Avila et al., 2010). Although tau is a well-characterised 
substrate for GSK3β, little is known about their interaction. PS1 has been 
shown to bind both GSK3β and tau, and might be an intermediate protein in tau 
phosphorylation (Takashima et al., 1998). Another study has shown that GSK3β 
is in a complex with tau in microtubules from bovine brains and interacts directly 
 Chapter 5 - NUB1 interacts with tau and GSK3β 
  155 
with tau (Sun et al., 2002). Nonetheless, the phosphorylation of tau by GSK3β 
and its consequences in tau aggregation are well established. 
In the previous chapter, we demonstrated that GSK3β overexpression 
phosphorylated ectopic tau, and participated in tau inclusion formation. 
Moreover, GSK3β was recruited to tau inclusions. NUB1 co-expression 
significantly reduced the formation of tau inclusions in SK-N-SH neuroblastoma 
cells. Furthermore, NUB1L and NUB1LΔUBL but not NUB1LΔUBA1-3 were 
able to reduce tau inclusions. NUB1 was recruited to both tau inclusions and 
microtubule bundles, and co-localised with GSK3β in the cytoplasm. 
In this chapter, the interactions between and co-localisation of exogenous 
NUB1, tau and GSK3β were explored. Moreover, the functional impact of their 
association in SK-N-SH neuroblastoma cells was investigated. The effect of 
NUB1, NUB1L and the NUB1L mutants on the levels of total and 
phosphorylated tau was quantitated, and their role in the turnover of GSK3β 
investigated. 
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5.2. Results 
5.2.1. GFP-tau and HA-GSK3β are in a binary complex 
GSK3β induces tau phosphorylation in vivo and in vitro (Johnson and Stoothoff, 
2004), and was recruited to GFP-tau aggregates in SK-N-SH neuroblastoma 
cells (Figure 4.7). Therefore, co-immunoprecipitation experiments of HA-GSK3β 
and GFP-tau were performed to analyse their interaction in SK-N-SH cells 
(Figure 5.1). 
Cells were transiently transfected with either HA-GSK3β or GFP-tau alone, or 
with both proteins and treated with MG132 (50 µM) 28 h post-transfection. Cells 
were lysed and proteins were immunoprecipitated with the anti-tau (Figure 5.1, 
A) or anti-HA antibody (Figure 5.1, B) with magnetic beads (Chapter 2.5.6). Cell 
lysates were resolved on a polyacrylamide gel (10%) and proteins were 
detected by WB using the anti-tau or anti-HA antibody. Both HA-GSK3β and 
GFP-tau were detected in the input fraction. The anti-tau antibody successfully 
immunoprecipitated GFP-tau, and 2.8% of the total levels of HA-GSK3β were 
specifically co-immunoprecipitated  (Figure 5.1, A) only when GFP-tau was also 
present. Moreover, neither GFP-tau nor GSK3β were immunoprecipitated with a 
non-specific antibody (IgG) or with the beads only (BO). Reciprocally, HA-
GSK3β was immunoprecipitated and GFP-tau co-immunoprecipitated (0.6% of 
the total levels) with the HA antibody (Figure 5.1, B). Less than 0.1% of total 
GFP-tau levels was non-specifcally immunoprecipitated with the HA antibody in 
the absence of HA-GSK3β, and with a non-specific antibody (IgG).  
These results confirmed that GFP-tau and HA-GSK3β interact reciprocally in a 
binary complex . 
5.2.2. NUB1-FLAG and GFP-tau are in a binary complex 
NUB1 was recruited to tau on microtubules and to aggregated tau in inclusions 
(Figure 4.12). Moreover, NUB1 reduced the formation of tau inclusions in SK-N-
SH cells (Figures 4.11 and 4.15). Therefore, the co-immunoprecipitation of 
GFP-tau and NUB1-FLAG was performed in SK-N-SH cells to investigate their 
interaction.  
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Figure 5.1. Immunoprecipitation of GFP-tau and HA-GSK3β. Cells were transfected 
with GFP-tau, HA-GSK3β or both plasmids, and 28 h post-transfection were treated 
with MG132 (50 µM) for 4h. Cells were lysed with RIPA buffer, and lysates were 
incubated with magnetic beads in the absence (BO, beads only) or presence of the 
anti-tau (1:1000, A), anti-HA (1:500, B), or a non-specific (IgG) antibody overnight at 
4°C. Five µl (INPUTS) or 10 µl (IP) of samples were resolved on a polyacrylamide gel 
(10%) and proteins were detected using the anti-tau or anti-HA antibody. 
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Myc-NUB1 was non-specifically immunoprecipitated by the anti-tau antibody in 
the absence of GFP-tau (data not shown). Moreover, the anti-Myc antibody 
immunoprecipitated only a low level of Myc-NUB1 (1.3% of the total levels) and 
the specific co-immunoprecipitation of GFP-tau was consequently not detected 
(data not shown).  
Therefore, as the anti-Myc antibody was not suitable for immunoprecipitation 
experiments, the interaction of GFP-tau and NUB1-FLAG was investigated in 
SK-N-SH cells. Cells were transiently transfected with GFP-tau and NUB1-
FLAG and 28 h post-transfection were treated with MG132 (50 µM) for 4 h.  
Cells were lysed and proteins were immunoprecipitated with the anti-tau (Figure 
5.2, A) or anti-FLAG (Figure 5.2, B) antibody with magnetic beads (Chapter 
2.5.6). Both GFP-tau and NUB1-FLAG were detected in the input fraction. The 
anti-tau antibody immunoprecipitated GFP-tau, and specifically co-
immunoprecipitated NUB1-FLAG (Figure 5.2, A)  in the presence of GFP-tau, 
with 0.44% of total NUB1-FLAG levels pulled-down. Moreover, neither GFP-tau 
nor NUB1-FLAG were immunoprecipitated with a non-specific antibody (IgG) or 
with the beads only (BO). Reciprocally, NUB1-FLAG was immunoprecipitated 
and 1.4% of the total GFP-tau levels was co-immunoprecipitated with the anti-
FLAG antibody (Figure 5.2, B). However, a small percentage (0.25% of input) of 
GFP-tau was non-specifically immunoprecipitated with the FLAG antibody and 
with a non-specific antibody (IgG) in the absence of NUB1-FLAG.  
These results therefore revealed that NUB1-FLAG and GFP-tau interact 
reciprocally in a binary complex . 
 
5.2.3. NUB1-FLAG and HA-GSK3β are in a binary complex  
HA-GSK3β and GFP-NUB1 co-localise in SK-N-SH cells (Figure 4.13), and both 
are recruited to GFP-tau inclusions (Figure 4.7 and 4.12), therefore the  
interaction between NUB1-FLAG and HA-GSK3β was asessed by co-
immunoprecipitation in SK-N-SH cells (Figure 5.3).  
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Figure 5.2. Immunoprecipitation of GFP-tau and NUB1-FLAG. Cells were transfected 
with GFP-tau, NUB1-FLAG or both plasmids, and 28 h post-transfection were treated 
with MG132 (50 µM) for 4 h. Cell were lysed with RIPA buffer, and lysates were 
incubated with magnetic beads in the absence (BO, beads only) or presence of the 
anti-tau (1:1000, A), anti-FLAG (1:500, B), or a non-specific (IgG) antibody overnight at 
4°C. Five µl (INPUTS) or 10 µl (IP) of samples were resolved on a polyacrylamide gel 
(10%) and proteins were detected using the anti-tau or anti-FLAG antibody. 
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Cells were transiently transfected with HA-GSK3β and NUB1-FLAG and 28 h 
post-transfection were treated with MG132 (50 µM) for 4 h. Cells were lysed 
and proteins were immunoprecipitated with the anti-GSK3β (Figure 5.3, A) or 
anti-FLAG antibody (Figure 5.3, B) with magnetic beads (Chapter 2.5.6). Cell 
lysates were resolved on a polyacrylamide gel (10%) and proteins were 
detected using the anti-FLAG or the anti-HA antibody. Both HA-GSK3β and 
NUB1-FLAG were detected in the input fraction. The anti-GSK3β antibody 
immunoprecipitated HA-GSK3β, and specifically co-immunoprecipitated NUB1-
FLAG (Figure 5.3, A) only in the presence of HA-GSK3β (0.44% of the total 
levels). Moreover, neither HA-GSK3β nor NUB1-FLAG were 
immunoprecipitated with a non-specific antibody (IgG) or with the beads only 
(BO). Reciprocally, NUB1-FLAG was immunoprecipitated and 7.4% of the total 
HA-GSK3β levels were specifically co-immunoprecipitated with the anti-FLAG 
antibody (Figure 5.4, B). No HA-GSK3β was non-specifcally co-
immunoprecipitated with the anti-FLAG antibody in the absence of NUB1-FLAG, 
or with a non-specific antibody (IgG). 
In conclusion, HA-GSK3β and NUB1-FLAG interact reciprocally in a binary 
complex. 
 
5.2.4. Tau, GSK3β and NUB1 are in a ternary complex 
Myc-NUB1 and HA-NUB1 reduced the percentage of GFP-tau inclusions in 
GFP-tau transfected cells (Figure 4.11 and Figure 4.15 respectively) and co-
localised with DsRed-tau inclusions in SK-N-SH cells (Figure 4.12). HA-GSK3β 
was also recruited to GFP-tau aggregates (Figure 4.7). GFP-tau, NUB1-FLAG 
and HA-GSK3β were able to immunoprecipitate one another in binary 
complexes in a reciprocal manner. Therefore, the formation of a ternary 
complex between GFP-tau, HA-GSK3β and NUB1-FLAG was explored in SK-N-
SH cells. 
Cells were transfected with GFP-tau, HA-GSK3β or NUB1-FLAG alone, with the 
binary combinations of the three proteins, or with all three proteins together. 
Twenty-eight hours post-transfection, cells were treated with MG132 (50 µM) for 
4 h.  
 Chapter 5 - NUB1 interacts with tau and GSK3β 
  161 
 
 
Figure 5.3. Immunoprecipitation of NUB1-FLAG and HA-GSK3β. Cells were 
transfected with NUB1-FLAG, HA-GSK3β or both plasmids, and 28h post-transfection 
were treated with MG132 (50 µM) for 4h. Cell were lysed with RIPA buffer, and lysates 
were incubated with magnetic beads in the absence (BO, beads only) or presence of 
the anti-GSK3β (1:100, A), anti-FLAG (1:500, B), or a non-specific (IgG) antibody 
overnight at 4°C. 5 µl (INPUTS) or 10 µl (IP) of samples were resolved on a 
polyacrylamide gel (10%) and proteins were detected using the anti-HA or anti-FLAG 
antibody. 
 Chapter 5 - NUB1 interacts with tau and GSK3β 
  162 
Cells were lysed and proteins were immunoprecipitated with the anti-tau (Figure 
5.4, A) or anti-FLAG antibody (Figure 5.4, B) with magnetic beads (Chapter 
2.5.6). 
Cell lysates were resolved on a polyacrylamide gel (10%) and proteins were 
detected using the anti-tau, anti-pS396, anti-FLAG or the anti-HA antibody. The 
three proteins, HA-GSK3β, NUB1-FLAG and GFP-tau could be detected in the 
input fractions (Figure 5.4, A and B, INPUTS). In the presence of HA-GSK3β, 
there was a small increase in the molecular weight of tau detected with anti-tau 
and anti-pS396, and increased levels of pS396-tau detected with anti-pS396, 
indicative of GSK3β-mediated phosphorylation of tau on serine 396. The anti-
tau antibody immunoprecipitated GFP-tau, and specifically co-
immunoprecipitated NUB1-FLAG and HA-GSK3β (Figure 5.4, A).  NUB1-FLAG 
and HA-GSK3β were not co-immunoprecipitated in the absence of GFP-tau or 
with non-specific IgG, nor were they pulled down non-specifically by the beads 
only. When all three proteins were co-expressed in SK-N-SH cells (Figure 5.4, 
A, last lane), less HA-GSK3β (0.6% instead of 1.3% for the binary GFP-tau/HA-
GSK3β co-IP) was co-immunoprecipitated with GFP-tau. The proportion of 
GFP-tau phosphorylated on Ser396 pulled down with the anti-tau antibody was 
similar when GFP-tau was co-transfected with NUB1-FLAG and HA-GSK3β or 
with HA-GSK3β alone. 
The anti-FLAG antibody immunoprecipitated NUB1-FLAG and specifically co-
immunoprecipitated GFP-tau and HA-GSK3β (Figure 5.4, B). GFP-tau and HA-
GSK3β were co-immunoprecipitated specifically in the absence of NUB1-FLAG. 
In the presence of HA-GSK3β, the levels of pS396-tau were increased and both 
total tau and pS396-tau were shifted to a higher molecular weight, indicating the 
HA-GSK3β phosphorylation of GFP-tau. The NUB1-FLAG co-
immunoprecipitated pS396-tau only when HA-GSK3β was present. When  all 
three proteins were co-expressed, the proportion of HA-GSK3β and GFP-tau 
co-immunoprecipitated by the anti-FLAG antibody was reduced (0.6% instead 
of 11.2%, and 0.1% instead of 0.4% for HA-GSK3β and GFP-tau respectively). 
GFP-tau co-immunoprecipitated with NUB1-FLAG was also decreased when  
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Figure 5.4. Immunoprecipitation of GFP-tau, NUB1-FLAG and HA-GSK3β. Cells were 
transfected with 50 ng of GFP-tau, 150 ng of GSK3β, or 100 ng of NUB1-FLAG plasmid 
alone, a combination of two plasmids or all three plasmids together. Twenty-eight hours 
post-transfection cells were treated with MG132 (50 µM) for 4 h. Cells were lysed with 
RIPA buffer, and lysates were incubated with magnetic beads in the presence of the 
anti-tau (1:1000, A) or anti-FLAG (1:500, B) antibody overnight at 4°C. Five µl 
(INPUTS) or 10 µl (IP) of samples were resolved on a polyacrylamide gel (10%) and 
proteins were detected using the anti-tau, anti-pS396, anti-HA or anti-FLAG antibody. 
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the all three proteins were co-expressed in cells, whereas the NUB1-FLAG 
immunoprecipitated remained unchanged.  
GFP-tau and HA-GSK3β, GFP-tau and NUB1-FLAG, and HA-GSK3β and 
NUB1-FLAG interacted specifically and reciprocally with one another. Moreover, 
GFP-tau, HA-GSK3β and NUB1-FLAG associated with one another in a ternary 
complex, and GFP-tau was phosphorylated by HA-GSK3β when all three 
proteins were co-expressed in SK-N-SH cells. However, NUB1-FLAG reduced 
the co-immunoprecipitation of HA-GSK3β with GFP-tau, and the co-
immunoprecipitation of both HA-GSK3β and GFP-tau with NUB1-FLAG in the 
ternary complex. Therefore, the three proteins may compete for an overlapping 
binding site on NUB1 within this complex. Furthermore, GFP-NUB1 was 
recruited to DsRed-tau microtubule bundles and inclusions, and co-localised 
with HA-GSK3β in the cytoplasm. Similarly, HA-GSK3β labelled GFP-tau 
inclusions. Thus, the localisation of each protein when the three are co-
expressed in SK-N-SH was investigated. 
Cells were transfected with GFP-NUB1, DsRed-tau, and HA-GSK3β, and 28 h 
post-transfection were treated with MG132 (50 µM) for 4 h. Cells were fixed with 
glutaraldehyde (0.3%, 10 min) and the distribution of GFP-NUB1, DsRed-tau 
and HA-GSK3β was examined (Figure 5.5). 
GFP-NUB1 localisation (Figure 5.5, green), was predominantly nuclear but was 
also stabilised in the cytoplasm with proteasome inhibition, as noted before 
(Figure 4.10). GFP-NUB1 co-labelled the microtubule-associated DsRed-tau in 
the bundles and in the rest of the microtubule network, and the DsRed-tau in 
the inclusions (white arrows and arrowheads respectively). On the other hand, 
HA-GSK3β localisation (Figure 5.5, blue) was both cytoplasmic and nuclear, 
similar to its localisation in the presence of GFP-NUB1 alone as described 
previously (Figure 4.13). HA-GSK3β was detected in some of the DsRed-tau 
bundles, yet  was excluded from the inclusions.This is contrary to what was 
described in chapter 4.2.5., where it was shown that in the absence of NUB1, 
GSK3β was recruited to the GFP-tau inclusions. 
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Figure 5.5. Localisation of GFP-NUB1, DsRed-tau and HA-GSK3β in SK-N-SH cells. 
Cells were transfected with 100 ng of GFP-NUB1, 50 ng of DsRed-tau and 150 ng of 
HA-GSK3β plasmids. Twenty-eight hours after transfection, cells were treated with 
MG132 (50 µM) for 4 h. Cells were fixed with 0.3% glutaraldehyde for 10 min at 37°C. 
Images were acquired with a laser scanning confocal microscope (Zeiss LSM 700). 
Microtubule bundles and inclusions are indicated by the white arrows and arrowheads 
respectively. Scale bars = 10 µm. 
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No difference in DsRed-tau distribution could be detected in the presence of 
both GFP-NUB1 and HA-GSK3β compared to tau localisation with either HA-
GSK3β (Figure 4.7) or with GFP-NUB1 (Figure 4.12) alone.  
In conclusion, when any binary combination of tau, NUB1 and GSK3β were co-
expressed in SK-N-SH cells, the proteins specifically interacted with one 
another and were co-localised. However, when the three proteins  were 
expressed together in cells, the interactions between  them appeared to be 
reduced. 
In fact, analysis of the localisation of the three proteins showed that GSK3β was 
no longer recruited to the tau inclusions in the presence of NUB1, whereas 
NUB1 and tau co-localised in both the microtubule bundles and inclusions. 
Therefore, NUB1 both reduced the interaction of tau and GSK3β and prevented 
the recruitment of GSK3β to tau inclusions. 
 
5.2.5. The effect of HA-NUB1 on GFP-tau levels 
Myc-NUB1, HA-NUB1, HA-NUB1L and HA-NUB1LΔUBL reduced the number of 
GFP-tau transfected cells with inclusions, while the mutant HA-NUB1LΔUBA1-3 
did not have a significant effect on GFP-tau inclusions (Figure 4.15). Moreover, 
NUB1-FLAG interacted with both GFP-tau and HA-GSK3β (Figure 5.2 and 5.3 
respectively) and reduced the association of HA-GSK3β with GFP-tau in the 
ternary complex (Figure 5.4). Therefore, the NUB1-mediated reduction of HA-
GSK3β interaction with GFP-tau could reduce HA-GSK3β-dependent 
phosphorylation of GFP-tau and consequently GFP-tau inclusion formation. 
Moreover, NUB1 could directly reduce the levels of HA-GSK3β and GFP-tau as 
shown for synphilin-1 (Tanji et al., 2006). To test these proposals, the ability of 
NUB1 to reduce the levels of total tau and phosphorylated tau in cells was 
analysed by WB using a quantitative protein assay (QPA, Chapter 2.5.5).  
In order to establish a standard curve for the detection of total GFP-tau levels, 
SK-N-SH cells were transfected with GFP-tau, and lysed 28 h post-transfection 
with SDS buffer. Serial dilutions of total cell lysates from 1:20 to 1:5000 were 
applied to a nitrocellulose membrane in triplicate on a dot-blot apparatus. 
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Figure 5.6. Standard curve for the detection of GFP-tau levels using the anti-tau 
antibody. Cells were transfected with 50 ng of GFP-tau plasmid. Twenty-eight hours 
post-transfection cells were lysed with 1% SDS buffer and a range of serial dilutions 
from 1:20 to 1:5000 of total cell lysates was applied to a nitrocellulose membrane on a 
dot-blot apparatus. Total levels of GFP-tau were detected with anti-tau (1:40 000). Spot 
intensities were measured using the ImageJ program. Error bars represent the SEM. 
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The total levels of GFP-tau were detected using the anti-tau antibody in the 
absence of proteasome inhibition (Figure 5.6). The titration curve of GFP-tau 
revealed that between the 1:10 and 1:100 dilutions, the detection of GFP-tau 
was saturated, while at the 1:1000 dilution and further the detection limits of 
available protein were reached. The linear range of the curve was between the 
1:200 and 1:500 dilutions. A dilution of 1:400 was therefore selected based on 
the optimal detection of GFP-tau at this dilution within the linear range 
To determine if HA-NUB1, HA-NUB1L and the HA-NUB1L mutants could 
influence the total levels of GFP-tau, SK-N-SH cells were transfected with GFP-
tau alone or with both GFP-tau and HA-GSK3β, and with either HA-NUB1, HA-
NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 (Figure 5.7). 
Twenty-eight hours after transfection, cells were treated with a vehicle (DMSO) 
(Figure 5.8, A) or with MG132 (50 µM) for 4 h (Figure 5.7, B). Cells were lysed 
with SDS buffer and a 1:400 dilution of cell lysates was applied to a 
nitrocellulose membrane in quadruplicate on a dot-blot apparatus. GFP-tau was 
detected with the anti-tau antibody (non-phospho-specific) and the spot intensity 
measured using ImageJ. All spot intensities were normalised to protein 
concentration and to GFP-tau levels alone (levels = 1). In the absence of 
MG132 (Figure 5.7, A), the levels of GFP-tau did not change significantly when 
HA-NUB1, HA-NUBL1, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 were co-
expressed in cells. Similarly, none of the NUB1 constructs significantly altered 
the levels of GFP-tau when it was also co-expressed with HA-GSK3β  (all p-
values > 0.07) (Figure 5.7, A). Proteasome inhibition only slightly increased the 
GFP-tau levels (a 1.1 fold-increase) in the absence of HA-GSK3β (Figure 5.7, 
B), and more significantly in the presence of HA-GSK3β (1.7 fold-increase, p-
value = 0.001). The co-expression of HA-NUB1, HA-NUB1L or HA-NUB1LΔUBL 
significantly reduced these levels by ~30%, ~41% and ~30% respectively (p-
value = 0.003, 0.000, and 0.001 respectively). Unexpectedly, the HA-
NUB1ΔUBA1-3 also significantly reduced the levels of GFP-tau by ~35% when 
it was co-expressed with HA-GSK3β in the presence of MG132 (p-value = 
0.001). 
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Figure 5.7. GFP-tau levels are reduced by HA-NUB1, HA-NUB1L and the HA-NUB1L 
mutants when co-expressed with HA-GSK3β in the presence of MG132. Cells were 
transfected with 50 ng of GFP-tau alone (GFP-tau), or with 50 ng of GFP-tau and 150 
ng of HA-GSK3β (GFP-tau + GSK3β),  either without (-) or with 100 ng of HA-NUB1, 
HA-NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 plasmids. Twenty-eight hours 
post-transfection cells were treated with a vehicle (DMSO), (A), or MG132 (50 µM), (B) 
for 4 h. Cells were lysed with SDS buffer and a 1:400 dilution of cell lysates was 
applied to a nitrocellulose membrane in quadruplicate on a dot-blot apparatus. Total 
levels of GFP-tau were detected with anti-tau (1:40 000). Spot intensities were 
measured using the ImageJ program, and normalised to levels of GFP-tau alone (= 1). 
The WB is a representation of one experiment out of three replicates. Statistical 
significance was determined using an unpaired Student’s t-test. *p-value<0.05, **p-
value<0.01,***p-value<0.001. Error bars represent the SEM. 
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5.2.6. The effect of HA-NUB1 on phosphorylated GFP-tau levels. 
The effect of HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 
on phosphorylated GFP-tau was observed in SK-N-SH cells.  
In order to derive a standard curve for the detection of pS396-tau, cells were 
transfected with both GFP-tau and HA-GSK3β, and lysed 28 h post-transfection 
with SDS buffer. Serial dilutions of cell lysates from 1:20 to 1:5000 were applied 
to a nitrocellulose membrane in triplicate on a dot-blot apparatus. The levels of 
GFP-tau phosphorylated on residue serine 396 (pS396-tau) were detected 
using the anti-pS396 antibody in the absence of proteasome inhibition (Figure 
5.8). The titration curve of pS396-tau revealed that between the 1:20 and 1:50 
dilutions, the membrane was saturated, while at the 1:500 dilution and further 
the detection limits of protein available were reached. A dilution factor of 1:100 
was therefore selected based on the optimal detection of pS396-tau at this 
dilution within the linear range. 
To determine if HA-NUB1, HA-NUB1L and the HA-NUB1L mutants could 
reduce the levels of tau phosphorylated on serine 396, SK-N-SH cells were 
transfected with GFP-tau alone or both GFP-tau and HA-GSK3β, either without 
(-) or with HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 
(Figure 5.9). Twenty-eight hours after transfection, cells were treated with a 
vehicle (Figure 5.9, A) or with MG132 (Figure 5.9, B). Cells were lysed with 
SDS buffer and a 1:100 dilution of total cell lysates was applied to a 
nitrocellulose membrane in quadruplicate on a dot-blot apparatus. The levels of 
pS396-tau were detected with the anti-pS396 antibody, and the intensity of the 
spots measured using ImageJ. The spot intensities were normalised to protein 
concentration and to GFP-tau + HA-GSK3β levels (levels = 1) (Figure 5.9). In 
the absence of HA-GSK3β, a basal level of pS396-tau was detected. pS396-tau 
was detected in the presence of HA-GSK3β, and the co-expression of HA-
NUB1, HA-NUBL1, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 significantly and 
efficiently reduced these levels by ~75%, ~80%, ~78% and ~81% respectively 
in the absence of MG132 (p-value = 0.005, 0.004, 0.004 and 0.004 
respectively).  
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Figure 5.8. Standard curve for the detection of GFP-tau phosphorylated on serine 396 
using the anti-pS396 antibody. SK-N-SH cells were transfected with 50 ng of GFP-tau 
and 150 ng of HA-GSK3β plasmids. Twenty-eight hours post-transfection cells were 
lysed with 1% SDS buffer and a range of serial dilutions from 1:20 to 1:5000 of cell 
lysates was applied to a nitrocellulose membrane in triplicate on a dot-blot apparatus. 
Levels of phosphorylated GFP-tau on Ser396 were detected with anti-pS396 (1:5000). 
Spot intensities were measured using the ImageJ program. Error bars represent the 
SEM. 
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Figure 5.9. pS396-tau levels are reduced by HA-NUB1, HA-NUB1L and the HA-
NUB1L mutants. SK-N-SH cells were transfected with 50 ng of GFP-tau alone (tau), or 
with 50 ng of GFP-tau and 150 ng of HA-GSK3β (tau + GSK3β),  either without (-) or 
with 100 ng of HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 
plasmids. Twenty-eight hours post-transfection, cells were treated with a vehicle 
(DMSO), (A), or MG132 (50 µM) (B), for 4 h. Cells were lysed with SDS buffer and a 
1:400 dilution of cell lysates was applied to a nitrocellulose membrane in quadruplicate 
on a dot-blot apparatus. Phosphorylated tau (pS396-tau) levels were detected with 
anti-pS396 (1:5000). Spot intensities were measured using the ImageJ program, and 
normalised to the levels of pS396-tau in the presence of HA-GSK3β (= 1). The WB is a 
representation of one experiment out of three replicates. Statistical significance was 
determined using an unpaired Student’s t-test, *p-value<0.05, **p-value<0.01, ***p-
value<0.001 Error bars represent the SEM. 
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In the presence of MG132, the levels of HA-GSK3β phosphorylated pS396-tau 
were increased slightly by ~4%, and HA-NUB1, HA-NUBL1, HA-NUB1LΔUBL or 
HA-NUB1LΔUBA1-3 significantly and effectively reduced pS396-tau levels 
(~81% p-value= 0.001, 89% p-value=0.000, 89% p-value = 0.000 and ~85% p-
value = 0.001 respectively).  
In conclusion, HA-NUB1, HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-
3 were able to reduce the levels of pS396-tau.  
5.2.7. HA-NUB1 alters HA-GSK3β levels. 
NUB1 has been shown to be involved in protein regulation (Liu and Xirodimas, 
2010; Tanaka et al., 2003). Indeed, it can target proteins, bind the proteasome 
and induce their proteasomal degradation (Tanji et al., 2006; Kamitani et al., 
2001). NUB1 reduced tau aggregation (Chapter 4.2.8 and 4.2.11), and 
significantly reduced the levels of phosphorylated tau (pS396-tau, Figure 5.9) 
compared to the total levels of tau (Figure 5.8). The pS396-tau levels detected 
were directly correlated with the levels and activity of GSK3β, as only basal 
levels of pS396-tau could be detected in the absence of GSK3β. Moreover, 
NUB1 co-localised (Figure 4.13) and interacted with GSK3β (Figure 5.3), and 
reduced the interaction of GSK3β and tau (Figure 5.4). Therefore, NUB1 might 
alter the levels or the activity of GSK3β. To assess this hypothesis, the 
influence of NUB1 on GSK3β turnover was investigated using a cycloheximide 
(CHX) assay in SK-N-SH cells. 
Cells were transfected with HA-GSK3β alone, or with both HA-GSK3β and HA-
NUB1. Twenty-eight hours after transfection, cells were treated with a vehicle 
(DMSO) or with MG132 (50 µM) for 4 h and with CHX for 0, 2, and 4 h. Cells 
were lysed with RIPA buffer and 10 µg of total protein was resolved on a 
polyacrylamide gel (10%). HA-NUB1, HA-GSK3β and GAPDH were detected by 
WB using the anti-HA and anti-GAPDH antibody respectively (Figure 5.10, A). 
GAPDH was used as a loading control, and the same results were obtained if 
protein levels were normalized to the loading control.  
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Figure 5.10. HA-NUB1 effect on HA-GSK3β turnover. Cells were transfected with HA-
GSK3β either alone (150 ng) or with HA-NUB1 (100 ng) plasmids. Twenty-eight hours 
post-transfection, cells were treated with a vehicle (DMSO) or MG132 (50 µM) for 4 h 
and with CHX (50 µg/ml) for 0, 2, and 4 h, and lysed with RIPA buffer. Proteins (10 µg) 
were resolved on a polyacrylamide gel (10%) and were detected by WB using the anti-
HA or anti-GAPDH antibody (A). The levels of GSK3β (band intensities) were 
measured using the ImageJ software (B, C). (B) Comparison of the GSK3β levels. (C) 
Rate of GSK3β degradation following CHX treatment for 0, 2 and 4 h. Statistical 
significance was determined using an unpaired Student’s t-test. *p-value<0.05, **p-
value<0.01. Error bars are the SEM  
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HA-NUB1 expression decreased over time with CHX treatment in the absence 
of MG132, and after 4 h of CHX treatment, the levels of NUB1 were reduced to 
26.1% compared to 0 h of CHX treatment. MG132 stabilised the levels of HA-
NUB1, as they did not decrease as much after 4 h of CHX treatment (39.1%).  
The levels of GSK3β (Figure 5.10, A) decreased temporally following the CHX 
treatment. However, in the cells co-transfected with HA-NUB1, HA-GSK3β 
levels decreased faster than in the cells transfected with HA-GSK3β alone. 
Moreover, HA-GSK3β levels were reduced in the cells co-transfected with HA-
NUB1 in the absence of cycloheximide treatment. To quantitate this effect, the 
GSK3β levels were measured by densitometry using the ImageJ software 
(Figure 5.10, B and C). 
Figure 5.10, B shows that in the cells transfected with HA-NUB1 and HA-
GSK3β, without any CHX or MG132 treatment, the HA-GSK3β levels were 
significantly decreased to 72.3±7.2% (p-value = 0.041). The HA-GSK3β levels 
declined further to 61.3±11.5% and 11±0.7% with 2 h and 4 h of CHX treatment 
respectively in the presence of HA-NUB1, significantly lower than in the 
absence of HA-NUB1 (103±6.9% 2 h, 55±7.1% 4 h). Moreover, with MG132 
treatment, HA-GSK3β levels increased to 159.3±19.2% in cells transfected with 
HA-GSK3β alone, whereas they were significantly lower in the cells co-
transfected with HA-NUB1 (79.9±5.2%, p-value = 0.002). The levels of HA-
GSK3β decreased further to 167.8±25.6% and 74±8% (2 h, 4 h CHX treatment 
respectively) in the absence of HA-NUB1, and to 60.3±5.9% and 9.8±3.8% (2 h, 
4 h CHX treatment respectively) in the presence of HA-NUB1. The data indicate 
that the turnover of HA-GSK3β is in part mediated by the proteasome and that 
HA-NUB1 reduces the levels of HA-GSK3β. However, in the presence of HA-
NUB1, HA-GSK3β levels did not seem to be stabilised by the proteasome 
inhibition. To directly compare the levels of GSK3β in the presence or absence 
of NUB1, the percentage of HA-GSK3β decrease from the levels measured in 
Figure 5.10, B was plotted in Figure 5.10, C. It shows that HA-NUB1 also 
accelerated the degradation of GSK3β. Indeed, the levels of HA-GSK3β were 
significantly lower in the cells co-transfected with HA-NUB1 compared to the 
cells transfected with HA-GSK3β alone when treated with CHX for 2 h 
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(87.6±7.7% and 103.4±6.9% respectively, p-value = 0.041) and for 4 h 
(15.2±7% and 55.1±7% respectively, p-value = 0.005). Interestingly, the MG132 
treatment increased the overall levels of HA-GSK3β in the absence of HA-
NUB1 (Figure 5.10, B), but it did not affect the rate of HA-GSK3β degradation. 
In the presence of HA-NUB1, the HA-GSK3β levels were significantly more 
rapidly degraded after 2 h (75.9±7.4% compared to 105.3±16%, p-value = 
0.026) and 4 h (16.3±6.2% compared to 46.4±5%, p-value = 0.011) of treatment 
with CHX.  
In conclusion, HA-NUB1 was able to significantly reduce HA-GSK3β levels and 
to accelerate its turnover.  
 
5.2.8. HA-NUB1L alters HA-GSK3β levels 
HA-NUB1 was able to accelerate GSK3β turnover (Chapter 5.2.7). Therefore, 
the influence of HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 on HA-
GSK3β levels was investigated.  
Cells were transfected with 150 ng of HA-GSK3β alone or in combination with 
100 ng of HA-NUB1L (Figure 5.11), HA-NUB1LΔUBL (Figure 5.12) or HA-
NUB1LΔUBA1-3 (Figure 5.13). Twenty-eight hours after transfection, Cells were 
treated with a vehicle (DMSO) or with MG132 (50 µM) for 4 h and with CHX for 
0, 2, and 4 h. Cells were lysed with RIPA buffer and 10 µg of total protein was 
resolved on a polyacrylamide gel (10%).  
HA-NUB1L, HA-NUB1LΔUBL, HA-NUB1LΔUBA1-3, HA-GSK3β and actin were 
detected by WB using the anti-HA and anti-actin antibody respectively. Actin 
was used as a loading control, and the same results were obtained if protein 
levels were normalised to the loading control. As for HA-NUB1, the HA-NUB1L 
expression (Figure 5.11, A) was decreased over time with CHX treatment, with 
only 25.3% of protein levels remaining after 4 h of CHX treatment compared to 
non-treated cells. Interestingly, the HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 
levels (Figure 5.12, A and 5.13, A respectively) did not decrease as much as 
the HA-NUB1 and HA-NUB1L levels, with 60,4% and 78,1% of levels remaining 
after 4 h of CHX treatment respectively.  
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Figure 5.11. HA-NUB1L effect on HA-GSK3β turnover. Cells were transfected with HA-
GSK3β alone (150 ng) or in combination with HA-NUB1L (100 ng) plasmids. Twenty-
eight hours post-transfection, cells were treated with a vehicle (DMSO) or MG132 (50 
µM) for 4 h and with CHX (50 µg/ml) for 0, 2, and 4 h, and lysed with RIPA buffer. 
Proteins (10 µg) were resolved on a polyacrylamide gel (10%) and were detected by 
WB using the anti-HA or anti-actin antibody (A). The levels of GSK3β (band intensities) 
were measured using the ImageJ software (B, C). (B) Comparison of the GSK3β 
levels. (C) Rate of GSK3β degradation following CHX treatment for 0, 2 and 4 h. 
Statistical significance was determined using an unpaired Student’s t-test. *p-
value<0.05, **p-value<0.01. Error bars are the SEM. 
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Similar results were obtained with proteasome inhibition, with 28.9%, 65.3% 
and 75.2% of HA-NUB1L, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 levels 
remaining after 4 h of CHX treatment. Figure 5.11, B, Figure 5.12, B and Figure 
5.13, B show the levels of HA-GSK3β alone and in the presence of HA-NUB1L, 
HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 respectively, both in the absence 
and in the presence of MG132. In the absence of CHX and MG132 treatment 
both HA-NUB1L and HA-NUB1LΔUBL significantly reduced the overall levels of 
GSK3β, (80±4.5%, p-value = 0.019 and 79.3±4.4%, p-value = 0.02 
respectively), whereas in cells co-transfected with HA-NUB1LΔUBA1-3, the HA-
GSK3β levels were not significantly lower (88.5±12.8%) (0 h, CHX). Both HA-
NUB1L and HA-NUB1LΔUBL significantly reduced the levels of HA-GSK3β over 
time compared to the levels of HA-GSK3β alone (after 4 h of CHX treatment, 
32.1±4.7% vs. 50.7±10.8% and 38.6±3.4% vs. 61.3±3.2% respectively). 
However, HA-NUB1LΔUBA1-3 did not significantly reduce HA-GSK3β levels 
over time (after 4 h of CHX treatment, 62.8±15.5% compared to 59.6±6.6%). 
Therefore, in the absence of MG132, HA-NUB1LΔUBA1-3 was defective in its 
ability to significantly reduce GSK3β levels. With proteasome inhibition, the HA-
GSK3β levels increased to 184±8.4%, 178.7±11.6% and 170.3±11.1% in the 
HA-NUB1, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 experiments respectively, 
and were significantly decreased to 160.5±9.9% (p-value = 0.035), 89.8±13.8% 
(p-value = 0.002) and 114.1±24.5% (p-value = 0.02) in the presence of HA-
NUB1L, HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 respectively (0 h, CHX). 
Surprisingly, in the presence of MG132, all three resulted in a significant decline 
in HA-GSK3β levels over time compared to HA-GSK3β alone. Indeed, at 4 h 
after CHX treatment, HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 decreased HA-
GSK3β levels from 98.8±6.9% and 114.6±32% to 65.3±7.4% and 68.2±6.2% 
respectively, with HA-NUB1L more effective at reducing HA-GSK3β levels (from 
125.6±3.7% to 34.1±3.4%). Interestingly, the overall levels of HA-GSK3β 
appeared to be stabilised upon proteasome inhibition with HA-NUB1L co-
expression compared to HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3, suggesting 
that the HA-NUB1L effect on HA-GSK3β is at least partially mediated by the 
proteasome.  
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Figure 5.12. HA-NUB1LΔUBL effect on HA-GSK3β turnover. Cells were transfected 
with HA-GSK3β alone (150 ng) or in combination with HA-NUB1LΔUBL (100 ng) 
plasmids. Twenty-eight hours post-transfection, cells were treated with a vehicle 
(DMSO) or MG132 (50 µM) for 4 h and with CHX (50 µg/ml) for 0, 2, and 4 h, and lysed 
with RIPA buffer. Proteins (10 µg) were resolved on a polyacrylamide gel (10%) and 
were detected by WB using the anti-HA or anti-actin antibody (A). The levels of GSK3β 
(band intensities) were measured using the ImageJ software (B, C). (B) Comparison of 
the GSK3β levels. (C) Rate of GSK3β degradation following CHX treatment for 0, 2 
and 4 h Statistical significance was determined using an unpaired Student’s t-test. *p-
value<0.05, **p-value<0.01. Error bars are the SEM. 
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Figure 5.13. HA-NUB1LΔUBA1-3 effect on HA-GSK3β turnover. Cells were 
transfected with HA-GSK3β alone (150 ng) or in combination with HA-NUB1LΔUBA1-3 
(100 ng) plasmids. Twenty-eight hours post-transfection, cells were treated with a 
vehicle (DMSO) or MG132 (50 µM) for 4 h and with CHX (50 µg/ml) for 0, 2, and 4 h, 
and lysed with RIPA buffer. Proteins (10 µg) were resolved on a polyacrylamide gel 
(10%) and were detected by WB using the anti-HA or anti-actin antibody (A). The 
levels of GSK3β (band intensities) were measured using the ImageJ software (B, C). 
(B) Comparison of the GSK3β levels. (C) Rate of GSK3β degradation following CHX 
treatment for 0, 2 and 4 h. Statistical significance was determined using an unpaired 
Student’s t-test. *p-value<0.05. Error bars are the SEM. 
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The percentage of HA-GSK3β decreased in the presence of HA-NUB1L (Figure 
5.11, C), HA-NUB1LΔUBL (Figure 5.12, C) and HA-NUB1LΔUBA1-3 (Figure 
5.13, C) were plotted respectively. Without MG132 treatment, the HA-GSK3β 
turnover was significantly accelerated by the presence of HA-NUB1L (Figure 
5.11, C), after 2 h (75.9±7.1% compared to 95.9±12.3%, p-value = 0.037) and 4 
h (40.2±5.9% compared to 59.6±5.6%, p-value = 0.006) of CHX treatment. On 
the other hand, the turnover of HA-GSK3β in the presence of HA-NUB1LΔUBL 
or HA-NUB1LΔUBA1-3 (Figure 5.12, C and 5.13, C) was similar to that of HA-
GSK3β alone after 2 h of CHX treatment. After 4 h of CHX treatment, a small 
but significant reduction of HA-GSK3β levels occurred in the presence of HA-
NUB1LΔUBL (45.4±4% compared to 61.3±3.2%, p-value = 0.032) but not HA-
NUB1LΔUBA1-3 (71±9.3% compared to 59.6±6.6%). With proteasome 
inhibition, the presence of HA-NUB1L accelerated the degradation of GSK3β 
after 2 h (62.1±6.8% compared to 67.3±12.6%, p-value = 0.008) and 4 h 
(21.3±2.2% compared 59.3±10.4%, p-value = 0.001) of CHX treatment, 
whereas the presence of HA-NUB1LΔUBL or HA-NUB1LΔUBA1-3 did not alter 
the rate of HA-GSK3β turnover.  
To conclude, similarly to HA-NUB1, HA-NUB1L was able to reduce GSK3β 
levels and accelerate its turnover. On the other hand, HA-NUB1LΔUBL reduced 
the overall levels of HA-GSK3β but did not alter its rate of turnover. HA-GSK3β 
levels did not decrease in the presence of HA-NUB1LΔUBA1-3 unless the 
proteasome was inhibited in cells, and HA-NUB1LΔUBA1-3 did not accelerate 
the rate of HA-GSK3β degradation irrespective of proteasome inhibition. 
Therefore, both HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 were defective 
compared to HA-NUB1L.  
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5.3. Discussion 
Chapter 4 demonstrated that GSK3β and inhibition of the proteasome induced 
the formation of tau inclusions in cells. Moreover, NUB1 was able to reduce the 
formation of tau inclusions, and its UBA domains were necessary for the 
efficient reduction of tau aggregation. NUB1 was recruited to tau inclusions and 
co-localised with GSK3β, which suggested the formation of a complex between 
the three proteins. 
Therefore, chapter 5 explored the possible interactions between NUB1, GSK3β 
and tau, and the consequences of this association on both total and 
phosphorylated levels of tau. Moreover, the effect of NUB1, as a potential 
shuttle for proteasomal degradation, on GSK3β stability was analysed. 
GSK3β is known to target GFP-tau for phosphorylation. Here we showed that 
GFP-tau and HA-GSK3β co-immunoprecipitated reciprocally with each other. 
This interaction could be part of a complex, for instance, with PS1. Indeed, in 
cells, exogenous PS1 was able to bind both exogenous GSK3β and tau 
(Takashima et al., 1998). Moreover, a small population of endogenous tau and 
GSK3β were precipitated with PS1 in AD brain fractions. Another possibility 
would be a direct interaction between GSK3β and tau, or via the protein 14-3-3 
(Sun et al., 2002; Agarwal-Mawal et al., 2003). 
 
GFP-tau was also able to interact with NUB1-FLAG in a reciprocal manner. This 
was consistent with the recruitment of GFP-NUB1 to tau associated with 
microtubules and tau inclusions. However, neither the co-localisation analysis 
nor the co-immunoprecipitation experiments prove a direct interaction between 
NUB1 and tau. Therefore, NUB1 and tau are in a complex together, but might 
interact either directly or indirectly via a complex of proteins.  
 
Similarly, HA-GSK3β and NUB1-FLAG co-immunoprecipitated reciprocally and 
their localisation overlapped in SK-N-SH cells. Therefore, the two proteins 
interact either directly or indirectly within in a complex, and suggest that GSK3β 
might be also modulated by NUB1. Conversely, it is possible that NUB1 might 
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be a substrate for phosphorylation-dependent regulation by GSK3β. Indeed, 
NUB1 possess several putative sites for GSK3 phosphorylation (10 sites, using 
the Group-based Prediction System (GPS), http://gps.biocuckoo.org/) although 
to date none of these have been confirmed experimentally, and a shift in NUB1 
molecular weight was not seen in the presence of GSK3β. More experimental 
evidence would be required to unequivocally rule out the possibility of NUB1 as 
a substrate for GSK3β, however our data suggests that it is in fact NUB1 that is 
likely involved in the regulation of GSK3β. 
 
As GFP-tau, HA-GSK3β and NUB1-FLAG interacted reciprocally in binary 
complexes, it was expected that when all three proteins were expressed in SK-
N-SH cells, they would form a complex. Indeed, when the three proteins were 
co-expressed, GFP-tau immunoprecipitated both NUB1-FLAG and HA-GSK3β. 
However, whilst GFP-tau immunoprecipitated NUB1-FLAG with the same 
efficiency as in the binary immunoprecipitation, there was an obvious reduction 
in the interaction of HA-GSK3β with GFP-tau in the presence of NUB1-FLAG. 
This result could be explained by competition for a shared binding site on GFP-
tau between NUB1-FLAG and HA-GSK3β. Another possibility is that HA-GSK3β 
might preferentially interact with NUB1-FLAG over GFP-tau, resulting in an 
increase in the HA-GSK3β/NUB1-FLAG complex over the GFP-tau/HA-GSK3β 
complex when the three proteins are expressed in SK-N-SH cells. However, 
NUB1-FLAG co-immunoprecipitation experiments revealed not only a reduction 
in the interaction of NUB1-FLAG with HA-GSK3β, but also with GFP-tau. These 
results suggest that NUB1-FLAG might disrupt the binding interface between 
HA-GSK3β and GFP-tau by sharing this interface in the ternary complex. 
Alternatively, epitope occlusion might occur when the three proteins are 
expressed and interact. In order to test these possibilities, experiments could be 
performed to map the binding interfaces of the proteins. Moreover, in vitro pull 
down experiments using heterologously expressed recombinant proteins could 
be performed to determine whether they are able to interact directly with one 
another. 
The investigation of the localisation of GFP-NUB1, DsRed-tau and HA-GSK3β 
in SK-N-SH cells when the three proteins were co-expressed showed that 
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indeed, HA-GSK3β was no longer associated with tau inclusions. GFP-NUB1 
remained recruited to inclusions, yet HA-GSK3β was completely excluded from 
them. However, both GFP-NUB1 and HA-GSK3β were found in structures 
similar to microtubule bundles formed in the presence of GFP-tau. Therefore, it 
is possible that NUB1 reduces the association of GSKβ with tau, thereby 
consequently reducing both the aggregation of tau and the recruitment of 
GSK3β to the aggregated tau. Alternatively, it is possible that a complex is 
formed between the three proteins which, when localised at inclusions of 
aggregated tau, prevents or occludes the detection of HA-GSK3β by the anti-
HA antibody.  
NUB1 can target proteins for proteasomal degradation. Hence, the ability of 
NUB1 to reduce tau inclusions could be via an increase in its proteasomal 
degradation. Thus, the effect of NUB1, NUB1L and the NUB1L mutants on the 
levels of total and phosphorylated tau was explored. Tau levels were not 
significantly decreased by HA-NUB1, HA-NUB1L or the HA-NUB1L mutants 
without proteasome inhibition in either the absence or presence of HA-GSK3β. 
With inhibition of the proteasome, GFP-tau levels were slightly increased in the 
absence of HA-GSK3β expression and were further enhanced when HA-GSK3β 
was co-expressed in cells. This data suggests that GFP-tau degradation is 
partially mediated by the proteasome, and that in the presence of HA-GSK3β, 
GFP-tau is more stable. A significant decline of GFP-tau levels was observed 
with the co-expression of HA-NUB1, HA-NUB1L or the HA-NUB1L mutants with 
proteasome inhibition and in the presence of HA-GSK3β. This suggests that 
HA-NUB1 might target a subpopulation of GFP-tau, probably a population that 
is also phosphorylated by GSK3β. Another possibility is that HA-NUB1, HA-
NUB1L and the HA-NUB1L mutants target HA-GSK3β, thus reducing tau 
phosphorylation and stabilisation. 
Indeed, the analysis of tau phosphorylated on S396 (pS396-tau) showed that 
HA-NUB1, HA-NUB1L and the HA-NUB1L mutants significantly and strongly 
reduced pS396-tau levels. It is therefore possible that NUB1 targets 
hyperphosphorylated tau for degradation. Noticeably, even the mutant HA-
NUB1LΔUBA1-3 could reduce tau and pS396-tau levels, although this mutant 
could not reduce tau aggregation. Thus, the effect of NUB1 on tau aggregation 
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might not only be mediated by the reduction of total or phosphorylated tau 
levels. However, only one phospho-epitope of tau was analysed in this study. 
Therefore, HA-NUB1LΔUBA1-3 might be able to target pS396-tau but not tau 
phosphorylated on other residues, such as the epitopes recognised by the AT8 
antibody that is mostly found in the inclusions. Thus, it would have been 
interesting to assess the levels of insoluble tau compared to soluble tau, and 
the resolution of tau phospho-epitopes in each of these fractions.  
The reduction of phosphorylated tau levels on S396 could also be mediated by 
a reduction of GSK3β-dependent phosphorylation of tau. Indeed, the reduced 
interaction of GFP-tau and HA-GSK3β observed in the ternary complex might 
result from a NUB1-mediated decrease in HA-GSK3β levels. The hypothesis of 
a proteasomal degradation of GSK3β by NUB1 was tested using a 
cycloheximide (CHX) assay. CHX inhibits the transcription of proteins, and 
therefore the levels of a protein observed upon CHX treatment are directly 
related to its degradation or turnover rate. HA-GSK3β is thought to be a stable 
protein with a half-life of 48 h. However, in SK-N-SH cells, overexpressed HA-
GSK3β levels started to decline after 4 h of CHX treatment. In the presence of 
HA-NUB1, the levels of HA-GSK3β were reduced even without CHX treatment 
and started to decline after only 2 h of CHX treatment. Moreover, the rate of 
HA-GSK3β degradation was accelerated, thus suggesting that HA-NUB1 
modulates HA-GSK3β turnover. With proteasome inhibition, the levels of HA-
GSK3β alone were stabilised although the rate of degradation was not 
significantly altered. This suggests that GSK3β degradation in the absence of 
NUB1 is partially mediated by the proteasome. HA-NUB1 accelerated the 
turnover of HA-GSK3β, however proteasome inhibition did not further stabilise 
or change the rate of degradation of HA-GSK3β, suggesting that the effect of 
HA-NUB1 on HA-GSK3β was not proteasome-dependent. A recent study 
proposes that HA-GSK3β is sequestered in MVBs and later degraded by 
lysosomes (Taelman et al., 2010). In chapter 4, the presence of GFP-NUB1 
induced a change of HA-GSK3β localisation, which was more particulate in 
nature than when it was expressed on its own and which was then also 
detected diffusely in the nucleus. The UBA domains of the human EPS15 and 
the yeast Ede1 proteins have been implicated in monoUb recognition and 
 Chapter 5 - NUB1 interacts with tau and GSK3β 
  186 
endosomal sorting. Therefore, HA-NUB1 could mediate HA-GSK3β 
endosomal/lysosomal degradation via its UBA domains. It would be interesting 
to confirm this hypothesis with the use of markers for the endosomal pathway, 
such as Vps4.  
The effect of HA-NUB1L and the HA-NUB1L mutants on HA-GSK3β turnover 
was also investigated. HA-NUB1L was able to significantly reduce the overall 
levels of HA-GSK3β and to accelerate its degradation rate. With proteasome 
inhibition, HA-NUB1L decreased the levels of HA-GSK3β although they were 
considerably stabilised in comparison to those in the absence of proteasome 
inhibition. Interestingly, although HA-NUB1L accelerated the turnover of GSK3β 
in both the absence and presence of MG132, the rate of degradation in each 
case was not significantly different, suggesting that the effect of HA-NUB1L on 
HA-GSK3β turnover was only partially mediated by the proteasome. Hence, 
both HA-NUB1 and HA-NUB1L significantly reduced the levels of GSK3β and 
accelerated the rate of degradation of GSK3β both in the presence and 
absence of proteasome inhibitor. MG132-dependent stabilization of GSK3β 
levels was significant only with HA-NUB1L, and the rate of turnover, although 
accelerated with both HA-NUB1 and HA-NUB1L, was the same irrespective of 
proteasome inhibition. Therefore, it is possible that the effect of NUB1 and 
NUB1L on GSK3β is only mediated in part by the proteasome.  
On the other hand, HA-NUB1ΔUBL did not accelerate the degradation of HA-
GSK3β, but did reduce the overall levels of HA-GSK3β. This suggests that the 
NUB1L mutant lacking the UBL domains is defective with respect to its 
proteasome-associated function and therefore did not accelerate HA-GSK3β 
degradation, but is consequently active in addressing HA-GSK3β to a 
degradation pathway other than proteasomal degradation. The mutant HA-
NUB1ΔUBA1-3 reduced the overall HA-GSK3β levels only with proteasome 
inhibition. The mutant did not accelerate HA-GSK3β turnover, suggesting that 
like HA-NUB1LΔUBL, HA-NUB1LΔUBA1-3 is defective with respect to a 
proteasome-associated function. It is interesting in this regard that both 
NUB1LΔUBL and NUB1LΔUBA1-3 levels themselves appeared considerably 
stable following CHX treatment, suggesting their defective clearance. Unlike 
HA-NUB1 and HA-NUB1L, both HA-NUB1LΔUBL and HA-NUB1LΔUBA1-3 
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were unable to accelerate the turnover of GSK3β, irrespective of proteasome 
inhibition, but both significantly decreased the levels of GSK3β with proteasome 
inhibition. This might suggest that the targeting of GSK3β to the proteasome by 
these mutants is defective, and that following inhibition of the proteasome, 
GSK3β is consequently targeted to an alternative pathway by the mutants. 
Since the regulation of GSK3β by NUB1 appears to be mediated only in part by 
the proteasome, it is also possible that the mutants are defective in alternative 
clearance pathways for GSK3β and unable to accelerate the clearance via 
these pathways. Though the underlying mechanism of NUB1 regulation of 
GSK3β appears complex, these findings nevertheless highlight the importance 
of both the UBL and UBA domains in the NUB1-mediated regulation of GSK3β.  
This chapter has demonstrated that NUB1 can interact with both tau and 
GSK3β, and is associated with these two proteins in a ternary complex. 
Moreover, NUB1 reduced the levels of phosphorylated tau in the presence of 
GSK3β, possibly as a result of an acceleration or increase in GSK3β 
degradation, via the proteasome and other degradation mechanisms. 
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Chapter 6  
NUB1 targets GSK3β  
 
6.1. Introduction 
NUB1 targets FAT10 and NEDD8 and their conjugated proteins for proteasomal 
degradation. Indeed, NUB1 is able to bind the S5a subunit of the 19S 
proteasome. NUB1 is a UBL/UBA domain protein. However, NUB1 is an 
unconventional member of this family. Indeed, its UBA domains, although 
necessary to bind FAT10, are not always necessary to bind proteins targeted 
for proteasomal degradation, and its UBL domain does not appear to be 
involved in its interaction with the proteasome (Tanji et al., 2005; Schmidtke et 
al., 2006). Indeed, NUB1 binds NEDD8, synphilin-1 and the proteasome via its 
C-terminus, near the PEST domain (Tanji et al., 2006). PEST domains are 
sequences of amino acids rich in proline (P), glutamic acid (E), serine (S) and 
threonine (T), thought to be characteristic of short-lived proteins and therefore 
involved in signalling that a protein be targeted for rapid proteasomal 
degradation. Thus, it is possible that the degradation of NUB1 itself or proteins 
associated with NUB1 is accelerated as the PEST domain acts as a 
degradation signal. Moreover, the UBA/UBL domains of NUB1 might be 
implicated in other regulatory mechanisms of protein degradation and turnover, 
such as autophagy and lysosomal degradation.  
In previous chapters, NUB1 was shown to influence tau levels and GSK3β 
turnover. NUB1 co-localised with tau and GSK3β in rat cortical neurons and in 
SK-N-SH neuroblastoma cells. Moreover, NUB1 interacted with both exogenous 
tau and GSK3β, reduced phosphorylated tau levels and aggregation, and 
enhanced GSK3β turnover. However, although NUB1 is expressed 
endogenously in human hippocampal neurons, the physiological role of NUB1 
in neurons is unknown. In this chapter, the expression of endogenous NUB1  
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was explored in SH-SY5Y neuroblastoma cells. Moreover, its interaction with 
endogenous GSK3β and its affect on the stability and turnover of endogenous 
GSK3β were investigated.  
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6.2. Results 
6.2.1. Expression of tau, NUB1 and GSK3β in SH-SY5Y 
neuroblastoma cells 
SK-N-SH neuroblastoma cells lack NUB1 and tau expression (Figure 4.1 and 
4.7). Therefore, to investigate the effect of NUB1 on endogenous tau and 
GSK3β, their expression was analysed in another neuroblastoma cell line, SH-
SY5Y.  
SK-N-SH and SH-SY5Y cells were harvested and 5, 10, 20 and 40 µg of total 
protein was resolved on a polyacrylamide gel. Endogenous NUB1, tau and 
GSK3β were detected by WB using the anti-NUB1, anti-tau or anti-GSK3β 
antibody respectively (Figure 6.1). Tau and NUB1 could not be detected in SK-
N-SH cells, even with 40 µg of total proteins resolved on the gel. In contrast, 
endogenous NUB1 was detected in SH-SY5Y cells at a molecular weight of ~66 
kDa as expected from the predicted size. The NUB1 levels detected increased 
proportionally with the amount of protein resolved, however, a minimum of 10 
µg of the total protein was necessary to detect endogenous NUB1. Several 
bands were detected by anti-tau in SH-SY5Y cells, with a prominent band 
detected at ~50 kDa corresponding to the smaller three isoforms of human tau, 
the molecular weight of which varies from 45 to 50 kDa. GSK3β was detected in 
both the SK-N-SH cells and SH-SY5Y cells as a single band of ~47 kDa. 
GSK3β levels increased proportionally with the amount of proteins resolved, 
and could be detected with only 5 µg of total protein. 
 
6.2.2. Localisation of GFP-NUB1 with endogenous tau and 
microtubules in SH-SY5Y cells 
It has been shown in Chapter 3 and 4 that NUB1 co-labelled GFP-tau. 
Therefore, the co-localisation of NUB1 with endogenous tau and microtubules 
was investigated in SH-SY5Y cells.  
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Figure 6.1. Expression of NUB1, tau and GSK3β in SK-N-SH and SH-SY5Y cells. 
Decreasing amounts (40, 20, 10, 5 µg) of SK-N-SH and SH-SY5Y cell lysates were 
resolved on a polyacrylamide gel (10%) and proteins were detected by WB using the 
anti-NUB1, anti-tau or anti-GSK3β antibody. 
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The NUB1 peptide-directed antibody is not suitable for immunocytochemical 
localisation. Therefore, the localisation of exogenous GFP-NUB1 was analysed 
in SH-SY5Y neuroblastoma cells. Cells were transfected with GFP-NUB1 and  
24 h after transfection, cells were treated with a vehicle (DMSO) (Figure 6.2, A) 
or with MG132 (50 µM) (Figure 6.2, B), and fixed with glutaraldehyde (0.3%).  
Tau was detected using the anti-tau antibody (Figure 6.2, A and B, red). Figure 
6.2, A shows that GFP-NUB1 was, as expected, mostly nuclear. Similar to its 
localisation in primary neurons (Figure 3.10), it was also detected in the primary 
neurites. Tau was mostly localised in the cytoplasm and the neurites. With 
MG132 treatment (Figure 6.2, B), GFP-NUB1 distribution was enhanced in the 
cytoplasm. In the magnified images of the cell body and the neurites (Figure 
6.2, A and B, I and II respectively), GFP-NUB1 partially co-localised with 
endogenous tau in both the absence and presence of proteasome inhibitor.  
As tau is a microtubule associated protein, the distribution of GFP-NUB1 and 
microtubules was analysed in SH-SY5Y cells. 
SH-SY5Y cells were transfected with GFP-NUB1. Twenty four hours post-
transfection, cells were treated with a vehicle (DMSO) (Figure 6.3, A) or MG132 
(50 µM) (Figure 6.3, B) and fixed with 0.3% glutaraldehyde. The microtubules 
were detected using the anti-β-tubulin antibody (Figure 6.3, red). As previously 
observed, GFP-NUB1 in SH-SY5Y cells was mostly nuclear but could also be 
detected in the cytoplasm and primary neurites, and its distribution in the 
cytoplasm was enhanced after proteasome inhibition (Figure 6.3, A and B). The 
microtubules (Figure 6.3, red) were detected as a filamentous network in the 
cytoplasm and the neurites but not in the nucleus. In the magnified images of 
the cell body and neurites, both in the absence and presence of MG132 (Figure 
6.3, A and B, I and II), a partial overlap of GFP-NUB1 and β-tubulin could be 
observed. However, in the cell body (Figure 6.3, A and B, I), GFP-NUB1 
generally did not co-localise with the microtubule network, and this was 
particularly evident at the cellular periphery (white arrows).   
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Figure 6.2. Distribution of GFP-NUB1 and endogenous tau in SH-SY5Y cells. Cells 
were transfected with GFP-NUB1. Twenty-four hours after transfection, cells were 
treated with a vehicle (A) or with MG132 (50 µM) (B) and fixed with glutaraldehyde 
(0.3%, 10 min at 37°C). Cells were labelled with the anti-tau primary antibody in 
conjunction with the AlexaFluor 594 secondary antibody and treated with DAPI to 
detect nuclei (blue). Images were acquired with a laser scanning confocal microscope 
(Zeiss LSM 700). The white squares highlight the magnified images of the cell body 
(soma, I) and neurites (II). Scale bars = 10 µm. 
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Figure 6.3. Distribution of GFP-NUB1 and microtubules in SH-SY5Y cells. Cells were 
transfected with GFP-NUB1. Twenty-four hours after transfection, cells were treated 
with a vehicle (A) or with MG132 (50 µM) (B) and fixed with glutaraldehyde (0.3%, 
10min at 37°C). Cells were labelled with the anti-β-tubulin primary antibody in 
conjunction with the AlexaFluor 594 secondary antibody and treated with DAPI to 
detect nuclei (blue). Images were acquired with a laser scanning confocal microscope 
(Zeiss LSM 700). The white squares highlight the magnified images of the cell body 
(soma, I) and neurites (II). The arrows and arrowheads underline the non-overlapping 
staining. Scale bars =10µm. 
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In the neurites (Figure 6.3, A and B, II), although there was again some partial 
overlap, GFP-NUB1 generally did not co-localise with microtubules which could 
be seen to “surround” the GFP-NUB1 (white arrowheads). This was similar to 
what was observed in the rat primary cortical neurons (Figure 3.12). 
The distribution of endogenous GSK3β was assessed, but although GSK3β 
was expressed in SH-SY5Y cells, the detection of the endogenous GSK3β with 
the anti-GSK3β antibody was unsuccessful. 
 
6.2.3. NUB1-FLAG and endogenous GSK3β are in a binary complex 
in SH-SY5Y cells 
NUB1-FLAG co-immunoprecipitated both GFP-tau and HA-GSK3β from SK-N-
SH cells (Figure 5.2, 5.3 and 5.4). The anti-NUB1 antibody could not be used to 
successfully immunoprecipitate endogenous NUB1 from SH-SY5Y cells. 
Therefore, the interaction between NUB1-FLAG and endogenous tau and 
GSK3β was explored without proteasome inhibition. It could not be determined 
if the co-immunoprecipitation of endogenous tau with NUB1-FLAG was 
successful under the conditions used, as tau resolved to the same molecular 
weight as the immunoglobulin heavy chain (~ 50 kDa) (data not shown). 
SH-SY5Y cells were transfected with NUB1-FLAG. Twenty-four hours after 
transfection, cells were lysed and proteins were immunoprecipitated with the 
anti-FLAG antibody (Figure 6.4, A) or anti-GSK3β antibody (Figure 6.4, B) using 
magnetic beads (Chapter 2.5.6). Cell lysates were resolved on a polyacrylamide 
gel (10%) and proteins were detected using the anti-FLAG or the anti-GSK3β 
antibody.  
Both GSK3β and NUB1-FLAG were detected in the input fractions. NUB1-FLAG 
was immunoprecipitated and endogenous GSK3β specifically co-
immunoprecipitated with the anti-FLAG antibody (Figure 6.4, A), although only 
0.25% of the total levels of GSK3β were co-immunoprecipitated. No GSK3β 
was non-specifically co-immunoprecipitated with the anti-FLAG antibody in the 
absence of NUB1-FLAG, or with a non-specific antibody (IgG).  
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Figure 6.4. Immunoprecipitation of NUB1-FLAG and GSK3β. SH-SY5Y cells were 
transfected with 100 ng of NUB1-FLAG. Twenty-four hours after transfection, cells 
were lysed with RIPA buffer, and lysates were incubated with magnetic beads in the 
absence (BO) or presence of anti-FLAG (1:500, A), anti-GSK3β (1:100, B) or a non-
specific (IgG) antibody overnight at 4°C. Five µl (INPUTS) or 10 µl (IP) of samples were 
resolved on a polyacrylamide gel (10%) and proteins were detected by WB using the 
anti-GSK3β or anti-FLAG antibody. 
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Reciprocally, the anti-GSK3β antibody immunoprecipitated endogenous GSK3β 
and specifically co-immunoprecipitated NUB1-FLAG  (Figure 6.4, B), with 0.24% 
of total NUB1  co-immunoprecipitated with the anti-GSKβ antibody. Moreover, 
neither GSK3β nor NUB1-FLAG were immunoprecipitated with a non-specific 
antibody (IgG) or with the beads only (BO).  
In conclusion, endogenous GSK3β and NUB1-FLAG interacted reciprocally in 
SH-SY5Y neuroblastoma cells. 
 
6.2.4. NUB1 accelerates GSK3β degradation in SH-SY5Y cells 
As shown in Chapter 5, HA-NUB1 reduced HA-GSK3β levels (Figure 5.10, A). 
Moreover, HA-NUB1 accelerated the degradation of HA-GSK3β after CHX 
treatment (Figure 5.10, B and C). Therefore, the effect of NUB1 on endogenous 
GSK3β levels was tested by silencing endogenous NUB1 with a small 
interfering RNA (siRNA) specific to NUB1 mRNA (Tanji et al., 2006). 
SH-SY5Y cells were transfected with a non-specific siRNA (NS siRNA) or 
NUB1-specific siRNA (NUB1 siRNA), or were mock transfected (Mock). Forty-
eight, 72 and 96 h after transfection, cells were lysed and 20 µg of total protein 
was resolved on a polyacrylamide gel (10%). NUB1, GSK3β and actin were 
detected by WB using the anti-NUB1, anti-GSK3β or anti-actin antibody 
respectively (Figure 6.5). The detection of actin was used as a loading control 
for equal amounts of protein resolved on the polyacrylamide gel. NUB1 was 
detected in the NS siRNA and mock transfected samples, whereas a strong 
decrease of NUB1 expression was observed in cells transfected with the NUB1 
siRNA at any given time after transfection. Interestingly, a corresponding 
increase in GSK3β levels  was noted following the silencing of endogenous 
NUB1.  
To investigate the role of NUB1 on GSK3β turnover, protein synthesis was 
inhibited by cycloheximide (CHX) following the silencing of endogenous NUB1 
expression (Figure 6.6). Cells were transfected with non-specific siRNA (NS 
siRNA) or NUB1-specific siRNA (NUB1 siRNA) for 72 h, or were mock 
transfected (Mock).  
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Figure 6.5. NUB1 silencing in SH-SY5Y cells. Cells were transfected with a non-
specific siRNA (NS siRNA), siRNA specific to NUB1 mRNA (NUB1 siRNA), or were 
mock transfected (Mock). Cell were lysed with RIPA buffer 48, 72 or 96 h post-
transfection and 20 µg of total protein was resolved on a polyacrylamide gel (10%). 
Proteins were detected by WB using the anti-NUB1, anti-GSK3β or anti-actin antibody. 
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Cells were treated with CHX for 0, 2, 4 and 6 h, lysed with RIPA buffer and 20 
µg of total protein was resolved on a polyacrylamide gel (10%). NUB1, GSK3β 
and actin were detected by WB using the anti-NUB1, anti-GSK3β and anti-actin 
antibody respectively (Figure 6.6, A). 
 
Actin, with a half-life of ~48 h (Antecol et al., 1986), was used as a loading 
control. NUB1 expression was detected in both the presence of non-specific 
siRNA (NS siRNA) and in mock transfected cells (Mock), and the levels of 
NUB1 decreased over time with CHX treatment (Figure 6.6, A). After 6 h of 
CHX treatment, the levels of endogenous NUB1 were 49.7±3.2% and 52.5±7% 
in cells transfected with non-specific siRNA and mock transfected cells 
respectively, compared to 0 h of CHX treatment.  
The levels of NUB1 were specifically and effectively silenced by the NUB1-
specific siRNA (Figure 6.6, A). The levels of endogenous GSK3β (Figure 6.6, A) 
decreased temporally following CHX treatment in the cells transfected with non-
specific siRNA (NS siRNA) and in the mock transfected cells (Mock). However, 
in the cells transfected with the NUB1-specific siRNA, GSK3β levels did not 
decrease as much nor as rapidly as in the control cells (Figure 6.6, A). The 
GSK3β levels were measured by densitometry (Figure 6.6, B and C) using 
ImageJ software. Figure 6.6, B shows that in the mock or NS siRNA transfected 
cells without any CHX treatment, the GSK3β levels were significantly decreased 
to 61.7±9.5% and 75.3±11% respectively compared to those in the NUB1 
siRNA transfected cells (p-value = 0.006 and p-value = 0.033 respectively). The 
GSK3β levels were significantly stabilised over time following the silencing of 
endogenous NUB1, after 2 h, 4 h and 6 h of CHX treatment (102.7±8.7%, 
70.6±10.6% and 46.8±5.6% respectively) compared to GSK3β levels in mock 
(31.2±5.4%, 17.6±5.4 and 11.2±3.2% respectively; all p-values < 0.004) or NS 
siRNA transfected cells (46.5±8.4%, 29.5±8.5% and 15.4±3% respectively; all 
p-values < 0.009). Moreover, the analysis of the degradation rate of GSK3β 
(Figure 6.6, C) shows that the silencing of NUB1 expression delayed the 
degradation of GSK3β.  
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Figure 6.6. NUB1 effect on GSK3β turnover. Cells were transfected with a non-specific 
siRNA (NS siRNA ), siRNA specific to NUB1 mRNA (NUB1 siRNA) or  were mock 
transfected (Mock). Seventy-two h post-transfection, cells were treated with CHX (50 
µg/ml) for 0, 2, 4, and 6 h, and lysed with RIPA buffer. Proteins (20 µg) were resolved 
on a polyacrylamide gel (10%) and were detected by WB using the anti-NUB1, anti-
GSK3β or anti-actin antibody (A). The levels of GSK3β were measured using  ImageJ 
software (B, C). (B) Comparison of the GSK3β levels. (C) Rate of GSK3β degradation 
following CHX treatment for 0, 2, 4 and 6 h. Statistical significance was determined 
using an unpaired Student’s t-test. *p-value<0.05, **p-value<0.01. Error bars are the 
SEM. 
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Indeed, after 2 h of CHX treatment in NUB1 siRNA transfected cells, the GSK3β 
levels were higher than at the 0 h time point (102.7±8.7%) and also significantly 
higher than the GSK3β levels in NS siRNA and mock transfected cells 
(61.9±7.5% and 50.6±5.1% respectively, p-values = 0.001). After 6 hours of 
CHX treatment, the levels of GSK3β were decreased to 18±4% and 20.7±3.8% 
in mock and NS siRNA transfected cells respectively, whereas they were 
significantly higher in NUB1 siRNA transfected cells (46.8±5.6%).  
In conclusion, the increased levels and stability of endogenous GSK3β following 
the siRNA-mediated silencing of NUB1 expression suggest a role for NUB1 in 
GSK3β turnover and degradation. 
    Chapter 6 - NUB1 targets GSK3β 
  202 
 
6.3. Discussion 
This chapter focused on the potential interactions between endogenous NUB1, 
tau and GSK3β. Previous chapters showed that NUB1 was a modulator of tau 
levels, phosphorylation state and aggregation. NUB1 could co-localise and 
interact with tau, but also with GSK3β. Indeed, chapter 5 demonstrated that 
NUB1 regulated GSK3β turnover and accelerated its degradation, probably via 
the proteasome and other pathways.  
SK-N-SH neuroblastoma cells did not express detectable levels of either tau or 
NUB1 and very low levels of GSK3β were detected. Therefore, SK-N-SH cells 
were a useful tool to analyse the functional impact of the overexpression of the 
three proteins on one another. However, analysis of the endogenous proteins 
was thus not possible. Hence, another neuroblastoma cell line, SH-SY5Y, that 
endogenously expresses NUB1, tau and GSK3β, was used. 
 
The NUB1 antibody raised in our laboratory was not suitable for 
immunocytochemistry. Thus, the localisation of NUB1 was investigated using 
GFP-NUB1. It is interesting that SH-SY5Y cells exhibited neurite-like processes, 
conversely to SK-N-SH cells. The distribution of GFP-NUB1 in SH-SY5Y cells 
was similar to its localisation in primary neurons and SK-N-SH cells, in that it 
was mostly nuclear but exhibited an increased cytoplasmic localisation with 
proteasome inhibition. Endogenous tau was expressed mainly in the cytoplasm, 
but surprisingly in the nucleus as well, although this could be a 
fixation/immunolabelling artefact. GFP-NUB1 co-labelled endogenous tau in the 
cytoplasm and the processes. Moreover, it was also localised with endogenous 
tau in swellings of the neurite-like processes similar to the varicosities in primary 
neurons, which were also co-labelled with endogenous tau. On the contrary, 
although the localisation of GFP-NUB1 appeared to overlap with that of β-
tubulin, it is uncertain if this was a specific co-localisation between them. 
Indeed, similarly to rat primary cortical neurons, GFP-NUB1 appeared to be 
surrounded by microtubules at the cell periphery and in the swellings of the 
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neurite-like processes. These results suggest that NUB1 could interact with 
endogenous tau to modulate its levels and activity. 
 
The anti-NUB1 antibody could not be used successfully in co-
immunoprecipitation experiments. Indeed, the NUB1 antibody is a polyclonal 
antiserum and therefore, purification of the antibody by affinity chromatography 
using the peptide against which it was raised may have been necessary before 
its successful use in immunoprecipitation. Thus, co-immunoprecipitation was 
performed using NUB1-FLAG. The specificity of the co-immunoprecipitation of 
endogenous tau could not be determined as it resolved to the same molecular 
weight as the IgG heavy chain on WB. Nonetheless, NUB1-FLAG and 
endogenous GSK3β were co-immunoprecipitated in a reciprocal manner 
suggesting that the two proteins interact with each other. 
To test the hypothesis that NUB1 could modulate the levels of endogenous 
GSK3β, GSK3β levels were measured in SH-SY5Y cells following the silencing 
of NUB1 expression by RNA interference, in the presence of CHX, that inhibits 
protein synthesis. Chapter 5 showed that overexpression of NUB1 in SK-N-SH 
cells decreased the stability and accelerated the degradation of GSK3β, 
therefore the silencing of endogenous NUB1 expression was expected to 
stabilise endogenous GSK3β levels. NUB1 siRNA successfully downregulated 
NUB1 levels as soon as 48 h after transfection. Moreover, the levels of GSK3β 
appeared to be increased in cells transfected with NUB1 siRNA compared to 
mock transfected cells or cells transfected with the non-specific siRNA. With 
CHX treatment, both GSK3β and NUB1 levels declined with time in mock 
transfected cells and cells transfected with the non-specific siRNA. However, in 
cells transfected with NUB1 siRNA, the levels of GSK3β remained the same 
after 2 h of treatment with CHX, after which it started to decline at a slower rate 
compared to the controls. Thus, knock-down of NUB1 delayed the degradation 
of GSK3β, suggesting that endogenous NUB1 is involved in regulating the 
turnover of GSK3β. Moreover,  both NUB1 and GSK3β levels decline in control 
cells following treatment with CHX, suggesting that both proteins are degraded 
and that NUB1 is degraded  at the same time as its target proteins. It would 
interesting to assess whether the effect is proteasome dependent.  
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To conclude, the analysis of endogenous NUB1, tau and GSK3β in SH-SY5Y 
neuroblastoma cells confirmed that NUB1 is involved in protein turnover. 
Indeed, it can co-localise with tau and interact with GSK3β. Moreover, it clearly 
influences GSK3β turnover, suggesting that NUB1 might be an important 
regulator of tau phosphorylation. 
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Chapter 7  
Discussion  
 
NUB1 alters tau aggregation and phosphorylated levels. Tau in SK-N-SH cells 
induced the formation of microtubule bundles, confirming the role of tau in 
microtubule binding and stabilisation. With the expression of GSK3β and 
inhibition of the proteasomal activity, a decrease in bundle formation and the 
formation of tau aggregates were observed. Moreover, the aggregation of tau 
correlated with an increase in the levels of phosphorylated tau, at least on the 
S396 and AT8 epitopes. Therefore, the accumulation of endogenous tau when 
hyperphosphorylated and with proteasome impairment was replicated in SK-N-
SH neuroblastoma cells.  
In this system, the expression of NUB1 clearly reduced the formation of tau 
inclusions. NUB1 co-localised with overexpressed tau in SK-N-SH cells, but 
also with endogenous tau in SH-SY5Y cells and rat primary cortical neurons. In 
SK-N-SH cells, NUB1 was clearly recruited to tau inclusions, and co-localised  
with tau in the microtubule bundles. Interestingly, although tau is a microtubule 
binding protein, NUB1 did not seem to co-localise with endogenous 
microtubules in rat cortical neurons and SH-SY5Y cells. Moreover, NUB1 and 
tau were reciprocally co-immunoprecipitated with one another, suggesting that 
the two proteins interact either directly or indirectly with each other in a 
complex. Taken together, these results suggest that NUB1 targets tau.  
NUB1 reduced the levels of tau phosphorylated on S396, but not the total levels 
of tau, unless GSK3β was co-expressed and the proteasome activity inhibited. 
Furthermore, NUB1 co-localised with hyperphosphorylated tau in the inclusions, 
and with tau in the microtubules. Thus, it is possible that NUB1 targets 
phosphorylated tau disrupting its binding with the microtubules. Alternatively, 
NUB1 could indirectly influence tau phosphorylation and aggregation by 
modulating the tau kinase GSK3β. 
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NUB1 modulates GSK3β turnover. The levels of tau phosphorylated on S396 
were greatly enhanced by the co-expression of GSK3β in SK-N-SH cells. The 
levels of tau phosphorylated on the AT8 epitope could not be detected without 
GSK3β co-expression, suggesting that the expression of endogenous kinases 
in SK-N-SH cells was not sufficient to induce tau hyperphosphorylation, or that 
their activity was compensated by the endogenous phosphatases. Furthermore, 
the exogenous expression of GSK3β greatly enhanced the formation of tau 
inclusions, suggesting that GSK3β, by phosphorylating tau, can promote wild-
type tau aggregation. Indeed, GSK3β was found to interact with tau, either 
directly or indirectly, and to co-label tau inclusions.  
The presence of NUB1 in SK-N-SH cells disrupted the interaction of tau and 
GSK3β, which correlated with the decreased levels of phosphorylated tau and 
with the fact that GSK3β could no longer be detected in tau inclusions. NUB1 
and GSK3β interacted reciprocally in both SK-N-SH and SH-SY5Y cells. 
Moreover, NUB1 co-localised with GSK3β in the cytoplasm in SK-N-SH cells 
and rat primary cortical neurons, and increased the levels of GSK3β detected in 
the nucleus. Thus, NUB1 could target GSK3β and influence its interaction with 
tau. Indeed, inhibition of transcription by CHX in SK-N-SH cells expressing 
NUB1 accelerated the turnover of GSK3β, with GSK3β levels reducing faster in 
the presence of NUB1 than in its absence. This was confirmed by the 
downregulation of NUB1 in SH-SY5Y cells, which greatly stabilised the levels of 
endogenous GSK3β following CHX treatment. Interestingly, the levels of NUB1 
were also decreased in the presence of CHX, suggesting that NUB1 was also 
degraded. Therefore, NUB1 might target GSK3β and be degraded along with its 
target.  
 
NUB1 as a potential proteasome shuttle. Impairment of the UPS is an important 
factor in inclusion formation in cells, and has been reported in amyloidosis such 
as AD. Indeed, Ub and proteasomal components are recruited to NFTs in AD, 
as a result of the failure of the UPS to degrade tau. In human brain sections 
used in this study, Ub was seen to accumulate in NFTs and dystrophic neurites 
in AD patients, confirming the presence of Ub in tau and Aβ inclusions. 
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Interestingly, the ULM FAT10 was also observed to accumulate in brain 
sections from AD patients. Although the increased expression of FAT10 could 
result from an increase in the neuroinflammatory response, FAT10 could be 
upregulated in AD as a consequence of targeting tau or Aβ for NUB1-mediated 
regulation. FAT10 and its conjugates interact with NUB1, which induces their 
proteasomal degradation. A role for NUB1 in regulating protein levels in 
neurons was also emphasised by the similarity between the localisation of 
NUB1 and NEDD8, another ULM targeted by NUB1 for proteasomal 
degradation. In AD patients, the localisation of both NEDD8 and NUB1 was 
predominantly cytoplasmic in the surviving pyramidal neurons of the 
hippocampus, suggesting a specific function for both proteins in this subcellular 
location or a result of dysregulation of the cell cycle.  
 
The proteasome independent influence of NUB1. NUB1 might also decrease 
GSK3β levels in a proteasome-independent manner. The fact that proteasome 
inhibition did not change the overall levels or the rate of degradation of GSK3β 
in the presence of NUB1 suggests that the increased rate of GSK3β turnover in 
the presence of NUB1 might be proteasome independent. GSK3β has been 
shown to be sequestered in MVBs upon Wnt signalling. It is therefore possible 
that NUB1 triggers GSK3β sequestration in MVBs or shuttles GSK3β to the 
endosomal pathway. Indeed, the expression of NUB1 induced a change in the 
GSK3β sub-localisation in cytoplasm, which was more particulate, perhaps as a 
result of sequestration to MVBs. Targeting of proteins into this degradative 
pathway is largely dependent on post-translation modification by Ub and 
proteins with UBA domains have been involved in ESCRT complex formation. 
FAT10 or NEDD8, similar to Ub, could be involved in substrate recognition and 
targeting to the MVBs. 
Interestingly, NUB1 might influence Wnt signalling by sequestration of GSK3β 
to the MVB/endosomal pathway. Indeed, NUB1-dependent targeting of GSK3β 
to MVB and the endosomal pathway would free β-catenin from GSK3β-
mediated phosphorylation and degradation. Therefore, β-catenin would be free 
to translocate into the nucleus and activate the transcription of its target genes, 
hence the canonical Wnt signalling pathway would be activated. On the other 
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hand, further regulation could occur at the level of the β-catenin CRL. NUB1, by 
targeting NEDD8 degradation, might inhibit β-catenin ubiquitination by the SCF, 
thus reducing β-catenin degradation. Therefore, the influence of NUB1 on Wnt 
signalling would be a double edged sword. 
The localisation of NUB1 in SK-N-SH cells, SH-SY5Y cells, and even rat 
primary cortical neurons was predominantly nuclear but was stabilised in the 
cytoplasm following inhibition of the proteasome. Therefore, NUB1 localisation 
in cells may be highly dynamic and regulated by complex mechanisms (such as 
cell cycle or signalling pathways, e.g. Wnt signalling) to target specific 
substrates.  
 
The UBA domains of NUB1 are necessary but not essential. The 
NUB1LΔUBA1-3 mutant was defective in mediating the accelerated turnover of 
GSK3β, suggesting that the UBA domains are required for the degradation of 
GSK3β. Notably, the proteasome binding site is thought to reside in the C-
terminal domain of NUB1, and this may be lost in the NUB1LΔUBA1-3 mutant. 
However, the mutant may still effectively interact with GSK3β or tau or both 
within a complex, thereby disrupting the interaction between them and reducing 
the levels of tau phosphorylated on S396. The reason why the NUB1LΔUBA1-3 
mutant was defective in reducing the aggregation of tau despite decreasing the 
levels of phosphorylated tau is still unclear. A potential explanation would be 
that even a small percentage of non-native oligomeric tau species would 
convert and sequester normal tau into an aggregation-prone conformation. 
NUB1 might be able to target tau as well as non-native oligomeric tau species 
and enhance their degradation before they form bigger aggregates of 
inclusions, which remains the end point of tau aggregation. Although the 
NUB1LΔUBA1-3 mutant might interfere with tau phosphorylation, its ability to 
induce tau degradation might also be impaired, thus the number of inclusions 
remain the same. 
With proteasome inhibition, the levels of GSK3β were only slightly but not 
significantly stabilised in the presence of NUB1, although they were 
considerably stabilised and the rate of degradation of GSK3β was increased in 
the presence of NUB1L. This suggests that the presence of a third UBA domain 
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in NUB1L is responsible for the accelerated turnover of GSK3β levels, and is 
implicated in the proteasome-dependent influence of NUB1L. Taken together, 
the UBA domains are unable to reduce inclusions and GSK3β levels, but can 
still reduce tau phosphorylation. Thus, the mutant NUB1LΔUBA1-3 could still 
interact with GSK3β, preventing GSK3β-dependent tau phosphorylation. 
Therefore, the UBA domains might be necessary for the protein degradation 
role of NUB1 but not essential for protein targeting and interaction. 
The mutant NUB1LΔUBL had a significant effect on tau aggregation and 
decreased the overall levels of GSK3β, although it did not accelerate the rate of 
GSK3β degradation. The UBL domain of NUB1L has been previously reported 
to be necessary for NUB1L acceleration of FAT10 proteasomal degradation 
(Schmidtke et al., 2006). Thus, it would seem that the UBL domain of NUB1 is 
not necessary for its effect on either tau aggregation or GSK3β degradation, but 
that the UBL domain might enhance the effect of NUB1 in terms of the 
accelerated turnover of substrates. 
 
In conclusion, the following model has been proposed for the function of NUB1 
in tau and GSK3β modulation. By interacting with both GSK3β and tau, NUB1 
might disrupt the GSK3β-dependent phosphorylation of tau, thus preventing tau 
inclusion formation. NUB1 can reduce GSK3β levels by proteasomal 
degradation, or may induce GSK3β sequestration in MVBs and lysosomal 
degradation. On the other hand, NUB1 might also be able to target tau or 
altered tau species (e.g. hyperphosphorylated tau) for proteasomal degradation 
(Figure 7.1).  
 
Therefore, this study has identified an important and novel role for NUB1 in the 
regulation of tau and GSK3β-dependent tau phosphorylation. Importantly, 
GSK3β has been found to be a novel target for NUB1-dependent degradation. 
The role of GSK3β in AD involves the anomalous phosphorylation of tau, but 
also anomalous cell-cycle regulation by targeting p53 and β-catenin, and might 
be a potential link between the Aβ and NFT pathologies in AD. On the other 
hand, NUB1 co-localises with and binds tau, and the duo NEDD8 and NUB1, 
both expressed in pyramidal neurons, might be implicated in targeting tau for 
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proteasomal degradation. Taken together, NUB1, by regulating tau and GSK3β 
may potentially be important in the neuropathogenesis of AD and other 
neurodegenerative disorders.  
 
 
 
Figure 7.1. Potential regulation of GSK3β and tau by NUB1. NUB1 disrupts the 
interaction between GSK3β and tau, thus reducing tau phosphorylation and preventing 
tau inclusion formation. NUB1 targets GSK3β for proteasomal degradation and 
potentially lysosomal degradation via MVBs. NUB1 also interacts with tau and could 
target tau for proteasomal degradation. NUB1 interaction with either GSK3β or tau 
might be direct, or necessitate the primer neddylation of the proteins, 
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Appendix A  
Reagents source 
 
Antibodies 
 
Name Catalogue number Supplier  Location 
Anti-FAT10 PW9680 
Anti-NEDD8 PW9340 
Biomol Enzo Life 
Science Exeter, UK 
Anti-GSK3β 1212010 Cell signalling Hertfordshire, UK 
Pan-tau A0024 
Anti-Ubiquitin Z0458 
Swine anti-rabbit polyclonal E0353 
Dako Cambridgeshire, UK 
Alexa Fluor® 488 anti-mouse A11001 
Alexa Fluor® 488 anti-rabbit A11008 
Alexa Fluor® 594 anti-mouse  A11005 
Alexa Fluor® 594 anti-rabbit A11012 
Alexa Fluor® 647 anti-mouse A21235 
Alexa Fluor® 647 anti-rabbit A21244 
pS396 44752G 
Invitrogen Paisley, UK 
Anti-Actin A-5060 
Anti-c-Myc M4439 
Anti-FLAG F1804 
Anti-GAPDH G8735 
Mouse anti-HA H9658 
Rabbit anti-HA H6908 
Anti-tubulin T4026 
Sigma Poole, UK 
AT8 MN1020 
GαM HRP 31430 
GαR HRP 31460 
Thermo Scientific Northumberland 
Anti-NUB1 N/A Genosys Biotechnology Cambridge, UK 
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Molecular techniques 
 
Name Catalogue number Supplier  Location 
HISpeed Plasmid Midi kit 12643 QIAGEN West Sussex, UK 
Ampicillin A1593 
Kanamycin  60615 
Luria Broth media L3522 
Sigma Poole, UK 
Agar LP0013 OXOID Hampshire, UK 
JM109 competent cells L1001 Promega Southampton, UK 
Petri dish FB51506 Fisher Scientific Loughborough, UK 
Ethanol 101077Y 
Isopropanol 102245K 
VWR Lutterworth, UK 
ON-TARGETplus Specificity-
Enhanced small interfering 
RNA 
N/A Dharmacon, Thermo Scientific 
Northumberland, 
UK 
 
Cell culture 
 
Name Catalogue number Supplier  Location 
B27 ® supplement 0080085-SA 
DMEM 31331 
FBS 10108 
HBSS 14170 
L-Glutamine (GlutaMAXTM) 35050038 
Lipofectamine TM 18324020 
Lipofectamine ® 2000 11668030 
Opti-MEM ® 31985-054 
Neurobasal ®-A media 12349 
Plus Reagent ®  11514015 
Penicillin-streptomycin 15140122 
Trypsin-EDTA 2530004 
Invitrogen Paisley, UK 
Lithium Chloride (LiCl)  L4408 
Corning® Costar® 12-well 
plates 3512 
Sigma Poole, UK 
T75 flask 353136 
6-well plates 351146 
BD Falcon Oxford, UK 
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Name Catalogue number Supplier  Location 
DharmaFECT buffer I T-2001-02 Thermo Scientific Northumberland, UK 
8-well Permanox chamber 
slide 17745 
Coverslips glass 12 mm 734-1006 
 
VWR 
 
 
Lutterworth, UK 
 
SK-N-SH 86012802 
SH-SY5Y cells 94030304 
ECACC Salisbury, UK 
 
Drugs 
 
Name Catalogue number Supplier  Location 
Cycloheximide C7698 
Epoxomicin E3652 
Lactacystin L6785 
Lithium Chloride (LiCl) L0505 
DMSO D4540 
Sigma Poole, UK 
MG132 BML-PI102-0025 
Biomol Enzo Life 
Science Exeter, UK 
 
Common supplies 
 
Name Catalogue number Supplier  Location 
Glycerol G6279 
BSA A2153 
SDS L4390 
Sodium pyrophosphate 
(Na2HPO4) 
71321 
Tris-HCl T3253 
Sigma Southampton, UK 
Sodium phosphate 
(NaH2PO4) 
567545 Merck Middlesex, UK 
PBS BR0014G OXOID Hampshire, UK 
Glycine 444495D 
Methanol 20847.320 
Sodium chloride (NaCl) 102415K 
VWR Lutterworth, UK 
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Immunohistochemistry 
 
Name Catalogue number Supplier  Location 
LSAB Dakocytomation kit K0679 Dako Cambridgeshire, UK 
IMS M/4400/17 Fisher Scientific Loughborough, UK 
Citric acid (C6H8O7) C0679 
DPX 44581 
Hydrogen peroxide (H2O2)  H-1009 
Sodium pyrophosphate 
(Na2HPO4) 
S7907 
Sigma Southampton, UK 
Normal Swine Serum 014.000.21 Stratech Newmarket Suffolk, UK 
Xylene 305 756 VWR Lutterworth, UK 
 
Immunocytochemistry  
 
Name Catalogue number Supplier  Location 
Dako mounting medium S3023 Dako Cambridgeshire, UK 
DAPI D9564 
Glutaraldehyde G6257 
Normal Goat serum G9023 
Sodium borohydride 
(NaBH4) 
71321 
IGEPAL-CA630 (NP-40) I3021 
Triton X-100 T8787 
Sigma Poole, UK 
PFA F017 TAAB Berks, UK 
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Biochemical assays 
Name Catalogue number Supplier  Location 
Protein Ladder  SM1811 Fermentas York, UK 
Acrylamide/Bisacrylamide 
30% EC-890-1 
SDS PAGE Buffer ELR-330-010Q 
Tris-glycine transfer buffer  ELR-322-010L 
Fisher Scientific 
 
Loughborough, UK 
 
ECL Plus reagent RPN2132 GE Healthcare Buckinghamshire, UK 
Dynabeads 100.04D Invitrogen Paisley, UK 
Super RX X-Ray Fuji film JTS010 Labtech East Sussex, UK 
Ammonium persulphate 
(APS), (NH4)2S2O8 
A 3678 
β-Mercaptoethanol M3148 
Dithiothreitol (DTT) D0632 
EGTA E8145 
Magnesium Chloride 
(MgCl2) 
63068 
PhIC P0044 
PIC P8340 
PIPES P-6757 
Ponceau-S P3504 
Sodium Deoxycholate 
(C24H39NaO4) 
D6750 
TEMED T92-81 
Tween -20  P9416 
Sigma 
 
Southampton, UK 
 
BCA Protein Assay Kit 23 227 Thermo Scientific Northumberland, UK 
Acetic acid (glacial) 64-19-7 
Bromophenol blue 44 305 
Nitrocellulose membrane 732 4007 
VWR Lutterworth, UK 
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Appendix B 
Solutions and buffers 
 
Block solution for ICC 
Goat serum       10 % (v/v) 
BSA        3 % (w/v) 
In PBS  
Block solution for IHC 
Swine serum       10 % (v/v) 
BSA        2 % (w/v) 
In PBS  
BSA solution for antibody in IHC 
BSA        0.1 % (w/v) 
In PBS  
BSA-T block solution for immunoprecipitation 
BSA        0.2 % (w/v) 
Tween 20       0.02% (v/v) 
In PBS 
Glutaraldehyde fixation 
Glutaraldehyde      0.3 % (v/v) 
Nonidet P-40 (NP-40)     0.5% (v/v) 
In PEM 
Glycine solution  
Glycine       0.1 M 
In PBS 
2x Laemli buffer 
Glycerol       10 % (v/v) 
SDS        2.5 % (w/v) 
Tris-HCl (pH 6.8)      60 mM 
DTT        1 M 
In ddH2O 
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Lithium Chloride (LiCl) 
LiCl        10 mM 
In ddH2O 
Luria-Bertani Broth (LB) medium 
Luria Broth        25 g/l 
In ddH2O, autoclaved 
LB agar 
Luria Broth        25 g/l 
Agar         15 g/l 
In ddH2O, autoclaved 
4X loading buffer 
β-Mercaptoethanol      10 % (v/v) 
Glycerol       20 % (v/v) 
SDS        5 % (w/v) 
Tris-HCl (pH 6.8)      125 mM 
In ddH2O 
Mc Ilvane’s buffer 
Citric acid       0.1 M 
Na2HPO4       0.2 M 
In ddH2O 
Paraformaldehyde (PFA) fixation  
PFA        3.7- 4 % (v/v) 
In PBS 
Phosphate buffered saline (PBS) 
NaCl         145 mM  
NaH2PO4       3.6 mM  
Na2HPO4       10.5 mM  
In ddH2O 
PBS-T 
Tween 20       0.01 % (v/v)  
In PBS 
Permeabilisation 
Triton X-100       0.1 % (v/v) 
In PBS 
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Pipes/EGTA/MgCl2 buffer (PEM)  
Pipes         80 mM  
EGTA        5 mM  
MgCl2        1 mM  
In ddH2O, pH 6.8 
Ponceau S solution  
Ponceau S red dye       0.1% (w/v) 
Acetic acid       5 % (v/v) 
In ddH2O 
RIPA buffer  
Sodium deoxycholate     1 % (w/v)  
NaCl        150 mM  
NP-40        1 % (v/v) 
SDS        0.1 % (w/v) 
Tris-HCl (pH7.5)      50 mM 
In ddH2O 
RIPA-Tween (RIPA-T) buffer  
Tween-20       0.02% (v/v) 
In RIPA buffer 
0.1% SDS buffer 
NaCl        150 mM 
SDS        0.1 % (v/v) 
Tris-HCl (pH 8)      10 mM 
In ddH2O 
SDS-PAGE resolving gel (10%) 
Tris-HCl (pH 8.8)       375 mM 
Acrylamide/Bis-acrylamide     10% (v/v) 
Ammonium persulfate     0.1% (v/v) 
SDS         0.1% (w/v) 
TEMED        0.05% (v/v) 
In ddH2O 
SDS-PAGE stacking gel (3%) 
Tris-HCl (pH 6.8)       125 mM 
Acrylamide/Bis-acrylamide     3 % (v/v) 
APS         0.05% (v/v) 
SDS         0.1% (w/v) 
TEMED        0.08% (v/v) 
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In ddH2O 
SDS-PAGE running buffer 
Tris-HCl       25 mM 
Glycine       190 mM 
SDS        3.5 mM 
Sodium borohydride (NaBH4) solution  
NaBH4       10 mg/l 
In PBS 
Transfer buffer 
Tris-HCl       25 mM 
Glycine        192 mM 
SDS         0.1% (w/v) 
Methanol       20 % (v/v) 
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Appendix C  
Supplementary figure 
 
 
 
 
Supplementary Figure 1. GFP-tau localisation with HA-GSK3β co-expression in live 
cells. SK-N-SH cells were seeded on MatTek (MatTex Corp, MA, USA) slide dishes at 
a density of 600,000 cells/dish and after 24 hours were transfected with 100 ng of GFP-
tau in the absence (-) or presence (+) of 150 ng of HA-GSK3β as described in chapter 
2.3.2.2. Twenty-eight hours after transfection, cells were live imaged at 37°C with a 
Zeiss LSM510 confocal microscope (Carl Zeiss Ltd., Welwyn Garden City, 
Hertfordshire, UK). For FRAP measurements (not shown), a total of 40 images were 
acquired at one image per second. Supplementary figure 1 is a Z projection of the 40 
images. Scale bar = 10 µm.  
 
 
 
 
 
